Original Article
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
N Engl J Med 2000; 343:1520-1528November 23, 2000
- Abstract
Background
Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis.
Methods
We randomly assigned 8076 patients who were at least 50 years of age (or at least 40 years of age and receiving long-term glucocorticoid therapy) and who had rheumatoid arthritis to receive either 50 mg of rofecoxib daily or 500 mg of naproxen twice daily. The primary end point was confirmed clinical upper gastrointestinal events (gastroduodenal perforation or obstruction, upper gastrointestinal bleeding, and symptomatic gastroduodenal ulcers).
Results
Rofecoxib and naproxen had similar efficacy against rheumatoid arthritis. During a median follow-up of 9.0 months, 2.1 confirmed gastrointestinal events per 100 patient-years occurred with rofecoxib, as compared with 4.5 per 100 patient-years with naproxen (relative risk, 0.5; 95 percent confidence interval, 0.3 to 0.6; P<0.001). The respective rates of complicated confirmed events (perforation, obstruction, and severe upper gastrointestinal bleeding) were 0.6 per 100 patient-years and 1.4 per 100 patient-years (relative risk, 0.4; 95 percent confidence interval, 0.2 to 0.8; P=0.005). The incidence of myocardial infarction was lower among patients in the naproxen group than among those in the rofecoxib group (0.1 percent vs. 0.4 percent; relative risk, 0.2; 95 percent confidence interval, 0.1 to 0.7); the overall mortality rate and the rate of death from cardiovascular causes were similar in the two groups.
Conclusions
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Media in This Article
Figure 1
Cumulative Incidence of the Primary End Point of a Confirmed Upper Gastrointestinal Event among All Randomized Patients.Table 1
Criteria for Gastrointestinal Events.Article Activity
- Article
Nonsteroidal antiinflammatory drugs (NSAIDs) are among the most commonly used medications in the world.1 A major factor limiting their use is gastrointestinal toxicity. Although endoscopic studies reveal that gastric or duodenal ulcers develop in 15 to 30 percent of patients who regularly take NSAIDs,2 the chief concern is clinically important gastrointestinal problems, such as bleeding. It has been estimated that more than 100,000 patients are hospitalized and 16,500 die each year in the United States as a result of NSAID-associated gastrointestinal events.3,4
Most NSAIDs inhibit both cyclooxygenase-1 and cyclooxygenase-2, isoenzymes involved in the synthesis of prostaglandins.5 Cyclooxygenase-1 is constitutively expressed and generates prostanoids involved in the maintenance of the integrity of gastrointestinal mucosa and platelet aggregation,6 whereas at sites of inflammation, cyclooxygenase-2 is induced to generate prostaglandins that mediate inflammation and pain.7 The antiinflammatory effects of nonselective NSAIDs (those that inhibit both cyclooxygenase-1 and cyclooxygenase-2) therefore appear to be mediated through the inhibition of cyclooxygenase-2,8 whereas their harmful effects in the gastrointestinal tract as well as their antiplatelet effects are believed to occur primarily through the inhibition of cyclooxygenase-1.5
Agents that selectively inhibit cyclooxygenase-2 have antiinflammatory and analgesic effects that are similar to those of nonselective NSAIDs,9-12 but they induced significantly fewer ulcers in endoscopic trials.12-15 Whether such a decrease in the number of ulcers translates into a similar decrease in the number of clinical gastrointestinal events is a matter of controversy. We performed a prospective, randomized, double-blind comparison of rofecoxib and naproxen in more than 8000 patients with rheumatoid arthritis.
Methods
Study Population
Patients with rheumatoid arthritis who were at least 50 years old (or at least 40 years old and receiving long-term glucocorticoid therapy) and who were expected to require NSAIDs for at least one year were eligible. Patients were excluded if they had a history of another type of inflammatory arthritis, upper gastrointestinal surgery, or inflammatory bowel disease; an estimated creatinine clearance of 30 ml or less per minute; a positive test for fecal occult blood (this test was performed at base line in all patients); an unstable medical condition; a history of cancer or alcohol or drug abuse in the five years before the study; a history of cerebrovascular events in the two years before the study; or a history of myocardial infarction or coronary bypass in the year before the study. Patients with morbid obesity and those who required or who had been receiving treatment with aspirin, ticlopidine, anticoagulants, cyclosporine, misoprostol, sucralfate, or proton-pump inhibitors or treatment with histamine H2–receptor antagonists in prescription-strength doses were also excluded from the study. Patients enrolled in the study were not thought to require the use of these agents by their treating physicians.
Study Design
The study was conducted at 301 centers in 22 countries. Three to 14 days after discontinuing NSAIDs, eligible patients were randomly assigned to receive either 50 mg of rofecoxib (Vioxx, Merck, Whitehouse Station, N.J.) once daily or 500 mg of naproxen (Novopharm Biotech, Toronto) twice daily. The groups were stratified according to the presence or absence of a history of gastroduodenal ulcer, upper gastrointestinal bleeding, and gastroduodenal perforation. Blinding was achieved through the use of a matching placebo for each study medication.
Patients were permitted to take acetaminophen, non-NSAID analgesic medications, glucocorticoids, and disease-modifying drugs (e.g., methotrexate) to control their rheumatoid arthritis. Patients were also allowed to take antacids and H2-receptor antagonists in the following maximal doses: ranitidine, 150 mg daily; famotidine, 20 mg daily; cimetidine, 400 mg daily; and nizatidine, 150 mg daily. Nonstudy NSAIDs were not allowed. After randomization, the patients returned to the clinic at six weeks and at four months and every four months thereafter until the end of the study. Patients were contacted by telephone at week 10 and every four months thereafter. Compliance was assessed by pill counts at clinic visits and by questioning of patients during the scheduled telephone calls. Serum was obtained from all patients for Helicobacter pylori testing (HM-CAP, Enteric Products, Stonybrook, N.Y.). Investigators were not informed of the results of these tests during the study.
The institutional review board or ethics review committee at each center approved the protocol, and all patients gave written informed consent. A steering committee oversaw the study design, conduct of the trial, analyses of data, and drafting of this report. This committee was composed of 14 members, 2 of whom were employees of the sponsoring pharmaceutical company. An independent data and safety monitoring board monitored the patients' safety. An independent, external (end-point) committee whose members were unaware of the patients' treatment assignments reviewed the data to determine which patients had reached the study end points. Because highly selective cyclooxygenase-2 inhibitors do not inhibit platelet aggregation, which is mediated by cyclooxygenase-1, there was a possibility that the incidence of thrombotic cardiovascular events would be lower among patients treated with nonselective cyclooxygenase inhibitors than among those treated with cyclooxygenase-2–selective inhibitors. Therefore, cardiovascular events were also assessed for a future meta-analysis by independent committees whose members were unaware of the patients' treatment assignments. A separate analysis of these events, however, was not specified in the study design.
Study End Points
Patients who had potential clinical upper gastrointestinal events were evaluated and treated according to the standard practice of the physicians who were caring for them. Patients who stopped taking the study medication before the study ended were followed until the end of the study to determine whether an upper gastrointestinal event had occurred. Only events that were confirmed by the end-point committee according to prespecified criteria (Table 1Table 1
Criteria for Gastrointestinal Events.) and that occurred during treatment or within 14 days after the discontinuation of treatment were included in the primary analysis.In addition, the protocol called for the analysis of all episodes of gastrointestinal bleeding, including confirmed and unconfirmed episodes of upper gastrointestinal bleeding, and bleeding from a site beyond the duodenum that resulted in hospitalization, discontinuation of treatment, or a decrease in the hemoglobin level of at least 2 g per deciliter.
Assessment of Efficacy
For each patient both the investigator and the patient answered a Global Assessment of Disease Activity question at base line (after the discontinuation of prestudy NSAIDs), 6 weeks, 4 months, and 12 months and at the end of the study or when treatment was discontinued. The score can range from 0 (“very well”) to 4 (“very poor”), and higher scores indicate more disease activity. The Modified Health Assessment questionnaire was administered only to patients enrolled at centers in the United States at base line, at six weeks, and at the end of the study or when treatment was discontinued. This questionnaire evaluates the extent of functional disability in eight types of tasks performed on a daily basis. The level of effort required to perform each task is assessed on a 4-point scale on which a score of 0 indicates no difficulty in performing the task and a score of 3 indicates an inability to perform the task.16 Higher scores indicate more severe disability.
Statistical Analysis
The primary hypothesis was that the risk of confirmed upper gastrointestinal events (gastroduodenal perforation or obstruction, upper gastrointestinal bleeding, and symptomatic gastroduodenal ulcers) would be lower among patients who were taking rofecoxib than among those who were taking naproxen. Secondary hypotheses were that the risk of confirmed complicated events (perforation, obstruction, and severe upper gastrointestinal bleeding) and the risk of both confirmed and unconfirmed upper gastrointestinal events would be lower among patients who were taking rofecoxib.
Cox proportional-hazards analysis was used to compare the effect of treatment; the presence or absence of a history of gastrointestinal events was a stratification factor in the analysis.17,18 The scores for the Global Assessment of Disease Activity question and Modified Health Assessment questionnaire were analyzed in terms of the mean change from base line during the treatment period. The primary population for analysis comprised all randomized patients. Subgroup analyses were conducted with use of Cox regression analysis.17,18 Interactions between treatments and subgroups were assessed to determine whether the effect of rofecoxib as compared with that of naproxen was consistent in the subgroups. We assessed data on general safety by evaluating 95 percent confidence intervals of the differences in the proportions of the treatment groups with each adverse event.19 All statistical tests were two-sided.
Results
Characteristics of the Patients
Between January 1999 and July 1999, we screened 9539 patients and enrolled 8076; 4047 were randomly assigned to receive rofecoxib, and 4029 to receive naproxen. The major reasons for exclusion were a contraindication to prolonged NSAID therapy (in the case of 246 patients), a positive test for fecal occult blood (203 patients), and a failure to meet inclusion criteria (355 patients). The median follow-up was 9.0 months in both treatment groups (range, 0.5 to 13). A total of 5742 patients (71.1 percent) continued to take their assigned medication until the end of the study. Rates of discontinuation were similar in the two groups: 29.3 percent in the rofecoxib group (16.4 percent because of adverse events, 6.3 percent because of a lack of efficacy, and 6.6 percent for other reasons) and 28.5 percent in the naproxen group (16.1 percent because of adverse events, 6.5 percent because of a lack of efficacy, and 5.9 percent for other reasons). Ninety-nine percent of the patients in both groups took their medication on at least 75 percent of the study days. The base-line characteristics were similar in the two groups (Table 2Table 2
Base-Line Characteristics of the Patients.).Efficacy
Rofecoxib and naproxen had similar efficacy against rheumatoid arthritis (Table 3Table 3
Effectiveness of Rofecoxib and Naproxen for Rheumatoid Arthritis.). In addition, the rates of discontinuation of treatment owing to a lack of efficacy were low in both groups (6.3 percent in the rofecoxib group and 6.5 percent in the naproxen group).Adverse Gastrointestinal Events
Confirmed upper gastrointestinal events occurred in 177 patients. In 53 of these patients the event was complicated. An additional 13 patients had events that were reported by investigators but that were judged by the end-point committee to be unconfirmed.
The time to the development of a confirmed upper gastrointestinal event is shown in Figure 1Figure 1
Cumulative Incidence of the Primary End Point of a Confirmed Upper Gastrointestinal Event among All Randomized Patients.. The rates per 100 patient-years and incidences of the prespecified clinical events are shown in Table 4Table 4
Incidence of Gastrointestinal Events in the Treatment Groups. and Table 5Table 5
Incidence of Confirmed Upper Gastrointestinal Events., respectively. The relative risk of confirmed upper gastrointestinal events for patients in the rofecoxib group as compared with those in the naproxen group was 0.5 (95 percent confidence interval, 0.3 to 0.6; P<0.001), whereas the relative risk of complicated confirmed upper gastrointestinal events was 0.4 (95 percent confidence interval, 0.2 to 0.8; P=0.005). The relative risk of complicated upper gastrointestinal bleeding for patients in the rofecoxib group as compared with those in the naproxen group was 0.4 (95 percent confidence interval, 0.2 to 0.7; P= 0.004), whereas the relative risk of bleeding beyond the duodenum was 0.5 (95 percent confidence interval, 0.2 to 0.9; P=0.03).A per-protocol analysis of the 7925 patients without substantial protocol violations demonstrated relative risks of confirmed upper gastrointestinal events and complicated confirmed events of 0.4 (95 percent confidence interval, 0.3 to 0.6; P<0.001) and 0.4 (95 percent confidence interval, 0.2 to 0.7; P= 0.003), respectively. The results of an intention-to-treat analysis of all confirmed upper gastrointestinal events throughout the study, including those that occurred at any time after the discontinuation of treatment, were similar and remained statistically significant (data not shown).
Subgroup analyses showed the following relative risks of clinical gastrointestinal events among the patients in the rofecoxib group as compared with those in the naproxen group: patients with no prior gastrointestinal events (relative risk, 0.5; 95 percent confidence interval, 0.3 to 0.7), patients with prior gastrointestinal events (relative risk, 0.4; 95 percent confidence interval, 0.2 to 0.8), patients with no glucocorticoid therapy at base line (relative risk, 0.7; 95 percent confidence interval, 0.4 to 1.2), and patients with glucocorticoid therapy at base line (relative risk, 0.4; 95 percent confidence interval, 0.2 to 0.6). The relative risks in these subgroups and the other prespecified subgroups (defined according to sex, race or ethnic group, and location of study center) were not significantly different, indicating that there was no significant interaction between the treatments and the subgroups.
Treatment with rofecoxib was associated with a significantly lower incidence of clinical gastrointestinal events regardless of the results of serologic tests for H. pylori. However, the relative risks of clinical events among H. pylori–negative patients and H. pylori–positive patients were significantly different (P=0.04, data not shown). Finally, the relative risk of gastrointestinal events remained significantly lower (0.1; 95 percent confidence interval, 0.02 to 1.0) in the rofecoxib group than in the naproxen group even in a subgroup at very low risk (i.e., patients who were younger than 65 years, who were negative for H. pylori, who had no history of a clinical gastrointestinal event, and who were not taking glucocorticoids at base line).
General Safety
The safety of both rofecoxib and naproxen was similar to that reported in previous studies.20,21 The mortality rate was 0.5 percent in the rofecoxib group and 0.4 percent in the naproxen group. The rate of death from cardiovascular causes was 0.2 percent in both groups. Ischemic cerebrovascular events occurred in 0.2 percent of the patients in each group. Myocardial infarctions were less common in the naproxen group than in the rofecoxib group (0.1 percent vs. 0.4 percent; 95 percent confidence interval for the difference, 0.1 to 0.6 percent; relative risk, 0.2; 95 percent confidence interval, 0.1 to 0.7). Four percent of the study subjects met the criteria of the Food and Drug Administration (FDA) for the use of aspirin for secondary cardiovascular prophylaxis (presence of a history of myocardial infarction, angina, cerebrovascular accident, transient ischemic attack, angioplasty, or coronary bypass)22 but were not taking low-dose aspirin therapy. These patients accounted for 38 percent of the patients in the study who had myocardial infarctions. In the other patients the difference in the rate of myocardial infarction between groups was not significant (0.2 percent in the rofecoxib group and 0.1 percent in the naproxen group). When the data showing a reduction in the rate of myocardial infarction in the naproxen group became available after the completion of this trial, Merck, the manufacturer of rofecoxib, notified all investigators in ongoing studies of a change in the exclusion criteria to allow patients to use low-dose aspirin. There was no association between hypertension and myocardial infarction; only a single patient (in the rofecoxib group) had both hypertension and a myocardial infarction as adverse events.
The most common adverse events leading to discontinuation of treatment, excluding the gastrointestinal end points, were dyspepsia, abdominal pain, epigastric discomfort, nausea, and heartburn. In the rofecoxib group, significantly fewer patients discontinued treatment as a result of any one of these five upper gastrointestinal symptoms than in the naproxen group (3.5 percent vs. 4.9 percent). The rates of discontinuation for any gastrointestinal events, including gastrointestinal end points, were also significantly lower in the rofecoxib group than in the naproxen group (7.8 percent vs. 10.6 percent). The incidence of adverse effects related to renal function was low and was similar in the two groups (1.2 percent in the rofecoxib group and 0.9 percent in the naproxen group); only 0.2 percent of patients in each group discontinued treatment because of these adverse effects.
Discussion
We found that, in patients with rheumatoid arthritis, treatment with rofecoxib at twice the maximal dose approved by the FDA for long-term use resulted in significantly lower rates of clinically important upper gastrointestinal events and complicated upper gastrointestinal events than did treatment with a standard dose (1000 mg per day) of naproxen. We also found that the incidence of complicated upper gastrointestinal bleeding and bleeding from beyond the duodenum was significantly lower among patients who received rofecoxib. Only 41 patients would need to be treated with rofecoxib rather than naproxen to avert one clinical upper gastrointestinal event in a one-year period. Although the optimal dose of rofecoxib for the treatment of rheumatoid arthritis has yet to be determined, data from a prior study indicate that maximal efficacy is achieved at a daily dose of 25 mg.23
A prospective study that compared NSAIDs alone with NSAIDs plus misoprostol reported that 0.95 percent of patients with rheumatoid arthritis who were taking an NSAID alone had upper gastrointestinal complications over a period of six months,24 with a relative reduction in the risk of such complications with combination treatment of 40 percent during this period. These results are similar to our finding of a cumulative incidence of serious upper gastrointestinal events over a six-month period of 0.75 percent in the naproxen group and a relative reduction in risk of 67 percent in the rofecoxib group (data not shown). A 50 percent reduction in the incidence of clinically important upper gastrointestinal events with rofecoxib as compared with a nonselective NSAID was also found in a prespecified combined analysis of eight double-blind studies that included 4921 patients with osteoarthritis, none of whom received glucocorticoids.25 Patients with rheumatoid arthritis have a higher risk of upper gastrointestinal events than do patients with osteoarthritis.4 Thus, the results of our study extend the results of the combined analysis to a group of patients at higher risk of bleeding.
The results of a randomized, double-blind comparison of the cyclooxygenase-2–selective inhibitor celecoxib and the nonselective NSAIDs ibuprofen and diclofenac were recently published.26 In this trial of 7968 patients, 73 percent of whom had osteoarthritis and 27 percent of whom had rheumatoid arthritis, data were reported from the first 6 months of a study period that extended for up to 13 months. Treatment with celecoxib was associated with a nonsignificant (P=0.09) trend toward a decrease in the incidence of the primary end point (complicated ulcers and erosions) and a significant decrease (P=0.02) in the incidence of the secondary end point (complicated and symptomatic ulcers).
The incidence of clinically important gastrointestinal events was lower in the rofecoxib group than in the naproxen group in all subgroups we examined. Concomitant glucocorticoid and NSAID therapy has been reported to be associated with a higher risk of a clinical gastrointestinal event than is NSAID therapy alone.4 Therefore, a larger reduction in the incidence of events might have been expected in the subgroup that received both an NSAID and glucocorticoids. There was a greater reduction in the relative risk of events in the subgroup of patients who were taking glucocorticoids at base line than in the subgroup of patients who were not taking glucocorticoids at base line, but the difference between the groups was not significant.
Whether ulcers identified by endoscopic examination are markers of a clinical gastrointestinal event has been a matter of controversy. The relative reduction in the risk of such ulcers in two identical studies that compared 50 mg of rofecoxib daily with 800 mg of ibuprofen three times a day was 71 percent at six months.13,14 Thus, our findings support the concept that the results of endoscopic studies of ulcers can be extrapolated to clinical gastrointestinal events.
In prior endoscopic studies, the frequency of ulcers was similar in patients taking rofecoxib and those taking placebo.13,14 We could not include a placebo group, and no studies have yet assessed whether a cyclooxygenase-2–selective inhibitor or the combination of nonselective NSAIDs plus gastroprotective drugs (such as misoprostol and proton-pump inhibitors) will achieve similar results.
Gastrointestinal symptoms are extremely common with NSAID therapy, as demonstrated by the fact that, in our study, the five most common adverse events leading to the discontinuation of treatment were upper gastrointestinal symptoms. Although gastrointestinal symptoms are poorly correlated with endoscopic findings of ulcers or clinical gastrointestinal events,27 significantly fewer patients in the rofecoxib group than in the naproxen group discontinued treatment because of gastrointestinal symptoms.
The overall mortality rate was similar in the two groups, as were the rates of death from gastrointestinal events and from cardiovascular causes. The rate of myocardial infarction was significantly lower in the naproxen group than in the rofecoxib group (0.1 percent vs. 0.4 percent). This difference was primarily accounted for by the high rate of myocardial infarction among the 4 percent of the study population with the highest risk of a myocardial infarction, for whom low-dose aspirin is indicated.22 The difference in the rates of myocardial infarction between the rofecoxib and naproxen groups was not significant among the patients without indications for aspirin therapy as secondary prophylaxis.
Naproxen inhibits the production of thromboxane by 95 percent and inhibits platelet aggregation by 88 percent, and this effect is maintained throughout the dosing interval28; therefore, the effects of regular use of naproxen may be similar to those of aspirin. Flurbiprofen, another NSAID that is a potent inhibitor of platelet-derived thromboxane, led to a 70 percent reduction in the rate of reinfarction as compared with placebo among patients in whom acute myocardial infarction was successfully treated with thrombolysis, angioplasty, or both.29
Analyses of 7535 patients in double-blind trials comparing rofecoxib with placebo and other NSAIDs (diclofenac, ibuprofen, and nabumetone) that do not produce sustained, maximal inhibition of platelet aggregation revealed similar rates of myocardial infarction in all groups30 (and unpublished data). Thus, our results are consistent with the theory that naproxen has a coronary protective effect and highlight the fact that rofecoxib does not provide this type of protection owing to its selective inhibition of cyclooxygenase-2 at its therapeutic dose and at higher doses. The finding that naproxen therapy was associated with a lower rate of myocardial infarction needs further confirmation in larger studies.
In summary, the use of the cyclooxygenase-2–selective inhibitor rofecoxib resulted in significantly fewer clinically important upper gastrointestinal events than did treatment with naproxen, a nonselective NSAID. The two drugs had similar rates of clinical effectiveness.
Supported by a grant from Merck.
Dr. Bombardier has received clinical research support from Aventis Pharma, Merck Research Laboratories, and Merck Frosst Canada. She has served as a consultant to Knoll Pharmaceutical, Aventis Canada, Schering Canada, Merck Research Laboratories, and Wyeth–Ayerst.
Dr. Laine has received clinical research support from Merck, Wyeth–Ayerst, and AstraZeneca. He has served as a consultant to Merck, Searle, Johnson & Johnson, AstraZeneca, Wyeth–Ayerst, and Tap Pharmaceuticals.
Dr. Burgos-Vargas has received clinical research support from Merck Sharp & Dohme, Pfizer, and Boehringer Ingelheim. He has served as a consultant to Merck and has been a member of a speakers' bureau sponsored by Merck Sharp & Dohme.
Dr. Davis has served as a consultant to Mirvant, Merck Research Laboratories, Parke-Davis, and SmithKline Beecham.
Dr. Day has received clinical research support from Merck, Searle, Pfizer, Roche, and Amgen. He has served as a consultant to Merck, Searle, and Pfizer. He has been a member of speakers' bureaus sponsored by Merck Sharp & Dohme, Searle, Pfizer, and SmithKline Beecham.
Dr. Ferraz has received clinical research support from Bristol-Myers Squibb, Merck Sharp & Dohme, and Aventis Pharma. He has served as a consultant to Aventis Pharma.
Dr. Hawkey has received clinical research support from AstraZeneca, Asta Medica, Boehringer Ingelheim, Boots Healthcare International, Cell Tech, Eisai, Elan, Merck Research Laboratories, NicOx, and Novartis. He has served as a consultant to AstraZeneca, Abbott, Cell Tech, Eisai, Merck Research Laboratories, NicOx, Novartis, Parke-Davis, and Synthelabo Pharmacie. He has been a member of speakers' bureaus sponsored by AstraZeneca, Boehringer Ingelheim, Boots Healthcare International, Takeda, Wyeth Lederle, and Merck Research Laboratories.
Dr. Hochberg has received clinical research support from Merck and Quintiles (Aventis Pharma). He has served as a consultant to Aventis Pharma, Biomatrix, Merck, Negma Laboratories, Procter & Gamble, Roche, and Wyeth–Ayerst. He owns stock in Johnson & Johnson, Eli Lilly, Merck, Procter & Gamble, and Schering-Plough.
Dr. Kvien has received clinical research support from Merck, Searle, Aventis Pharma, and Schering-Plough. He has served as a consultant to Merck, Searle, Aventis Pharma, and Schering-Plough. He has been a member of a speakers' bureau sponsored by Merck and Aventis Pharma.
Dr. Schnitzer has received clinical research support from Abbott, Boehringer Ingelheim, Johnson & Johnson, McNeil Consumer Products, Merck, Novartis, Ortho-McNeil, Parke-Davis, Searle, and Wyeth–Ayerst. He has served as a consultant to Boehringer Ingelheim, Merck, Novartis, Ortho-McNeil, Searle, and SmithKline Beecham. He has been a member of speakers' bureaus sponsored by Boehringer Ingelheim, Merck, Ortho-McNeil, Wyeth–Ayerst, and Searle.
Dr. Weaver has received clinical research support from Merck, Searle, Immunex, Wyeth–Ayerst, Aventis Pharma, Pharmacia–Upjohn, Eli Lilly, Connetics, Parke-Davis, Procter & Gamble, Pfizer, Hoffmann–LaRoche, Centocor, Amgen, Cyprus Bioscience, Helsinn, Novartis, and Boehringer Ingelheim. He has served as a consultant to Merck, Searle, Immunex, Wyeth–Ayerst, Aventis Pharma, Pharmacia–Upjohn, Eli Lilly, Connetics, Parke-Davis, Procter & Gamble, Pfizer, Hoffmann–LaRoche, Centocor, Amgen, Cyprus Bioscience, Helsinn, Novartis, and Boehringer Ingelheim. He has been a member of speakers' bureaus sponsored by Merck, Searle, Immunex, Wyeth–Ayerst, Aventis Pharma, Pharmacia–Upjohn, Eli Lilly, Connetics, Parke-Davis, Procter & Gamble, Pfizer, Hoffmann–LaRoche, Centocor, Amgen, Cyprus Bioscience, Helsinn, Novartis, and Boehringer Ingelheim. He is on the board of directors of MGI Pharma.
We are indebted to Christopher T. Brett, Dayna Carroll, Russell Cender, Edward Chafart, Laurine Connors, Gary Gartenberg, Nicole Gillies, Richard Holmes, Paige Reagan, Douglas J. Watson, Debora P.L. Weiss, and Qinfen Yu for their substantial contributions.
Source Information
From the Institute for Work and Health, Mount Sinai Hospital, and the University Health Network, Toronto (C.B.); the Gastrointestinal Division, Department of Medicine, University of Southern California School of Medicine, Los Angeles (L.L.); Merck, Rahway, N.J. (A.R., D.S.); the Faculty of Medicine and Research Division, Universidad Nacional Autonoma de Mexico, and Hospital General de Mexico, Mexico City, Mexico (R.B.-V.); University of Texas–Houston School of Public Health, Houston (B.D.); the Department of Clinical Pharmacology, University of New South Wales and St. Vincent's Hospital, Sydney, Australia (R.D.); the Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil (M.B.F.); the Division of Gastroenterology, School of Medical and Surgical Sciences, University Hospital, Nottingham, United Kingdom (C.J.H.); the Division of Rheumatology and Clinical Immunology, University of Maryland, Baltimore (M.C.H.); Oslo City Department of Rheumatology, and Diakonhjemmet Hospital, Oslo, Norway (T.K.K.); and the Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago (T.J.S.). Arthur Weaver, M.D., Arthritis Center of Nebraska, Lincoln, was another author.
Address reprint requests to Dr. Bombardier at the Institute for Work and Health, 250 Bloor St. E., Suite 702, Toronto, ON M4W 1E6, Canada, or at claire.bombardier@utoronto.ca.
Appendix
The following persons participated in the study: International Steering Committee: C. Bombardier (chair), L. Laine (cochair), A. Reicin, M. Hochberg, R. Day, T. Capizzi, P. Brooks, R. Burgos-Vargas, B. Davis, M. Ferraz, C. Hawkey, T.K. Kvien, T. Schnitzer, A. Weaver; Data Safety Board: M. Weinblatt (chair); D. Bjorkman, J. Neaton, A. Silman, R. Sturrock; End-Point Adjudication Committee: M. Griffin (chair), D. Jensen, M. Langman; Investigators: Argentina: E. DiGiorgio, H. Laborde, O. Messina, A. Strusberg; Australia: J. Bertouch, R. Day, G. McColl, P. Ryan, S. Sharma; Brazil: R. Bonfiglioli, C. Borges, J. Brenol, N. da Silva, M. Ferraz, F. Lima, C. Moreira, G. Novaes, A. Pessoa, F. Petean, S. Radominski, A. Samara, B. Souza; Canada: T. Anastassiades, M. Atkinson, A. Beaulieu, M. Bell, M. Camerlain, J. Canvin, M. Cohen, J. Hanly, J. Karsh, T. McCarthy, W. Olszynski, P. Patel, Y. Pesant, W. Pruzanski, K. Siminovitch, J. Thome, V. Verdejo-Aguilar; Chile: L. Barria, C. Fuentealba, L. Massardo, P. Riedemann, L. Roca, H. Rossi; China (Hong Kong): C. Lau; Colombia: M. Abello, P. Chalem, M. Jannault, J. Molina; Costa Rica: R. Alpizar, H. Garcia-Sancho; Czech Republic: L. Konecna, K. Pavelka, M. Sealackova, J. Vitova, R. Ahora; Ecuador: R. Villacis; Finland: M. Hakala, P. Hannonen, T. Helve, M. Nissila; Germany: R. Alten, M. Gaubitz, E. Gromnica-Ihle, H. Hantzschel, G. Hein, M. Keysser, R. Kurthen, B. Lang, F. Mielke, U. Muller-Ladner, C. Richter, M. Schattenkirchner, M. Schneider, H. Sorenson, E. Waldorf-Bolten, H. Watnatz, S. Wassenberg; Guatemala: E. Julian, R. Palomo; Israel: D. Buskila, A. Nahir, I. Rosner; Malaysia: S. Yeap; Mexico: R. Burgos, I. Garcia de la Torre, F. Irazoque, J. Arozco Alcala; New Zealand: P. Jones, L. McLean, C. Rajapakse; Norway: H. Gulseth, K. Helgetveit, A. Johannessen, C. Kaufmann, O. Knudsrod, T. Kvien, K. Mikkelsen, B. Rossebo, G. Sidenwall; Peru: A. Calvo Quioz, M. Gustavo, A. Hilgado, L. Portocarrero, E. Vera Bejar; Poland: J. Badurski, J. Brzezicki, M. Bykowska, I. Fiedorowicz-Fabrycy, J. Gaweda, P. Gluszki, B. Konieczna, S. Mackiewicz, J. Pazdur, L. Szczepanski, J. Szechinski; South Africa: I. Anderson, D. Gotlieb, A. Jacovides, A. Lubbe, G. Mody, M. Tikly; United States: Alabama: G. Divititorio, S. Fallahi, D. McLaine, W. Shergy, M.S. Touger, G. Williams; Arizona: B. Harris, P. Howard, D. Michel, L. Taber, J. Tesser, M. Maricic; California: E. Boiling, M. Brandon, G. Dolan, R. Dore, M. Greenwald, D. Haselwood, M. Keller, K. Kolba, C. Multz, R. Reid, D. Stanton, C. Weidmann, S. Weiner, J. Higashida; Colorado: S. Kassan, R. Lapidus, D. Scott, J. Thompson, C. Van Kerchov; Connecticut: E. Feinglass, J. Green, R. Schoen; Florida: M. Beilian, C. Chappel, J. Forstot, P. Freeman, N. Gaylis, B. Germain, M. Guttierrez, M. Heier, T. Johnson, M. Kaufman, R. Levin, M. Lowenstein, A. Marcadis, M. Mass, S. Matthews, H. McIlwain, J. Miller, M. Nunez, H. Offenberg, J. Popp, A. Reddy, W. Riskin, A. Rosen, Y. Sherrer, K. Stark, A. Torres; Georgia: J. Lieberman; Iowa: M. Brooks; Idaho: F. Dega, C. Scoville, C. Wiesenhutter; Illinois: F. Dietz, I. Fenton, M. Pick, R. Trapp, J. Zuzga, M. Ellman, G. Liang; Indiana: C. Arsever, R. Khairi, M. Stack, R. Fife; Kansas: N. Becker, P. Ginder, R. Lies; Louisiana: W. Eversmeyer, P. Sedrish, L. Serebro; Maine: L. Anderson, S. Block; Maryland: R. Marcus, D. McGinnis, N. Wei, T. Zizic, M. Hochberg; Massachusetts: C. Birbara, A. Dahdul, S. Helfgott, J. Hosey, S. Miller, R. Rapoport; Michigan: P. Coleman, R. Roschmann, H. Uhl, J. Taborn; Missouri: T. Weiss; Montana: S. English; Nebraska: W. Palmer, A. Weaver; Nevada: S. Miller; New Hampshire: B. Samuels, J. Trice; New Jersey: S. Golombek, H. Hassman, R. Hymowitz, C. Knee, D. Macpeek, R. Marcus, G. Rihacek, J. Rohlf, D. Worth; New Mexico: K. Bordenave; New York: P. Chatpar, M. Farber, A. Kaell, A. Porges, P. Riccardi, C. Ritchlin; North Carolina: G. Arnold, W. Chmelewski, G. Collins, W. Harperm, R. Harrell, T. Littlejohn, G. Schimizzi, R. Senter, A. Kashif; Ohio: T. Isakov, B. Long, D. Mandel, B. Rothschild, D. Schumacher, R. Sievers, S. Wolfe, K. Hackshaw, M. Hooper, R. Rothenberg; Oklahoma: C. Codding, R. Hynd, J. McKay, L. Jacobs; Pennsylvania: R. Kimelheim, A. Kivitz, W. Makarowski, G. McLaughlin, J. McMillen, R. Reese, J. Weisberg; Rhode Island: J. Scott; South Carolina: C. Barfiels, M. Brabham, K. Flint; Tennessee: C. Arkin, R. Gupta, R. Krause, H. Marker, T. Namey, L. Robinson, P. Wheeler, B. Tanner; Texas: A. Brodsky, F. Burch, W. Chase, A. Chubick, D. Halter, J. Rutstein; Utah: J. Booth; Virginia: C. Fisher, A. Goldstein; Washington: W. Eider, R. Ettlinger, R. Levy; Wisconsin: M. Pearson, G. Fiocco.
- References
References
1
Misoprostol for co-prescription with NSAIDsDrug Ther Bull 1990;28:25-26
Medline2
Laine L . Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996;6:489-504
Medline3
Wolfe MM ,Lichtenstein DR ,Singh G . Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-1899[Erratum, N Engl J Med 1999;341:548.]
Full Text | Web of Science | Medline4
Singh G ,Rosen Ramey D . NSAID induced gastrointestinal complications: the ARAMIS perspective -- 1997. J Rheumatol Suppl 1998;51:8-16
Medline5
Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology/diagnosis/management. 6th ed. Vol. 1. Philadelphia: W.B. Saunders, 1998:343-57.
6
Meade EA ,Smith WL ,DeWitt DL . Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-6614
Web of Science | Medline7
Fosslein E . Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998;28:67-81
Web of Science | Medline8
Mitchell JA ,Akarasereenont P ,Thiemermann C ,Flower RJ ,Vane JR . Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993;90:11693-11697
CrossRef | Web of Science | Medline9
Day R ,Morrison B ,Luza A , et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-1787
CrossRef | Web of Science | Medline10
Cannon GW ,Caldwell JR ,Holt P , et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978-987
CrossRef | Web of Science | Medline11
Ehrich EW ,Schnitzer TJ ,McIlwain H , et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999;26:2438-2447
Web of Science | Medline12
Simon LS ,Weaver AL ,Graham DY , et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-1928
CrossRef | Web of Science | Medline13
Laine L ,Harper S ,Simon T , et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-783
CrossRef | Web of Science | Medline14
Hawkey C ,Laine L ,Simon T , et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-377
CrossRef | Web of Science | Medline15
Emery P ,Zeidler H ,Kvien KT , et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-2111
CrossRef | Web of Science | Medline16
Pincus T ,Summey JA ,Soraci SA Jr ,Wallston KA ,Hummon NP . Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-1353
CrossRef | Web of Science | Medline17
Cox DR . Regression models and life-tables. J Stat Soc [B] 1972;34:187-22018
Cox DR . Partial likelihood. Biometrika 1975;62:269-276
CrossRef | Web of Science19
Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981.
20
Vioxx (rofecoxib tablets and oral suspension). Whitehouse Station, N.J.: Merck, 1999 (package insert).
21
Naproxen. Nutley, N.J.: Roche Laboratories, 1999 (package insert).
22
Genuine Bayer aspirin. Morristown, N.J.: Bayer Consumer Care Division, 1999 (package insert).
23
Schnitzer TJ ,Truitt K ,Fleischmann R , et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther 1999;21:1688-1702
CrossRef | Web of Science | Medline24
Silverstein FE ,Graham DY ,Senior JR , et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-249
Web of Science | Medline25
Langman MJ ,Jensen DM ,Watson DJ , et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-1933
CrossRef | Web of Science | Medline26
Silverstein FE ,Faich G ,Goldstein JL , et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study: a randomized controlled trial. JAMA 2000;284:1247-1255
CrossRef | Web of Science | Medline27
Singh G ,Ramey DR ,Morfeld D ,Shi H ,Hatoum HT ,Fries JF . Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996;156:1530-1536
CrossRef | Web of Science | Medline28
VanHecken A ,Schwartz JI ,Depre M , et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-1120
Web of Science | Medline29
Brochier ML . Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: the Flurbiprofen French Trial. Eur Heart J 1993;14:951-957
CrossRef | Web of Science | Medline30
Daniels B ,Seidenberg B . Cardiovascular safety profile of rofecoxib in controlled clinical trials. Arthritis Rheum 1999;42:Suppl:S143-S143 abstract.
Web of Science
- Citing Articles (1302)
Citing Articles
1
Jatinder Kaur, Atul Bhardwaj, Zhangjian Huang, Edward E. Knaus. (2012) N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters
CrossRef2
Helga Radner, Sofia Ramiro, Rachelle Buchbinder, Robert BM Landewé, Désirée van der Heijde, Daniel Aletaha, Helga Radner. 2012. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. .
CrossRef3
Mary-Clare Cathcart, Kenneth J. O'Byrne, John V. Reynolds, Jacintha O'Sullivan, Graham P. Pidgeon. (2012) COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1825:1, 49-63
CrossRef4
Yen-Chieh Lee, Chia-Hsuin Chang, Jou-Wei Lin, Hsi-Chieh Chen, Min-Shung Lin, Mei-Shu Lai. (2012) Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Internationaln/a-n/a
CrossRef5
Jeremy A. Rassen, Sebastian Schneeweiss. (2012) Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiology and Drug Safety 21, 41-49
CrossRef6
Philip G. Conaghan. (2011) A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International
CrossRef7
Yuji Maehata, Motohiro Esaki, Toshibumi Morishita, Shuji Kochi, Shingo Endo, Kentaro Shikata, Hiroyuki Kobayashi, Takayuki Matsumoto. (2011) Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam. Journal of Gastroenterology
CrossRef8
K Pavelka. (2011) A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. Current Medical Research and Opinion1-52
CrossRef9
Paul L. McCormack. (2011) Celecoxib. Drugs 71:18, 2457-2489
CrossRef10
Rosa Madridejos Mora. (2011) AINE y riesgo cardiovascular. Atención Primaria
CrossRef11
Nulgumnalli Manjunathaiah Raghavendra, Aitha Jyothsna, Alapati Venkateswara Rao, C.V.S. Subrahmanyam. (2011) Synthesis, pharmacological evaluation and docking studies of N-(benzo[d]thiazol-2-yl)-2-(piperazin-1-yl)acetamide analogs as COX-2 inhibitors. Bioorganic & Medicinal Chemistry Letters
CrossRef12
Joseph S. Ross, Cary P. Gross, Harlan M. Krumholz. (2011) Promoting Transparency in Pharmaceutical Industry–Sponsored Research. American Journal of Public Healthe1-e9
CrossRef13
M. Back, L. Yin, E. Ingelsson. (2011) Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. European Heart Journal
CrossRef14
Jatinder Kaur, Atul Bhardwaj, Zhangjian Huang, Edward E. Knaus. (2011) Aspirin Analogues as Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitors: Synthesis, Nitric Oxide Release, Molecular Modeling, and Biological Evaluation as Anti-Inflammatory Agents. ChemMedChemn/a-n/a
CrossRef15
S Schneeweiss, J J Gagne, R J Glynn, M Ruhl, J A Rassen. (2011) Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development. Clinical Pharmacology & Therapeutics
CrossRef16
Andrew Whelton, Allan Gibofsky. (2011) Minimizing Cardiovascular Complications During the Treatment of Osteoarthritis. American Journal of Therapeutics 18:6, 466-476
CrossRef17
Hui-Hua Chang, Emmanuelle J Meuillet. (2011) Identification and development of mPGES-1 inhibitors: where we are at?. Future Medicinal Chemistry 3:15, 1909-1934
CrossRef18
Claire Bombardier, Loren Laine, Richard Day, Christopher J. Hawkey, Marc C. Hochberg, Thomas J. Schnitzer. (2011) Rofecoxib and Clinically Significant Gastrointestinal Events. The American Journal of the Medical Sciences 342:5, 438-439
CrossRef19
Nicholas R. Ferreri, Shoujin Hao, Paulina L. Pedraza, Bruno Escalante, Carlos P. Vio. (2011) Eicosanoids and Tumor Necrosis Factor-alpha in the kidney. Prostaglandins & Other Lipid Mediators
CrossRef20
Sung-Yeol Lee, Hyoung-Keun Kwon, Sun-Mee Lee. (2011) SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease: First therapeutic application for the treatment of osteoarthritis. Archives of Pharmacal Research 34:11, 1773-1777
CrossRef21
Luigi Piero Stasi, Kanji Bhimani, Manuela Borriello, Luca Canciani, Gianfranco Caselli, Fabrizio Colace, Cristian Ferioli, Mehul Kaswala, Laura Mennuni, Tiziana Piepoli, Sabrina Pucci, Matteo Salvi, Vikas Shirsath, Tiziano Zanelli, Silvia Zerbi. (2011) Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor. Bioorganic & Medicinal Chemistry Letters 21:21, 6336-6340
CrossRef22
Mariangela Biava, Giulio Cesare Porretta, Giovanna Poce, Claudio Battilocchio, Salvatore Alfonso, Michele Rovini, Salvatore Valenti, Gianluca Giorgi, Vincenzo Calderone, Alma Martelli, Lara Testai, Lidia Sautebin, Antonietta Rossi, Giuseppina Papa, Carla Ghelardini, Lorenzo Di Cesare Mannelli, Antonio Giordani, Paola Anzellotti, Annalisa Bruno, Paola Patrignani, Maurizio Anzini. (2011) Novel Analgesic/Anti-Inflammatory Agents: Diarylpyrrole Acetic Esters Endowed with Nitric Oxide Releasing Properties. Journal of Medicinal Chemistry111031140354009
CrossRef23
Jonathan A.L. Gelfond, Elizabeth Heitman, Brad H. Pollock, Craig M. Klugman. (2011) Principles for the ethical analysis of clinical and translational research. Statistics in Medicine 30:23, 2785-2792
CrossRef24
Elmar Friderichs, Thomas Christoph, Helmut Buschmann. 2011. Analgesics and Antipyretics, 2. Nonsteroidal Anti-inflammatory Drugs. .
CrossRef25
Claudia Bocca, Francesca Bozzo, Monica Ievolella, Antonella Miglietta. (2011) A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth. Molecular and Cellular Biochemistry
CrossRef26
Y Sasaki, D Kamei, Y Ishikawa, T Ishii, S Uematsu, S Akira, M Murakami, S Hara. (2011) Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene
CrossRef27
Jonathan L Marks, Alexandra N Colebatch, Rachelle Buchbinder, Christopher J Edwards, Jonathan L Marks. 2011. Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity. .
CrossRef28
Iris Lee, Byron Cryer. (2011) Epidemiology and Role of Nonsteroidal Antiinflammatory Drugs in Causing Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America 21:4, 597-612
CrossRef29
Carlos Sostres, Angel Lanas. (2011) Epidemiology and Demographics of Upper Gastrointestinal Bleeding: Prevalence, Incidence, and Mortality. Gastrointestinal Endoscopy Clinics of North America 21:4, 567-581
CrossRef30
David Y. Graham, Nicholas P. Jewell, Francis K.L. Chan. (2011) Rofecoxib and Clinically Significant Upper and Lower Gastrointestinal Events Revisited Based on Documents From Recent Litigation. The American Journal of the Medical Sciences1
CrossRef31
Warwick B Dunn, Royston Goodacre, Ludwig Neyses, Mamas Mamas. (2011) Integration of metabolomics in heart disease and diabetes research: current achievements and future outlook. Bioanalysis 3:19, 2205-2222
CrossRef32
J. L. Goldstein, F. K. L. Chan, A. Lanas, C. M. Wilcox, D. Peura, G. H. Sands, M. F. Berger, H. Nguyen, J. M. Scheiman. (2011) Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials. Alimentary Pharmacology & Therapeutics 34:7, 808-816
CrossRef33
Junko Imanishi, Yoshiaki Morita, Eiji Yoshimi, Kanae Kuroda, Tomoko Masunaga, Kaoru Yamagami, Masako Kuno, Emi Hamachi, Satoshi Aoki, Fumie Takahashi, Katsuya Nakamura, Susumu Miyata, Yoshitaka Ohkubo, Seitaro Mutoh. (2011) Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor. Biochemical Pharmacology 82:7, 746-754
CrossRef34
Cristina Varas-Lorenzo, Nuria Riera-Guardia, Brian Calingaert, Jordi Castellsague, Antoine Pariente, Lorenza Scotti, Miriam Sturkenboom, Susana Perez-Gutthann. (2011) Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef35
Rosa Calvello, Maria Antonietta Panaro, Maria Luigia Carbone, Antonia Cianciulli, Maria Grazia Perrone, Paola Vitale, Paola Malerba, Antonio Scilimati. (2011) Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells. Pharmacological Research
CrossRef36
Dilek SOLMAZ, Ismail SARI, Gercek CAN, Servet AKAR, Isin CEYLAN, Mustafa SECIL, Nurullah AKKOC. (2011) The effect of non-steroidal anti-inflammatory drugs on the endothelial function of patients with osteoarthritis in short term. International Journal of Rheumatic Diseasesno-no
CrossRef37
Jie Chen, John A Rizzo. (2011) Who Pays for Drug Quality?. Eastern Economic Journal 36:2, 239-254
CrossRef38
Louis M. Chu, Michael P. Robich, Antonio Lassaletta, Thomas Burgess, Yuhong Liu, Nicholas Sellke, Frank W. Sellke. (2011) Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition. The Journal of Thoracic and Cardiovascular Surgery 142:3, 675-681
CrossRef39
William B. White, Christina Cruz. (2011) Impact of NSAIDs on cardiovascular risk and hypertension. Italian Journal of Medicine 5:3, 175-183
CrossRef40
Amjad M. Qandil, Farah H. El Mohtadi, Bassam M. Tashtoush. (2011) Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. International Journal of Pharmaceutics 416:1, 85-96
CrossRef41
Louis M. Chu, Michael P. Robich, Antonio D. Lassaletta, Jun Feng, Shu Hua Xu, Robert Heinl, Yuhong Liu, Eric Sellke, Frank W. Sellke. (2011) High-fat diet alters prostanoid balance and perfusion in ischemic myocardium of naproxen-treated swine. Surgery 150:3, 490-496
CrossRef42
Paola Patrignani, Stefania Tacconelli, Annalisa Bruno, Carlos Sostres, Angel Lanas. (2011) Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Review of Clinical Pharmacology 4:5, 605-621
CrossRef43
Guy Sisson, Ingvar Bjarnason. (2011) Serious upper gastrointestinal complications of NSAIDs and COX-2 selective agents. Inflammopharmacology 19:4, 183-186
CrossRef44
Jeffrey R. Curtis, Shih-Yin Chen, Winifred Werther, Ani John, David A. Johnson. (2011) Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef45
Liana Guimarães Sachett, Hugo Verli. (2011) Dynamics of different arachidonic acid orientations bound to prostaglandin endoperoxide synthases. European Journal of Medicinal Chemistry
CrossRef46
Xiangwei Wu, Sherri Patterson, Ernest Hawk. (2011) Chemoprevention – History and general principles. Best Practice & Research Clinical Gastroenterology 25:4-5, 445-459
CrossRef47
Jorge Mimoso. (2011) Comentário a «Duração do tratamento com anti-inflamatórios não esteroides e impacto no risco de morte e recorrência de enfarte do miocárdio em pacientes com enfarte do miocárdio prévio. Um estudo de coorte Nacional». Revista Portuguesa de Cardiologia 30:7-8, 689-690
CrossRef48
Jorge Mimoso. (2011) Comment on «Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction. A Nationwide Cohort Study». Revista Portuguesa de Cardiologia (English Edition) 30:7-8, 689-690
CrossRef49
Anthony A. Bavry, Asma Khaliq, Yan Gong, Eileen M. Handberg, Rhonda M. Cooper-DeHoff, Carl J. Pepine. (2011) Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease. The American Journal of Medicine 124:7, 614-620
CrossRef50
Jennifer Prah Ruger. (2011) Shared Health Governance. The American Journal of Bioethics 11:7, 32-45
CrossRef51
Stanley Snowden, Robert Nelson. (2011) The Effects of Nonsteroidal Anti-Inflammatory Drugs on Blood Pressure in Hypertensive Patients. Cardiology in Review 19:4, 184-191
CrossRef52
Chia-Hsuin Chang, Hsi-Chieh Chen, Jou-Wei Lin, Chuei-Wen Kuo, Wen-Yi Shau, Mei-Shu Lai. (2011) Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiology and Drug Safety 20:7, 763-771
CrossRef53
Khaled R.A. Abdellatif, Zhangjian Huang, Morshed A. Chowdhury, Susan Kaufman, Edward E. Knaus. (2011) A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: Synthesis, biological evaluation and nitric oxide release studies. Bioorganic & Medicinal Chemistry Letters 21:13, 3951-3956
CrossRef54
L. PELLIGAND, J. N. KING, P. L. TOUTAIN, J. ELLIOTT, P. LEES. (2011) Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. Journal of Veterinary Pharmacology and Therapeuticsno-no
CrossRef55
J. A. Rassen, R. J. Glynn, M. A. Brookhart, S. Schneeweiss. (2011) Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples. American Journal of Epidemiology 173:12, 1404-1413
CrossRef56
Srilatha Swami, Aruna V. Krishnan, David Feldman. (2011) Vitamin D metabolism and action in the prostate: Implications for health and disease. Molecular and Cellular Endocrinology
CrossRef57
Howard S. Smith. (2011) Perioperative Intravenous Acetaminophen and NSAIDs. Pain Medicine 12:6, 961-981
CrossRef58
Naoki Yamakawa, Shintaro Suemasu, Masaaki Matoyama, Ken-ichiro Tanaka, Takashi Katsu, Keishi Miyata, Yoshinari Okamoto, Masami Otsuka, Tohru Mizushima. (2011) Synthesis and biological evaluation of loxoprofen derivatives. Bioorganic & Medicinal Chemistry 19:11, 3299-3311
CrossRef59
Stephen J. Kerr, Debra S. Rowett, Geoffrey P. Sayer, Susan D. Whicker, Deborah C. Saltman, Andrea Mant. (2011) All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study. British Journal of Clinical Pharmacology 71:6, 936-942
CrossRef60
Marc C. Hochberg, John G. Fort, Ola Svensson, Clara Hwang, Mark Sostek. (2011) Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Current Medical Research and Opinion 27:6, 1243-1253
CrossRef61
F Salvo, A Fourrier-Réglat, F Bazin, P Robinson, N Riera-Guardia, M Haag, A P Caputi, N Moore, M C Sturkenboom, A Pariente. (2011) Cardiovascular and Gastrointestinal Safety of NSAIDs: A Systematic Review of Meta-Analyses of Randomized Clinical Trials. Clinical Pharmacology & Therapeutics 89:6, 855-866
CrossRef62
Paul W. Elsinghorst, Martina Kinzig, Michael Rodamer, Ulrike Holzgrabe, Fritz Sörgel. (2011) An LC–MS/MS procedure for the quantification of naproxen in human plasma: Development, validation, comparison with other methods, and application to a pharmacokinetic study. Journal of Chromatography B 879:19, 1686-1696
CrossRef63
Sara Biere-Rafi, Marcello Di Nisio, Victor Gerdes, Ettore Porreca, Patrick Souverein, Anthonius Boer, Harry Büller, Pieter Kamphuisen. (2011) Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiology and Drug Safety 20:6, 635-642
CrossRef64
Caroline Ashley. (2011) Drugs and renal insufficiency. Medicine 39:6, 353-355
CrossRef65
Zulkhurnain Utar, Mohamed Isa Abdul Majid, Mohd Ilham Adenan, Mohd Fadzly Amar Jamil, Tan Mei Lan. (2011) Mitragynine inhibits the COX-2 mRNA expression and prostaglandin E2 production induced by lipopolysaccharide in RAW264.7 macrophage cells. Journal of Ethnopharmacology 136:1, 75-82
CrossRef66
Olivier Barthélémy, Tobias Limbourg, Jean Philippe Collet, Farzin Beygui, Johanne Silvain, Anne Bellemain-Appaix, Guillaume Cayla, Thomas Chastre, Iris Baumgartner, Joachim Röther, Uwe Zeymer, Deepak L. Bhatt, Gabriel Steg, Gilles Montalescot. (2011) Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. International Journal of Cardiology
CrossRef67
Rui Wang, James H. Ware. (2011) Detecting Moderator Effects Using Subgroup Analyses. Prevention Science
CrossRef68
Henry Krum, Gary Swergold, Arnold Gammaitoni, Paul M. Peloso, Steven S. Smugar, Sean P. Curtis, D. Craig Brater, Hongwei Wang, Amarjot Kaur, Loren Laine, Matthew R. Weir, Christopher P. Cannon. (2011) Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs. Cardiovascular Therapeuticsno-no
CrossRef69
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, Alexander G.G. Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology 27:3, S1-S59
CrossRef70
Klefah A. K. Musa, Viraja R. Palwai, Leif A. Eriksson. (2011) New nonsteroidal anti-inflammatory molecules with reduced photodegradation side effects and enhanced COX-2 selectivity. International Journal of Quantum Chemistry 111:6, 1184-1195
CrossRef71
Mark B. Sostek, John G. Fort, Lennart Estborn, Kerstin Vikman. (2011) Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Current Medical Research and Opinion 27:4, 847-854
CrossRef72
Daniel J. Luther, Vahagn Ohanyan, Patricia E. Shamhart, Cheryl M. Hodnichak, Hamayak Sisakian, Tristan D. Booth, J. Gary Meszaros, Anupam Bishayee. (2011) Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Investigational New Drugs 29:2, 380-391
CrossRef73
Masako Isono, Tatsunori Suzuki, Kanako Hosono, Izumi Hayashi, Hiroyuki Sakagami, Satoshi Uematsu, Shizuo Akira, Yves A. DeClerck, Hirotugu Okamoto, Masataka Majima. (2011) Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. Life Sciences 88:15-16, 693-700
CrossRef74
Chi-Yang Chang, Ming-Shiang Wu, Ching-Tai Lee, Jau-Chung Hwang, Chi-Ming Tai, Daw-Shyong Perng, Chih-Wen Lin, Wen-Lun Wang, Jung-Der Wang, Jaw-Town Lin. (2011) Prospective Survey for the Etiology and Outcome of Peptic Ulcer Bleeding: A Community Based Study in Southern Taiwan. Journal of the Formosan Medical Association 110:4, 223-229
CrossRef75
Chin-wern Chan, Philip Peng. (2011) Failed Back Surgery Syndrome. Pain Medicine 12:4, 577-606
CrossRef76
Jeong-Eun Huh, Jang-Mu Hong, Yong-Hyeon Baek, Jae-Dong Lee, Do-Young Choi, Dong-Suk Park. (2011) Anti-inflammatory and anti-nociceptive effect of Betula platyphylla var. japonica in human interleukin-1β-stimulated fibroblast-like synoviocytes and in experimental animal models. Journal of Ethnopharmacology 135:1, 126-134
CrossRef77
Mohammed Naseer A. Khan, Yong Sup Lee. (2011) Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy. Medicinal Research Reviews 31:2, 161-201
CrossRef78
Alexander Lyon, Julien C. Mirivel. (2011) Reconstructing Merck's Practical Theory of Communication: The Ethics of Pharmaceutical Sales Representative–Physician Encounters. Communication Monographs 78:1, 53-72
CrossRef79
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, A. Graham Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology 27:2, 208-221
CrossRef80
Steven B. Abramson. (2011) Clinical guidelines: Expert recommendations for NSAID use: a user-friendly model?. Nature Reviews Rheumatology 7:3, 133-134
CrossRef81
Patricia McGettigan, Lisa F Lincz, John Attia, Patrick McElduff, Barrie Stokes, Linda Bissett, Roseanne Peel, Stephen Hancock, Kim Henderson, Michael Seldon, David Henry. (2011) The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene. British Journal of Clinical Pharmacologyno-no
CrossRef82
Vance W. Berger, Behrang Vali. (2011) Intent-to-Randomize Corrections for Missing Data Resulting from Run-In Selection Bias in Clinical Trials for Chronic Conditions. Journal of Biopharmaceutical Statistics 21:2, 263-270
CrossRef83
Kelly C Wade, Jonas H Ellenberg, Tilo Grosser MD, Colleen M Brensinger, Stephen E Kimmel, Sean Hennessy. (2011) Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women. Journal of Cardiovascular Pharmacology 57:2, 194-200
CrossRef84
Jason D. Burch, Julie Farand, John Colucci, Claudio Sturino, Yves Ducharme, Richard W. Friesen, Jean-François Lévesque, Sébastien Gagné, Mark Wrona, Alex G. Therien, Marie-Claude Mathieu, Danielle Denis, Erika Vigneault, Daigen Xu, Patsy Clark, Steve Rowland, Yongxin Han. (2011) Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor. Bioorganic & Medicinal Chemistry Letters 21:3, 1041-1046
CrossRef85
Sigbjørn Dimmen. (2011) Effects of cox inhibitors on bone and tendon healing. Acta Orthopaedica 82:S342, 1-22
CrossRef86
B. Cryer, X. Luo, A.R. Assaf, G. Sands, J. Mardekian. (2011) Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis. Current Medical Research and Opinion 27:2, 295-302
CrossRef87
Kamran Anwar, Iryna Voloshyna, Michael J. Littlefield, Steven E. Carsons, Peter A. Wirkowski, Nadia L. Jaber, Andrew Sohn, Sajan Eapen, Allison B. Reiss. (2011) COX-2 Inhibition and Inhibition of Cytosolic Phospholipase A2 Increase CD36 Expression and Foam Cell Formation in THP-1 Cells. Lipids 46:2, 131-142
CrossRef88
A. V. Kyriakidis, I. Perysinakis, I. Alexandris, K. Athanasiou, Ch. Papadopoulos, I. Mpesikos. (2011) Parecoxib sodium in the treatment of postoperative pain after Lichtenstein tension-free mesh inguinal hernia repair. Hernia 15:1, 59-64
CrossRef89
Jonathan L Marks, Alexandra N Colebatch, Rachelle Buchbinder, Christopher J Edwards, Jonathan L Marks. 2011. Pain management for rheumatoid arthritis and cardiovascular or renal co-morbidity. .
CrossRef90
Gudrun Stefansdottir, Marie L. De Bruin, Mirjam J. Knol, Diederick E. Grobbee, Hubert G.M. Leufkens. (2011) Randomized Controlled Trials of COX-2 Inhibitors : An Analysis of Doses Used and Trends Over Time to Investigate Implications for Comparative Safety. Drug Safety 34:9, 783
CrossRef91
Shunji Fujimori, Yoko Takahashi, Katya Gudis, Tsuguhiko Seo, Akihito Ehara, Tsuyoshi Kobayashi, Keigo Mitsui, Masaoki Yonezawa, Shu Tanaka, Atsushi Tatsuguchi, Choitsu Sakamoto. (2011) Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. Journal of Gastroenterology 46:1, 57-64
CrossRef92
Jeeyoun Jung, Minhwa Park, Hye Jin Park, Sun Bo Shim, Yang Ha Cho, Jinho Kim, Ho-Sub Lee, Do Hyun Ryu, Donwoong Choi, Geum-Sook Hwang. (2011) 1H NMR-based metabolic profiling of naproxen-induced toxicity in rats. Toxicology Letters 200:1-2, 1-7
CrossRef93
Cristina Varas-Lorenzo, Nuria Riera-Guardia, Brian Calingaert, Jordi Castellsague, Antoine Pariente, Lorenza Scotti, Miriam Sturkenboom, Susana Perez-Gutthann. (2011) Stroke risk and NSAIDs: a systematic review of observational studies : STROKE AND NSAIDS. Pharmacoepidemiology and Drug Safetyn/a
CrossRef94
Xin Wang, Hui Jin Tian, Hu Ke Yang, Pingping Wanyan, Ye Ji Peng. (2011) Meta-analysis : cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. European Journal of Gastroenterology & Hepatology 23:10, 876
CrossRef95
Chikara Muraki, Noritaka Ohga, Yasuhiro Hida, Hiroshi Nishihara, Yasutaka Kato, Kunihiko Tsuchiya, Kohei Matsuda, Yasunori Totsuka, Masanobu Shindoh, Kyoko Hida. (2011) Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells. International Journal of Cancern/a-n/a
CrossRef96
Ning Li, Jun-Yan Liu, Hong Qiu, Todd R. Harris, Padmini Sirish, Bruce D. Hammock, Nipavan Chiamvimonvat. (2011) Use of Metabolomic Profiling in the Study of Arachidonic Acid Metabolism in Cardiovascular Disease. Congestive Heart Failure 17:1, 42-46
CrossRef97
Sam T. Mathew, Gayathri Devi S, V. V. Prasanth, B. Vinod. (2011) Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review. ISRN Pharmacology 2011, 1-4
CrossRef98
Ananth Kadambi, Daniel L. Young, Kapil Gadkar. 2011. , 239.
CrossRef99
Michael P Robich, Louis M Chu, Thomas A Burgess, Jun Feng, Cesario Bianchi, Frank W Sellke. (2011) Effects of Selective Cyclooxygenase-2 and Nonselective Cyclooxygenase Inhibition on Myocardial Function and Perfusion. Journal of Cardiovascular Pharmacology 57:1, 122-130
CrossRef100
Margaret T Whitstock, Christopher M Pearce, Stephen C Ridout, Elizabeth J Eckermann. (2011) Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process. BMC Public Health 11:1, 361
CrossRef101
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi, Paolo Verdecchia. (2011) Emerging therapies in the management of hypertensive patients with osteoarthritis. Clinical Investigation 1:1, 125-136
CrossRef102
David M Goldberg. (2011) Science at the Crossroads: Fact or Fiction?. Journal of Medical Biochemistry 30:2, 79-92
CrossRef103
AC Anand. (2011) Professional conferences, unprofessional conduct. Medical Journal Armed Forces India 67:1, 2-6
CrossRef104
Mary-Clare Cathcart, Kathy Gately, Robert Cummins, Elaine Kay, Kenneth J O'Byrne, Graham P Pidgeon. (2011) Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Molecular Cancer 10:1, 25
CrossRef105
Michael C. Owen, Milán Szó´ri, Balázs Jojárt, Bela Viskolcz, Imre G. Csizmadia. (2011) Conformational and thermodynamic analysis of the COXIB scaffold using quantum chemical calculations. International Journal of Quantum Chemistryn/a-n/a
CrossRef106
Michele Tony, Monika Wagner, Hanane Khoury, Donna Rindress, Tina Papastavros, Paul Oh, Mireille M Goetghebeur. (2011) Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Services Research 11:1, 329
CrossRef107
Aruna V. Krishnan, David Feldman. 2011. Vitamin D and Prostate Cancer. , 1675-1709.
CrossRef108
Nicholas F. Marko, Robert J. Weil. (2010) The Role of Observational Investigations in Comparative Effectiveness Research. Value in Health 13:8, 989-997
CrossRef109
Divij Mehta, DK Bhargava. (2010) Non-steroidal Anti Inflammatory Drugs and Gastrointestinal Toxicity. Apollo Medicine 7:4, 251-262
CrossRef110
Nista Ingale, Veeresh Maddi, Mahesh Palkar, Pradeepkumar Ronad, Shivalingrao Mamledesai, A. H. M. Vishwanathswamy, Darbhamulla Satyanarayana. (2010) Synthesis and evaluation of anti-inflammatory and analgesic activity of 3-[(5-substituted-1,3,4-oxadiazol-2-yl-thio)acetyl]-2H-chromen-2-ones. Medicinal Chemistry Research
CrossRef111
Michael P. Robich, Louis M. Chu, Jun Feng, Thomas A. Burgess, Roger J. Laham, Cesario Bianchi, Frank W. Sellke. (2010) Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium. The Journal of Thoracic and Cardiovascular Surgery 140:5, 1143-1152
CrossRef112
Matt Koehler. (2010) Letters. Canadian Pharmacists Journal 143:6, 260-260
CrossRef113
Conan MacDougall, Tamar Udkow, B. Joseph Guglielmo, Eric Vittinghoff, Jeffrey Martin. (2010) National estimates and predictors of prescription medication sample use in the United States, 1999-2005. Journal of the American Pharmacists Association 50:6, 677-685
CrossRef114
Larry D. Lynd, Carlo A. Marra, Mehdi Najafzadeh, Mohsen Sadatsafavi. (2010) A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework. Pharmacoepidemiology and Drug Safety 19:11, 1172-1180
CrossRef115
L. Laine, S. P. Curtis, B. Cryer, A. Kaur, C. P. Cannon. (2010) Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Alimentary Pharmacology & Therapeutics 32:10, 1240-1248
CrossRef116
Robert M. Levy, Alexander Khokhlov, Sergey Kopenkin, Boris Bart, Tatiana Ermolova, Raiasa Kantemirova, Vadim Mazurov, Marjorie Bell, Paul Caldron, Lakshmi Pillai, Bruce P. Burnett. (2010) Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Advances in Therapy 27:10, 731-742
CrossRef117
K. Brune. (2010) Kardiovaskuläre Komplikationen unter Zyklooxygenasehemmern. Zeitschrift für Rheumatologie 69:8, 712-718
CrossRef118
W.K. Lau, Y.M. Lau, H.Q. Zhang, S.C. Wong, Z.X. Bian. (2010) Electroacupuncture versus celecoxib for neuropathic pain in rat SNL model. Neuroscience 170:2, 655-661
CrossRef119
Dong-juan Zhang, Li-hong Chen, Ya-hua Zhang, Guang-rui Yang, Dou Dou, Yuan-sheng Gao, Xiao-yan Zhang, Xiao-mu Kong, Pan Zhao, Dan Pu, Ming-fen Wei, Matthew-D Breyer, You-fei Guan. (2010) Enhanced pressor response to acute Ang II infusion in mice lacking membrane-associated prostaglandin E2 synthase-1. Acta Pharmacologica Sinica 31:10, 1284-1292
CrossRef120
Stephen Senn. (2010) Significant errors. The Lancet 376:9750, 1390-1391
CrossRef121
Robert L. Barkin, Mihail Beckerman, Steven L. Blum, Frank M. Clark, Eun-Kyu Koh, Dickson S. Wu. (2010) Should Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) be Prescribed to the Older Adult?. Drugs & Aging 27:10, 775-789
CrossRef122
Włodzimierz Matysiak, Barbara Jodłowska-Jędrych. (2010) Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies. Protoplasma 246:1-4, 109-118
CrossRef123
J.-Y. Liu, N. Li, J. Yang, N. Li, H. Qiu, D. Ai, N. Chiamvimonvat, Y. Zhu, B. D. Hammock. (2010) Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proceedings of the National Academy of Sciences 107:39, 17017-17022
CrossRef124
Stephen A. Douglas, Giora Z. Feuerstein. 2010. The Role of Translational Medicine and Predictive Biomarkers in the Development of Novel, Innovative Treatments for the Management of Chronic Heart Failure: A Pharmaceutical Industry Perspective. .
CrossRef125
Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Peter Tugwell, George Wells. 2010. Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity. , 139-164.
CrossRef126
D. C. Montrose, K. Kadaveru, J. N. M. Ilsley, S. H. Root, T. V. Rajan, M. Ramesh, F. C. Nichols, B. T. Liang, D. Sonin, A. R. Hand, S. Zarini, R. C. Murphy, G. S. Belinsky, M. Nakanishi, D. W. Rosenberg. (2010) cPLA2 Is Protective Against COX Inhibitor-Induced Intestinal Damage. Toxicological Sciences 117:1, 122-132
CrossRef127
Matt Koehler. (2010) Who's calling the shots? The influence of pharmaceutical industry advertising on drug use. Canadian Pharmacists Journal 143:5, 249-251
CrossRef128
Alberto Pilotto, Daniele Sancarlo, Filomena Addante, Carlo Scarcelli, Marilisa Franceschi. (2010) Non-steroidal anti-inflammatory drug use in the elderly. Surgical Oncology 19:3, 167-172
CrossRef129
Carmelo Scarpignato, Richard H. Hunt. (2010) Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and Prevention. Gastroenterology Clinics of North America 39:3, 433-464
CrossRef130
Vincent E. Friedewald, Joel S. Bennett, J. Paul Christo, James L. Pool, James M. Scheiman, Lee S. Simon, Vibeke Strand, William B. White, Gary W. Williams, William C. Roberts. (2010) AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk. The American Journal of Cardiology 106:6, 873-884
CrossRef131
Khaled R.A. Abdellatif, Morshed A. Chowdhury, Carlos A. Velázquez, Zhangjian Huang, Ying Dong, Dipankar Das, Gang Yu, Mavanur R. Suresh, Edward E. Knaus. (2010) Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Synthesis, biological evaluation and nitric oxide release studies. Bioorganic & Medicinal Chemistry Letters 20:15, 4544-4549
CrossRef132
Ian G.V. James, Catherine M. O'Brien, Chris J. McDonald. (2010) A Randomized, Double-Blind, Double-Dummy Comparison of the Efficacy and Tolerability of Low-Dose Transdermal Buprenorphine (BuTrans® Seven-Day Patches) With Buprenorphine Sublingual Tablets (Temgesic®) in Patients With Osteoarthritis Pain. Journal of Pain and Symptom Management 40:2, 266-278
CrossRef133
William J. Elliott. (2010) Do the Blood Pressure Effects of Nonsteroidal Antiinflammatory Drugs Influence Cardiovascular Morbidity and Mortality?. Current Hypertension Reports 12:4, 258-266
CrossRef134
Kyriakos N. Papanicolaou, John M. Streicher, Tomo-o Ishikawa, Harvey Herschman, Yibin Wang, Kenneth Walsh. (2010) Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. Journal of Molecular and Cellular Cardiology 49:2, 196-209
CrossRef135
Hsin-Wei Kuo, Shang-Shyue Tsai, Mao-Meng Tiao, Yi-Chun Liu, I-Ming Lee, Chun-Yuh Yang. (2010) Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiology and Drug Safety 19:7, 745-751
CrossRef136
Muhammad Amer, Valeriani R. Bead, Joan Bathon, Roger S. Blumenthal, David N. Edwards. (2010) Use of Nonsteroidal Anti-Inflammatory Drugs in Patients With Cardiovascular Disease. Cardiology in Review 18:4, 204-212
CrossRef137
Francis KL Chan, Angel Lanas, James Scheiman, Manuela F Berger, Ha Nguyen, Jay L Goldstein. (2010) Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. The Lancet 376:9736, 173-179
CrossRef138
Tong J. Gan. (2010) Diclofenac: an update on its mechanism of action and safety profile. Current Medical Research and Opinion 26:7, 1715-1731
CrossRef139
John M. Streicher, Kenichiro Kamei, Tomo-o Ishikawa, Harvey Herschman, Yibin Wang. (2010) Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. Journal of Molecular and Cellular Cardiology 49:1, 88-94
CrossRef140
Peter Jones, Rain Lamdin. (2010) Oral Cyclo-Oxygenase 2 Inhibitors versus Other Oral Analgesics for Acute Soft Tissue Injury. Clinical Drug Investigation 30:7, 419-437
CrossRef141
Kuo-Wei Hsiang, Tseng-Shing Chen, Hsiao-Yi Lin, Jiing-Chyuan Luo, Ching-Liang Lu, Han-Chieh Lin, Kuei-Chuan Lee, Full-Young Chang, Shou-Dong Lee. (2010) Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan. Clinical Therapeutics 32:7, 1294-1303
CrossRef142
Ilyssa O. Gordon, Vani Konda, Amy E. Noffsinger. (2010) Drug-induced Injury of the Gastrointestinal Tract. Surgical Pathology Clinics 3:2, 361-393
CrossRef143
Maarten Boers, Peter Brooks, James F. Fries, Lee S. Simon, Vibeke Strand, Peter Tugwell. (2010) A first step to assess harm and benefit in clinical trials in one scale. Journal of Clinical Epidemiology 63:6, 627-632
CrossRef144
Cynthia L. Feucht, Dilip R. Patel. (2010) Analgesics and Anti-inflammatory Medications in Sports: Use and Abuse. Pediatric Clinics of North America 57:3, 751-774
CrossRef145
C. CAMERON, S. V. VAN ZANTEN, C. SKEDGEL, G. FLOWERDEW, P. MOAYYEDI, I. SKETRIS. (2010) Cost-utility analysis of proton pump inhibitors and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents. Alimentary Pharmacology & Therapeutics 31:12, 1354-1364
CrossRef146
Merel M. Tielemans, Ties Eikendal, Jan B.M.J. Jansen, Martijn G.H. van Oijen. (2010) Identification of NSAID Users at Risk for Gastrointestinal Complications. Drug Safety 33:6, 443-453
CrossRef147
K.M. Amin, M.M. Kamel, M.M. Anwar, M. Khedr, Y.M. Syam. (2010) Synthesis, biological evaluation and molecular docking of novel series of spiro [(2H,3H) quinazoline-2,1′- cyclohexan]-4(1H)- one derivatives as anti-inflammatory and analgesic agents. European Journal of Medicinal Chemistry 45:6, 2117-2131
CrossRef148
V. E. VALKHOFF, E. M. VAN SOEST, M. C. J. M. STURKENBOOM, E. J. KUIPERS. (2010) Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Alimentary Pharmacology & Therapeutics 31:11, 1218-1228
CrossRef149
Elvira L. Massó González, Paola Patrignani, Stefania Tacconelli, Luis A. García Rodríguez. (2010) Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis & Rheumatism 62:6, 1592-1601
CrossRef150
R. Ward. (2010) Identifying and assessing benefit-risk in primary care--a family physician's perspective. Rheumatology 49:Supplement 2, ii18-ii23
CrossRef151
T. M. MacDonald, D. Richard, K. Lheritier, G. Krammer. (2010) The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. International Journal of Clinical Practice 64:6, 746-755
CrossRef152
Mesfin Yimam, Yuan Zhao, Wenwen Ma, Qi Jia, Seon-Gil Do, Jae-Ho Shin. (2010) 90-Day oral toxicity study of UP446, a combination of defined extracts of Scutellaria baicalensis and Acacia catechu, in rats. Food and Chemical Toxicology 48:5, 1202-1209
CrossRef153
Roger Chou, Naomi Aronson, David Atkins, Afisi S. Ismaila, Pasqualina Santaguida, David H. Smith, Evelyn Whitlock, Timothy J. Wilt, David Moher. (2010) AHRQ Series Paper 4: Assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. Journal of Clinical Epidemiology 63:5, 502-512
CrossRef154
Lakshmi Pillai, Bruce P. Burnett, Robert M. Levy. (2010) GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Current Medical Research and Opinion 26:5, 1055-1063
CrossRef155
Raymond CHEUNG, Tien-Tsai CHENG, Yi DONG, Hsiao-Yi LIN, Kamchuen LAI, Chak-sing LAU, Huang FENG, Bruce PARSONS. (2010) Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. International Journal of Rheumatic Diseases 13:2, 151-157
CrossRef156
K. D. Rainsford. (2010) Cardiovascular adverse reactions from NSAIDs are more than COX-2 inhibition alone. Rheumatology 49:5, 834-836
CrossRef157
J. W. J. Bijlsma. (2010) Patient benefit-risk in arthritis--a rheumatologist's perspective. Rheumatology 49:Supplement 2, ii11-ii17
CrossRef158
Anna L. Blobaum, Lawrence J. Marnett. 2010. NSAID Action and the Foundations for Cardiovascular Toxicity. , 257-285.
CrossRef159
Asli Deniz, Asli Sade, Feride Severcan, Dilek Keskin, Aysen Tezcaner, Sreeparna Banerjee. (2010) Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics. Bioscience Reports 30:5, 365-373
CrossRef160
Antonio González-Pérez, Luis Alberto García Rodriguez. 2010. Cardiovascular Toxicities of NSAIDS: Epidemiologic Aspects. , 287-312.
CrossRef161
James M. Scheiman, Clemence E. Hindley. (2010) Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clinical Therapeutics 32:4, 667-677
CrossRef162
Warren A. Katz, Robert L. Barkin. (2010) Dilemmas in Chronic/Persistent Pain Management. Disease-a-Month 56:4, 233-250
CrossRef163
Anders W. Jørgensen, Karsten Juhl Jørgensen, Peter C. Gøtzsche. (2010) Unbalanced reporting of benefits and harms in abstracts on rofecoxib. European Journal of Clinical Pharmacology 66:4, 341-347
CrossRef164
Neena S. Abraham, Christine Hartman, Jennifer Hasche. (2010) Reduced Hospitalization Cost for Upper Gastrointestinal Events That Occur Among Elderly Veterans Who Are Gastroprotected. Clinical Gastroenterology and Hepatology 8:4, 350-356
CrossRef165
Carlos Sostres, Carla J. Gargallo, Maria T. Arroyo, Angel Lanas. (2010) Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Practice & Research Clinical Gastroenterology 24:2, 121-132
CrossRef166
Jonathan Planton, Barbara J. Edlund. (2010) Regulatory Components for Treating Persistent Pain in Long-Term Care. Journal of Gerontological Nursing 36:4, 49-56
CrossRef167
Peter Bytzer. (2010) Dyspepsia as an adverse effect of drugs. Best Practice & Research Clinical Gastroenterology 24:2, 109-120
CrossRef168
V. B. SCHMID, D. E. SPRENG, W. SEEWALD, M. JUNG, P. LEES, J. N. KING. (2010) Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog. Journal of Veterinary Pharmacology and Therapeutics 33:2, 118-131
CrossRef169
A I Vitry. (2010) Reporting of Studies on New Medicines in Major Medical Journals: A Case Study in Breast Cancer. Clinical Pharmacology & Therapeutics 87:4, 398-400
CrossRef170
John Goffin. 2010. Introduction to Clinical Trials. .
CrossRef171
Ali Miraj Khan. 2010. Phase IV and Postmarketing Clinical Trials. .
CrossRef172
Domenico D'Arca, James LeNoir, Bernadette Wildemore, Fedra Gottardo, Emma Bragantini, Dolores Shupp-Byrne, Nicola Zanesi, Matteo Fassan, Carlo M. Croce, Leonard G. Gomella, Raffaele Baffa. (2010) Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor. Urologic Oncology: Seminars and Original Investigations 28:2, 189-194
CrossRef173
P. A. KOUIDES, P. F. FOGARTY. (2010) How do we treat: upper gastrointestinal bleeding in adults with haemophilia. Haemophilia 16:2, 360-362
CrossRef174
David Laharie, Cécile Droz-Perroteau, Jacques Bénichou, Michel Amouretti, Patrick Blin, Bernard Bégaud, Estelle Guiard, Sylvie Dutoit, Stéphanie Lamarque, Yola Moride, Fanny Depont, Annie Fourrier-Réglat, Nicholas Moore. (2010) Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. British Journal of Clinical Pharmacology 69:3, 295-302
CrossRef175
Stephen J. Kim, Allan J. Flach, Lee M. Jampol. (2010) Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. Survey of Ophthalmology 55:2, 108-133
CrossRef176
Chad T. Whelan, Connie Chen, Peter Kaboli, Juned Siddique, Micah Prochaska, David O. Meltzer. (2010) Upper versus lower gastrointestinal bleeding: A direct comparison of clinical presentation, outcomes, and resource utilization. Journal of Hospital Medicine 5:3, 141-147
CrossRef177
G. Enrico Rovati, Angelo Sala, Valérie Capra, Sven-Erik Dahlén, Giancarlo Folco. (2010) Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends in Pharmacological Sciences 31:3, 102-107
CrossRef178
Eija Kalso. 2010. Introduction to Evaluation of Evidence. , 31-41.
CrossRef179
Tilo Grosser, Ying Yu, Garret A. FitzGerald. (2010) Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga. Annual Review of Medicine 61:1, 17-33
CrossRef180
Harald E. Vonkeman, Mart A.F.J. van de Laar. (2010) Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention. Seminars in Arthritis and Rheumatism 39:4, 294-312
CrossRef181
Kohei Tanaka, Yasutaka Yamamoto, Shunsuke Tsujimoto, Naonori Uozumi, Yoshihiro Kita, Akio Yoshida, Takao Shimizu, Ichiro Hisatome. (2010) The cyclooxygenase-2 selective inhibitor, etodolac, but not aspirin reduces neovascularization in a murine ischemic hind limb model. European Journal of Pharmacology 627:1-3, 223-228
CrossRef182
Jeffrey R. Curtis, Lang Chen, Leslie R. Harrold, Pongthorn Narongroeknawin, George Reed, Daniel H. Solomon. (2010) Physician preference motivates the use of antiâtumor necrosis factor therapy independent of clinical disease activity. Arthritis Care & Research 62:1, 101-107
CrossRef183
Daisuke Kamei, Makoto Murakami, Yuka Sasaki, Yoshihito Nakatani, Masataka Majima, Yukio Ishikawa, Toshiharu Ishii, Satoshi Uematsu, Shizuo Akira, Shuntaro Hara, Ichiro Kudo. (2010) Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochemical Journal 425:2, 361-371
CrossRef184
Gerard Thiéfin, Thierry Schaeverbeke, Philippe Barthélémy, Christine Soufflet, René-Marc Flipo. (2010) Upper gastrointestinal symptoms in patients treated with nonsteroidal anti-inflammatory drugs: prevalence and impact – the COMPLAINS study. European Journal of Gastroenterology & Hepatology 22:1, 81-87
CrossRef185
Bum-Kee Hong. (2010) Cardiovascular Safety of Celecoxib on Top of Dual Antiplatelet Therapy. Korean Circulation Journal 40:7, 306
CrossRef186
DA Vásquez-Bahena, UE Salazar-Morales, MI Ortiz, G Castañeda-Hernández, IF Trocóniz. (2010) Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats. British Journal of Pharmacology 159:1, 176-187
CrossRef187
Marc Bardou, Alan N. Barkun. (2010) Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: From risk factor identification to risk factor intervention. Joint Bone Spine 77:1, 6-12
CrossRef188
Hyoung-Woo Bai, Bao Ting Zhu. (2010) Myricetin and quercetin are naturally occurring co-substrates of cyclooxygenases in vivo. Prostaglandins, Leukotrienes and Essential Fatty Acids 82:1, 45-50
CrossRef189
Hyung Seok Nam, Gwang Ha Kim. (2010) Risk Factors of Peptic Ulcer Disease in Korea. The Korean Journal of Gastroenterology 56:4, 268
CrossRef190
Naoki Yamakawa, Shintaro Suemasu, Ayumi Kimoto, Yasuhiro Arai, Tomoaki Ishihara, Kazumi Yokomizo, Yoshinari Okamoto, Masami Otsuka, Ken-ichiro Tanaka, Tohru Mizushima. (2010) Low Direct Cytotoxicity of Loxoprofen on Gastric Mucosal Cells. Biological & Pharmaceutical Bulletin 33:3, 398-403
CrossRef191
Clara C Chan, Christopher M Reid, Tai-Juan Aw, Danny Liew, Steven Joseph Haas, Henry Krum. (2009) Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. Journal of Hypertension 27:12, 2332-2341
CrossRef192
Sebastian Schneeweiss, Robert J. Glynn, Jerry Avorn, Muhammad Mamdani, Helen Mogun, Daniel H. Solomon. (2009) NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiology and Drug Safety 18:12, 1134-1142
CrossRef193
(2009) Guidelines or external regulation?. Internal Medicine Journal 39:12, 789-791
CrossRef194
K. D. Rainsford. (2009) Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 17:6, 275-342
CrossRef195
Jordi Castellsague, Crystal N Holick, Clorinda C Hoffman, Victoria Gimeno, Mary-Rose Stang, Susana Perez-Gutthann. (2009) Risk of Upper Gastrointestinal Complications Associated with Cyclooxygenase-2 Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Pharmacotherapy 29:12, 1397-1407
CrossRef196
Stephen Senn, Steven Julious. (2009) Measurement in clinical trials: A neglected issue for statisticians?. Statistics in Medicine 28:26, 3189-3209
CrossRef197
Dongmei Wu, Detlev Mennerich, Kirsten Arndt, Kenji Sugiyama, Naoko Ozaki, Karoline Schwarz, Jianqin Wei, Heng Wu, Nanette H. Bishopric, Henri Doods. (2009) Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice. Prostaglandins & Other Lipid Mediators 90:1-2, 21-25
CrossRef198
Christianne L. Roumie, Neesha N. Choma, Lisa Kaltenbach, Edward F. Mitchel, Jr, Patrick G. Arbogast, Marie R. Griffin. (2009) Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiology and Drug Safety 18:11, 1053-1063
CrossRef199
Andrew Moore, Ingvar Bjarnason, Byron Cryer, Luis Garcia–Rodriguez, Larry Goldkind, Angel Lanas, Lee Simon. (2009) Evidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm. Clinical Gastroenterology and Hepatology 7:11, 1156-1163
CrossRef200
Benedict W. Wheeler, Chris Metcalfe, David Gunnell, Peter Stephens, Richard M. Martin. (2009) Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. British Journal of Clinical Pharmacology 68:5, 752-764
CrossRef201
Louise K. Brennan, Brian H. Harte, Desmond J. Fitzgerald, Connail R. McCrory. (2009) Surgery Induces Cyclooxygenase-2 Expression in the Rat Cervical Spinal Cord. Regional Anesthesia and Pain Medicine 34:6, 549-552
CrossRef202
Cristina Varas-Lorenzo, Jordi Castellsague, Mary Rose Stang, Susana Perez-Gutthann, Jaume Aguado, Luis Alberto García Rodriguez. (2009) The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiology and Drug Safety 18:11, 1016-1025
CrossRef203
Michael Schiff, Marc C. Hochberg, John Oldenhof, Kay Brune. (2009) Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Current Medical Research and Opinion 25:10, 2471-2477
CrossRef204
Maneesh Gupta, Glenn M. Eisen. (2009) NSAIDs and the gastrointestinal tract. Current Gastroenterology Reports 11:5, 345-353
CrossRef205
Rachid Zagani, Nadim Hamzaoui, Wulfran Cacheux, Aurélien de Reyniès, Benoît Terris, Stanislas Chaussade, Béatrice Romagnolo, Christine Perret, Dominique Lamarque. (2009) Cyclooxygenase-2 Inhibitors Down-regulate Osteopontin and Nr4a2—New Therapeutic Targets for Colorectal Cancers. Gastroenterology 137:4, 1358-1366.e3
CrossRef206
James M. Ritter, Idris Harding, John B. Warren. (2009) Precaution, cyclooxygenase inhibition, and cardiovascular risk. Trends in Pharmacological Sciences 30:10, 503-508
CrossRef207
Silvio Garattini, Vittorio Bertele’. (2009) Ethics in clinical research. Journal of Hepatology 51:4, 792-797
CrossRef208
Donato Santovito, Andrea Mezzetti, Francesco Cipollone. (2009) Cyclooxygenase and prostaglandin synthases: roles in plaque stability and instability in humans. Current Opinion in Lipidology 20:5, 402-408
CrossRef209
Dong-Suk Park, Jeung-Eun Huh, Yong-Hyeon Baek. (2009) Therapeutic effect of Aralia cordata extracts on cartilage protection in collagenase-induced inflammatory arthritis rabbit model. Journal of Ethnopharmacology 125:2, 207-217
CrossRef210
Cécile Courivaud, Jamal Bamoulid, Pierre Tiberghien, Philippe Saas, Jean-Marc Chalopin, Didier Ducloux, Christophe Legendre, Eric Thervet. (2009) G-765C COX-2 Gene Promoter Polymorphism and Risk of Atherosclerosis After Kidney Transplantation. Transplantation 88:6, 851-852
CrossRef211
D. R. McArthur, E. Leung, A. Morris, N. Williams. (2009) COX-2 expression is unexpectedly high in viable colorectal mucosal cells: is there life for chemoprophylaxis after VICTOR?. Colorectal Disease 11:7, 775-782
CrossRef212
Ya-shuang Zhao, Sui Zhu, Xiang-wei Li, Fan Wang, Fu-lan Hu, Dan-dan Li, Wen-cui Zhang, Xia Li. (2009) Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Research and Treatment 117:1, 141-150
CrossRef213
Chad T. Whelan, Peter Kaboli, Qi Zhang, Juned Siddique, Siqin Ye, David O. Meltzer. (2009) Upper gastrointestinal hemorrhage: Have new therapeutics made a difference?. Journal of Hospital Medicine 4:7, E6-E10
CrossRef214
Lisa Hill, Stephan A Schug. (2009) Recent advances in the pharmaceutical management of pain. Expert Review of Clinical Pharmacology 2:5, 543-557
CrossRef215
W. L. Lanier. (2009) Bidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?. Mayo Clinic Proceedings 84:9, 771-775
CrossRef216
Aurora Flórez, Joaquín de Haro, Esther Martínez, César Varela, Silvia Bleda, Francisco Acín. (2009) La inhibición selectiva de la ciclooxigenasa-2 mejora la disfunción endotelial y disminuye el estado inflamatorio en pacientes claudicantes. Revista Española de Cardiología 62:8, 851-857
CrossRef217
Angel Lanas. (2009) Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase Inhibition in the Gastrointestinal Tract: A Trip From Peptic Ulcer to Colon Cancer. The American Journal of the Medical Sciences 338:2, 96-106
CrossRef218
Denis M. McCarthy. (2009) GI bleeding: problems that persist. Gastrointestinal Endoscopy 70:2, 225-228
CrossRef219
Filippo Crea, Simona Giubilato. (2009) La dolorosa lección de los fármacos analgésicos: no infravalorar nunca la complejidad de los sistemas biológicos. Revista Española de Cardiología 62:8, 839-842
CrossRef220
Ganne S Umamaheswara Rao, Adrian W Gelb. (2009) To use or not to use: the dilemma of NSAIDs and craniotomy. European Journal of Anaesthesiology 26:8, 625-626
CrossRef221
Dongmei Wu, Detlev Mennerich, Kirsten Arndt, Kenji Sugiyama, Naoko Ozaki, Karoline Schwarz, Jianqin Wei, Heng Wu, Nanette H. Bishopric, Henri Doods. (2009) The effects of microsomal prostaglandin E synthase-1 deletion in acute cardiac ischemia in mice. Prostaglandins, Leukotrienes and Essential Fatty Acids 81:1, 31-33
CrossRef222
CJ Hawkey. (2009) NSAIDs and aspirin: notorious or FAMOUS?. The Lancet 374:9684, 93-94
CrossRef223
Richard D. Wilson. (2009) Analgesic Prescribing for Musculoskeletal Complaints in the Ambulatory Care Setting After the Introduction and Withdrawal of Cyclooxygenase-2 Inhibitors. Archives of Physical Medicine and Rehabilitation 90:7, 1147-1151
CrossRef224
Raymond Tang, Holly Evans, Alan Chaput, Christopher Kim. (2009) Multimodal Analgesia for Hip Arthroplasty. Orthopedic Clinics of North America 40:3, 377-387
CrossRef225
Y. YU, E. RICCIOTTI, T. GROSSER, G. A. FITZGERALD. (2009) The translational therapeutics of prostaglandin inhibition in atherothrombosis. Journal of Thrombosis and Haemostasis 7, 222-226
CrossRef226
Gaurav Arora, Gurkirpal Singh, George Triadafilopoulos. (2009) Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions for Clinical Practice. Clinical Gastroenterology and Hepatology 7:7, 725-735.e4
CrossRef227
Shunji Fujimori, Tsuguhiko Seo, Katya Gudis, Akihito Ehara, Tsuyoshi Kobayashi, Keigo Mitsui, Masaoki Yonezawa, Shu Tanaka, Atsushi Tatsuguchi, Choitsu Sakamoto. (2009) Prevention of nonsteroidal anti-inflammatory drug–induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointestinal Endoscopy 69:7, 1339-1346
CrossRef228
Stefano Fiorucci. (2009) Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Ulcer: Looking to the Future. Gastroenterology Clinics of North America 38:2, 315-332
CrossRef229
James M. Scheiman. (2009) Balancing Risks and Benefits of Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology Clinics of North America 38:2, 305-314
CrossRef230
H. Krum, S. P. Curtis, A. Kaur, H. Wang, S. S. Smugar, M. R. Weir, L. Laine, D. C. Brater, C. P. Cannon. (2009) Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. European Journal of Heart Failure 11:6, 542-550
CrossRef231
Emilie Pecchi, Michel Dallaporta, André Jean, Sylvie Thirion, Jean-Denis Troadec. (2009) Prostaglandins and sickness behavior: Old story, new insights. Physiology & Behavior 97:3-4, 279-292
CrossRef232
Gunnar H Gislason, Peter R Hansen. (2009) NSAIDs in elderly patients with heart failure: stuck between a rock and a hard place?. Aging Health 5:3, 259-262
CrossRef233
C.A.C. Hyde, S. Missailidis. (2009) Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. International Immunopharmacology 9:6, 701-715
CrossRef234
Linsey McGoey. (2009) Pharmaceutical Controversies and the Performative Value of Uncertainty. Science as Culture 18:2, 151-164
CrossRef235
Jeong-Eun Huh, Yong-Hyeon Baek, Yeo-Jin Kim, Jae-Dong Lee, Do-Young Choi, Dong-Suk Park. (2009) Protective effects of butanol fraction from Betula Platyphyla var. japonica on cartilage alterations in a rabbit collagenase-induced osteoarthritis. Journal of Ethnopharmacology 123:3, 515-521
CrossRef236
Frank G. Bottone, William T. Barry. (2009) Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999–2002. Current Medical Research and Opinion 25:6, 1535-1550
CrossRef237
B. Jespersen, H. C. Thiesson, C. Henriksen, K. Therland, C. Falk, T. Poulsen, B. Fogh, K. Madsen, S. Walther, B. L. Jensen. (2009) Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. Nephrology Dialysis Transplantation 24:5, 1644-1655
CrossRef238
Michael E. Farkouh, Bruce P. Greenberg. (2009) An Evidence-Based Review of the Cardiovascular Risks of Nonsteroidal Anti-Inflammatory Drugs. The American Journal of Cardiology 103:9, 1227-1237
CrossRef239
Scott Gleim, Zsolt Kasza, Kathleen Martin, John Hwa. (2009) Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Current Atherosclerosis Reports 11:3, 227-235
CrossRef240
Salomeh Keyhani, Alex Federman. (2009) Fact or Fiction: The Need for Independent Pharmaceutical Policy Research. Journal of General Internal Medicine 24:5, 692-694
CrossRef241
L. A. GARCÍA RODRÍGUEZ, P. PATRIGNANI, A. GONZÁLEZ-PÉREZ. (2009) Risk of myocardial infarction persisting after discontinuation of non-steroidal anti-inflammatory drugs in the general population. Journal of Thrombosis and Haemostasis 7:5, 892-894
CrossRef242
Katja S. Galliard-Grigioni, Walter H. Reinhart. (2009) A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. European Journal of Pharmacology 609:1-3, 96-99
CrossRef243
Joel Katz, Ze’ev Seltzer. (2009) Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Review of Neurotherapeutics 9:5, 723-744
CrossRef244
Christine Dawczynski, Rainer Schubert, Gert Hein, Andreas Müller, Thorsten Eidner, Heinz Vogelsang, Samar Basu, Gerhard Jahreis. (2009) Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis. British Journal of Nutrition 101:10, 1517
CrossRef245
Bernardino Saccomanni. (2009) RETRACTED ARTICLE: Inflammation and shoulder pain—a perspective on rotator cuff disease, adhesive capsulitis, and osteoarthritis: conservative treatment. Zeitschrift für Kardiologie 28:5, 495-500
CrossRef246
Xin-Pu Miao, Jian-Sheng Li, Qin Ouyang, Ren-Wei Hu, Yan Zhang, Hui-Yan Li, Qin Ouyang. 2009. Selective cyclooxygenase 2 inhibitors for the treatment of rheumatological manifestations of inflammatory bowel disease. .
CrossRef247
T.N. de Boer, A.M. Huisman, A.A. Polak, A.G. Niehoff, A.C. van Rinsum, D. Saris, J.W.J. Bijlsma, F.J.P.G. Lafeber, S.C. Mastbergen. (2009) The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. Osteoarthritis and Cartilage 17:4, 482-488
CrossRef248
Qin Chen, Li Dong, Lian Wang, Lina Kang, Biao Xu. (2009) Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochemical and Biophysical Research Communications 381:2, 192-197
CrossRef249
Nayoung Kim, Chung Hyun Kim, Dong-Won Ahn, Kyoung Soo Lee, Soo-Jeong Cho, Ji Hyun Park, Mi Kyoung Lee, Joo Sung Kim, Hyun Chae Jung, In Sung Song. (2009) Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. Journal of Gastroenterology and Hepatology 24:3, 480-487
CrossRef250
SARAH E. BENSON, STUART RATCLIFFE, PETRONELLA VAN RADERS, PATRICIO G. SCHLOTTMANN, IFTY KHAN, RICHARD NEWSOM, RICHARD M. LANGFORD, DAVID G. CHARTERIS. (2009) A RANDOMIZED COMPARISON OF PARECOXIB/VALDECOXIB AND PLACEBO FOR THE PREVENTION OF CYSTOID MACULAR EDEMA AFTER SCLERAL BUCKLING SURGERY. Retina 29:3, 387-394
CrossRef251
Frank L Lanza, Francis K L Chan, Eamonn M M Quigley. (2009) Guidelines for Prevention of NSAID-Related Ulcer Complications. The American Journal of Gastroenterology 104:3, 728-738
CrossRef252
(2009) Dietary fats and inflammation: The medicinal use of fish oil. Nutrition & Dietetics 66:1, 4-6
CrossRef253
Jeong-Eun Huh, Yong-Hyeon Baek, Seong-Ryong Ryu, Jae-Dong Lee, Do-Young Choi, Dong-Suk Park. (2009) Efficacy and mechanism of action of KHBJ-9B, a new herbal medicine, and its major compound triterpenoids in human cartilage culture and in a rabbit model of collagenase-induced osteoarthritis. International Immunopharmacology 9:2, 230-240
CrossRef254
Matthias Hermann. (2009) Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Current Rheumatology Reports 11:1, 31-35
CrossRef255
Ratan Singh, Raj Kumar, D.P. Singh. (2009) Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drugs: Gastrointestinal-Sparing Potential Drugs. Journal of Medicinal Food 12:1, 208-218
CrossRef256
Helena T.J.I. De Leest, Kirsti S. Steen, Elisabeth Bloemena, Willem F. Lems, Ernst J. Kuipers, Mart A.F.J. Van de Laar, J.W.J. Bijlsma, Matthijs Janssen, Harry H.M.L. Houben, Piet J. Kostense, Maarten Boers, Ben A.C. Dijkmans. (2009) Helicobacter pylori Eradication in Patients on Long-term Treatment With NSAIDs Reduces the Severity of Gastritis. Journal of Clinical Gastroenterology 43:2, 140-146
CrossRef257
J. N. KING, J. DAWSON, R. E. ESSER, R. FUJIMOTO, E. F. KIMBLE, W. MANIARA, P. J. MARSHALL, L. O’BYRNE, E. QUADROS, P. L. TOUTAIN, P. LEES. (2009) Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. Journal of Veterinary Pharmacology and Therapeutics 32:1, 1-17
CrossRef258
EL Fosbøl, GH Gislason, S Jacobsen, F Folke, ML Hansen, TK Schramm, R Sørensen, JN Rasmussen, SS Andersen, SZ Abildstrom, J Trærup, HE Poulsen, S Rasmussen, L Køber, C Torp-Pedersen. (2009) Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort Study. Clinical Pharmacology & Therapeutics 85:2, 190-197
CrossRef259
Lawrence J. Marnett. (2009) The COXIB Experience: A Look in the Rearview Mirror. Annual Review of Pharmacology and Toxicology 49:1, 265-290
CrossRef260
M. Chandra, P.J. Kent. (2009) Cyclo-oxygenase-2 Inhibitors and Peripheral Thrombosis – A Case Report Demonstrating a Possible Adverse Effect. EJVES Extra 17:2, 14-16
CrossRef261
M. Cohen. (2009) Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care. Mayo Clinic Proceedings 84:2, 149-160
CrossRef262
B. Combe, G. Swergold, J. McLay, T. McCarthy, C. Zerbini, P. Emery, L. Connors, A. Kaur, S. Curtis, L. Laine, C. P. Cannon. (2009) Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 48:4, 425-432
CrossRef263
Stephan A. Schug, Girish P. Joshi, Frederic Camu, Sharon Pan, Raymond Cheung. (2009) Cardiovascular Safety of the Cyclooxygenase-2 Selective Inhibitors Parecoxib and Valdecoxib in the Postoperative Setting: An Analysis of Integrated Data. Anesthesia & Analgesia 108:1, 299-307
CrossRef264
Natsuko KUSUNOKI, Shinichi KAWAI. (2009) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:1, 29-34
CrossRef265
Gianfranco Nardulli, Ángel Lanas. (2009) Riesgo de hemorragia digestiva con aspirina y antiagregantes plaquetarios. Gastroenterología y Hepatología 32:1, 36-43
CrossRef266
Panagiotis G. Tsailas, George C. Babis, Konstantinos Nikolopoulos, Panayotis N. Soucacos, Dimitrios S. Korres. (2009) The Effectiveness of Two COX-2 Inhibitors in the Prophylaxis Against Heterotopic New Bone Formation: An Experimental Study in Rabbits. Journal of Surgical Research 151:1, 108-114
CrossRef267
Xin Fu, Lin Lin, Jiying Zhang, Changlong Yu. (2009) Assessment of the efficacy of joint lavage in rabbits with osteoarthritis of the Knee. Journal of Orthopaedic Research 27:1, 91-96
CrossRef268
Mitsuyoshi URASHIMA. (2009) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:3, 121S-122S
CrossRef269
Markku Kerola, Katriina Vuolteenaho, Outi Kosonen, Hannu Kankaanranta, Seppo Sarna, Eeva Moilanen. (2009) Effects of Nimesulide, Acetylsalicylic Acid, Ibuprofen and Nabumetone on Cyclooxygenase-1- and Cyclooxygenase-2-Mediated Prostanoid Production in Healthy Volunteers ex vivo. Basic & Clinical Pharmacology & Toxicology 104:1, 17-21
CrossRef270
Bhahwal Ali Shah, Ghulam Nabi Qazi, Subhash Chandra Taneja. (2009) Boswellic acids: a group of medicinally important compounds. Natural Product Reports 26:1, 72
CrossRef271
Tore K. Kvien. 2009. Nonsteroidal Anti-Inflammatory Drugs and Coxibs. , 295-299.
CrossRef272
Laurence Maiden. (2009) Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy. Journal of Gastroenterology 44:S19, 64-71
CrossRef273
Jun Haeng Lee, Yong Chan Lee, Seong Woo Jeon, Jeong Wook Kim, Sang Woo Lee, , . (2009) Guidelines of Prevention and Treatment for NSAID-related Peptic Ulcers. The Korean Journal of Gastroenterology 54:5, 309
CrossRef274
Marco Lazzaroni, Gabriele Bianchi Porro. (2009) Management of NSAID-Induced Gastrointestinal Toxicity. Drugs 69:1, 51-69
CrossRef275
Tetsuya Tanigawa, Toshio Watanabe, Kazuhide Higuchi, Kazunari Tominaga, Yasuhiro Fujiwara, Nobuhide Oshitani, Andrzej S. Tarnawski, Tetsuo Arakawa. (2009) Long-term use of nonsteroidal anti-inflammatory drugs normalizes the kinetics of gastric epithelial cells in patients with Helicobacter pylori infection via attenuation of gastric mucosal inflammation. Journal of Gastroenterology 44:S19, 8-17
CrossRef276
Dae Young Cheung, Hwoon-Yong Jung, Ho June Song, Sung Woo Jung, Hyun Chae Jung, , . (2009) Guidelines of Treatment for Non-bleeding Peptic Ulcer Disease. The Korean Journal of Gastroenterology 54:5, 285
CrossRef277
Scott S. Reuben. 2009. PERIOPERATIVE USE OF COX-2 AGENTS. , 59-72.
CrossRef278
Barry Schlansky, Joo Ha Hwang. (2009) Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. Journal of Gastroenterology 44:S19, 44-52
CrossRef279
Rhema Vaithianathan, Peter M. Hockey, Thomas J. Moore, David W. Bates. (2009) Iatrogenic Effects of COX-2 Inhibitors in the US Population. Drug Safety 32:4, 335-343
CrossRef280
Vincent Wai-Sun Wong, Francis Ka-Leung Chan. (2009) Cyclooxygenase-2 inhibitors in patients with high gastrointestinal risk: are we there yet?. Journal of Gastroenterology 44:S19, 53-56
CrossRef281
Gerardo Bori Segura, Blanca Hernández Cruz, Milena Gobbo, Ángel Lanas Arbeloa, Mario Salazar Páramo, Leobardo Terán Estrada, José Federico Díaz González, Rolando Espinosa Morales, Federico Galván Villegas, Luis Alberto García Rodríguez, José María Álvaro-Gracia Álvaro, Hilario Ávila Armengol, Loreto Carmona, Javier Rivera Redondo, Lucio Ventura Ríos. (2009) Appropriate Use of Non-steroidal Anti-inflammatory Drugs in Rheumatology: Guidelines From the Spanish Society of Rheumatology and the Mexican College of Rheumatology. Reumatolog ía Cl ínica (English Edition) 5:1, 3-12
CrossRef282
Dan M. Roden. 2009. Toxicology and Genetics of Adverse Drug Events. , 339-344.
CrossRef283
N. Foudi, L. Louedec, T. Cachina, C. Brink, X. Norel. (2008) Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. Cardiovascular Research 81:2, 269-277
CrossRef284
Neil Jobalia. (2008) The Multiply Operated Spine: Chronic Pain Medical Management. Seminars in Spine Surgery 20:4, 240-247
CrossRef285
T. A. Koncz, S. P. Lister, G. T. Makinson. (2008) Gastroprotection in patients prescribed non-selective NSAIDs, and the risk of related hospitalization. Current Medical Research and Opinion 24:12, 3405-3412
CrossRef286
Daniel Brzusek, David Petron. (2008) Treating knee osteoarthritis with intra-articular hyaluronans. Current Medical Research and Opinion 24:12, 3307-3322
CrossRef287
Loren Laine, William B. White, Alaa Rostom, Marc Hochberg. (2008) COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Seminars in Arthritis and Rheumatism 38:3, 165-187
CrossRef288
Giuseppe D'Argenio, Giovanna Mazzone, Concetta Tuccillo, Ilenia Grandone, Antonietta G. Gravina, Giulia Graziani, Vincenzo Fogliano, Marco Romano. (2008) Apple polyphenol extracts prevent aspirin-induced damage to the rat gastric mucosa. British Journal of Nutrition 100:06, 1228
CrossRef289
Arthur L Weaver. (2008) Current and Emerging Treatments for Mild/Moderate Acute Ambulatory Pain. American Journal of Therapeutics 15:Supplement 10, S12-S16
CrossRef290
Loren Laine, Sean P. Curtis, Michael Langman, Dennis M. Jensen, Byron Cryer, Amarjot Kaur, Christopher P. Cannon. (2008) Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac. Gastroenterology 135:5, 1517-1525
CrossRef291
E. Paresce, A. Murgo, L. Pisoni, O. Lucia, E. Schito, E. Valcamonica, A. Celant, A. Ferrara, D. Comi. (2008) La terapia farmacologica delle ernie discali. Archivio di Ortopedia e Reumatologia 119:2, 10-12
CrossRef292
Deepak L. Bhatt, James Scheiman, Neena S. Abraham, Elliott M. Antman, Francis K.L. Chan, Curt D. Furberg, David A. Johnson, Kenneth W. Mahaffey, Eamonn M. Quigley, Robert A. Harrington, Eric R. Bates, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, Mark A. Hlatky, Sanjay Kaul, Jonathan R. Lindner, David J. Moliterno, Debabrata Mukherjee, Richard S. Schofield, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2008) ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal of Gastroenterology 103:11, 2890-2907
CrossRef293
G. Jackson. (2008) Seeds of doubt - ADVANTAGE no one. International Journal of Clinical Practice 62:11, 1637-1637
CrossRef294
Luis Alberto García Rodríguez, Stefania Tacconelli, Paola Patrignani. (2008) Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population. Journal of the American College of Cardiology 52:20, 1628-1636
CrossRef295
Bill McCarberg, Robert L Barkin, Leslie Fish, Ronald J Kulich, Louis Kuritzky, Bruce D Nicholson, Joshua Rittenberg, Eugene Viscusi, Arthur L Weaver. (2008) Panel Discussion. American Journal of Therapeutics 15:Supplement 10, S24-S27
CrossRef296
John A Baron, Robert S Sandler, Robert S Bresalier, Angel Lanas, Dion G Morton, Robert Riddell, Erik R Iverson, David L DeMets. (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. The Lancet 372:9651, 1756-1764
CrossRef297
T.-P. van Staa, S. Rietbrock, E. Setakis, H. G. M. Leufkens. (2008) Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?. Journal of Internal Medicine 264:5, 481-492
CrossRef298
Laura T. Letendre, Ronald K. Tessman, Scott R. McClure, Valerie J. Kvaternick, James B. Fischer, Peter D. Hanson. (2008) Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses. American Journal of Veterinary Research 69:11, 1399-1405
CrossRef299
Hedi Harizi, Jean-Benoît Corcuff, Norbert Gualde. (2008) Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends in Molecular Medicine 14:10, 461-469
CrossRef300
Katja S. Galliard-Grigioni, Martin Fehr, Walter H. Reinhart. (2008) Influence of combinations of acetylsalicylic acid, acetaminophen, and diclofenac on platelet aggregation. European Journal of Pharmacology 595:1-3, 65-68
CrossRef301
W. Jaksch, C. Dejaco, M. Schirmer. (2008) 4 years after withdrawal of rofecoxib: where do we stand today?. Rheumatology International 28:12, 1187-1195
CrossRef302
V. Ramana Feeser, Jeremy R. Simon. (2008) The Ethical Assignment of Authorship in Scientific Publications: Issues and Guidelines. Academic Emergency Medicine 15:10, 963-969
CrossRef303
Deepak L. Bhatt, James Scheiman, Neena S. Abraham, Elliott M. Antman, Francis K.L. Chan, Curt D. Furberg, David A. Johnson, Kenneth W. Mahaffey, Eamonn M. Quigley, Robert A. Harrington, Eric R. Bates, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, Mark A. Hlatky, Sanjay Kaul, Jonathan R. Lindner, David J. Moliterno, Debabrata Mukherjee, Richard S. Schofield, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2008) ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology 52:18, 1502-1517
CrossRef304
Vincent E. Friedewald, Joel S. Bennett, Milton Packer, William C. Roberts, Gary W. Williams. (2008) The Editor's Roundtable: Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk. The American Journal of Cardiology 102:8, 1046-1055
CrossRef305
Erin Anne Booth, RaShonda Renee Flint, Kathryn Louise Lucas, Andrea Kathleen Knittel, Benedict R Lucchesi. (2008) Estrogen Protects the Heart From Ischemia-Reperfusion Injury via COX-2-Derived PGI2. Journal of Cardiovascular Pharmacology 52:3, 228-235
CrossRef306
Peter Ian Pillans. (2008) Clinical perspectives in drug safety and adverse drug reactions. Expert Review of Clinical Pharmacology 1:5, 695-705
CrossRef307
E. Setakis, H. G. M. Leufkens, T. P. van Staa. (2008) Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis & Rheumatism 59:8, 1105-1111
CrossRef308
Daniel H. Solomon, Robert J. Glynn, Kenneth J. Rothman, Sebastian Schneeweiss, Soko Setoguchi, Helen Mogun, Jerry Avorn, Til Stürmer. (2008) Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis & Rheumatism 59:8, 1097-1104
CrossRef309
(2008) Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: An American College of Rheumatology white paper. Arthritis & Rheumatism 59:8, 1058-1073
CrossRef310
Emil Loldrup Fosbøl, Gunnar H Gislason, Søren Jacobsen, Steen Z Abildstrom, Morten Lock Hansen, Tina Ken Schramm, Fredrik Folke, Rikke Sørensen, Jeppe N Rasmussen, Lars Køber, Mette Madsen, Christian Torp-Pedersen. (2008) The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiology and Drug Safety 17:8, 822-833
CrossRef311
F. L. LANZA, U. K. MARATHI, B. S. ANAND, L. M. LICHTENBERGER. (2008) Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Alimentary Pharmacology & Therapeutics 28:4, 431-442
CrossRef312
Gábor Lakatos, László Herszényi, Zsolt Tulassay. (2008) A COX-2-gátlók biztonságossága. Orvosi Hetilap 149:33, 1539-1547
CrossRef313
Burkhard Hinz, Kay Brune. (2008) Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends in Pharmacological Sciences 29:8, 391-397
CrossRef314
A. Sommet, S. Grolleau, H. Bagheri, M. Lapeyre-Mestre, J. L. Montastruc, . (2008) Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 September 2004?. European Journal of Clinical Pharmacology 64:8, 829-834
CrossRef315
José W. van der Hoorn, J Wouter Jukema, Marian E. Bekkers, Hans M. Princen, Stefano Corda, Jeff J. Emeis, Paul Steendijk. (2008) Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). Critical Care Medicine1
CrossRef316
W.K. Lau, W.K. Chan, J.L. Zhang, K.K.L. Yung, H.Q. Zhang. (2008) Electroacupuncture inhibits cyclooxygenase-2 up-regulation in rat spinal cord after spinal nerve ligation. Neuroscience 155:2, 463-468
CrossRef317
Loren Laine, Koji Takeuchi, Andrzej Tarnawski. (2008) Gastric Mucosal Defense and Cytoprotection: Bench to Bedside. Gastroenterology 135:1, 41-60
CrossRef318
Denis A Poddubnyy, In-Ho Song, Joachim Sieper. (2008) The safety of celecoxib in ankylosing spondylitis treatment. Expert Opinion on Drug Safety 7:4, 401-409
CrossRef319
Christopher P. Cannon, Cong Chen, Sean P. Curtis, John Viscusi, Tuli Ahmed, Peter M. DiBattiste. (2008) A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Archives of Drug Information 1:1, 4-13
CrossRef320
Greg Barron, Stephen Leider, Jennifer Stack. (2008) The effect of safe experience on a warnings’ impact: Sex, drugs, and rock-n-roll. Organizational Behavior and Human Decision Processes 106:2, 125-142
CrossRef321
Ling-dong Quan, Geoffrey M Thiele, Jun Tian, Dong Wang. (2008) The development of novel therapies for rheumatoid arthritis. Expert Opinion on Therapeutic Patents 18:7, 723-738
CrossRef322
Ángel Lanas. (2008) Introducción. Gastroenterología y Hepatología 31, 32-33
CrossRef323
Mohsin Farooq, I Haq, Amer S Qureshi. (2008) Cardiovascular risks of COX inhibition: current perspectives. Expert Opinion on Pharmacotherapy 9:8, 1311-1319
CrossRef324
Christopher M Herndon, Rob W Hutchison, Hildegarde J Berdine, Zachary A Stacy, Judy T Chen, David D Farnsworth, Devra Dang, Joli D Fermo. (2008) Management of Chronic Nonmalignant Pain with Nonsteroidal Antiinflammatory Drugs. Pharmacotherapy 28:6, 788-805
CrossRef325
Javier de Teresa Galván. (2008) Aproximación B. Evidencia de prescripción de un antiinflamatorio no esteroideo tradicional asociado a inhibidor de la bomba de protones en un paciente al que se le administra aspirina como prevención cardiovascular. Gastroenterología y Hepatología 31, 42-44
CrossRef326
Carlos Martín de Argila de Prados. (2008) Aproximación A. Evidencias a favor de la prescripción de los inhibidores selectivos de la COX-2. Gastroenterología y Hepatología 31, 34-41
CrossRef327
Ryuichi Iwakiri, Kazuma Fujimoto. (2008) Roles of NSAIDs and aspirin in bleeding peptic ulcers. Clinical Journal of Gastroenterology 1:2, 33-39
CrossRef328
Maheshwar Pauriah, Allan D. Struthers, Chim C. Lang. (2008) Biomarkers and Surrogate Endpoints in Cardiovascular Therapeutics Research: Under Scrutiny Following Results of the ENHANCE Study. Cardiovascular Therapeutics 26:2, 85-88
CrossRef329
Roger Jones, Greg Rubin, Francis Berenbaum, James Scheiman. (2008) Gastrointestinal and Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs. The American Journal of Medicine 121:6, 464-474
CrossRef330
Marianne Cunnington, David Webb, Nawab Qizilbash, David Blum, Adrian Mander, Michele Jonsson Funk, John Weil. (2008) Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiology and Drug Safety 17:6, 601-608
CrossRef331
J. J. VAN VEEN, D. C. GLEESON, M. MAKRIS. (2008) Paracetamol/acetaminophen usage in haemophilia: more caution needed?. Haemophilia 14:3, 434-435
CrossRef332
Christopher J. Hawkey, Christian Ell, Bernd Simon, Jörg Albert, Martin Keuchel, Mark McAlindon, Paul Fortun, Stefan Schumann, Wolfgang Bolten, Anthony Shonde, Jean–Louis Hugot, Vincent Yu, Udayasankar Arulmani, Gerhard Krammer, Rosemary Rebuli, Ervin Toth. (2008) Less Small-Bowel Injury With Lumiracoxib Compared With Naproxen Plus Omeprazole. Clinical Gastroenterology and Hepatology 6:5, 536-544
CrossRef333
Andrei Calin. (2008) Celecoxib and ankylosing spondylitis. Expert Review of Clinical Immunology 4:3, 339-349
CrossRef334
Sjef van der Linden. (2008) Issues in the Treatment of Ankylosing Spondylitis with Non-Steroidal Anti-Inflammatory Drugs. Wiener Medizinische Wochenschrift 158:7-8, 195-199
CrossRef335
Elliot V. Hersh, Ramesh Balasubramaniam, Andres Pinto. (2008) Pharmacologic Management of Temporomandibular Disorders. Oral and Maxillofacial Surgery Clinics of North America 20:2, 197-210
CrossRef336
Francesco Cipollone, Giancarlo Cicolini, Marco Bucci. (2008) Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectives. Pharmacology & Therapeutics 118:2, 161-180
CrossRef337
C. J. HAWKEY, W. M. WEINSTEIN, K. STRICKER, V. MURPHY, D. RICHARD, G. KRAMMER, R. REBULI. (2008) Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment - findings from the Therapeutic Arthritis Research and Gastrointestinal Eve. Alimentary Pharmacology & Therapeutics 27:9, 838-845
CrossRef338
T. P. van Staa, L. Smeeth, I. Persson, J. Parkinson, H. G. M. Leufkens. (2008) Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?. Pharmacoepidemiology and Drug Safety 17:5, 475-484
CrossRef339
S JACOB, L LAURYKLEINTOP, S LANZAJACOBY. (2008) The Select Cyclooxygenase-2 Inhibitor Celecoxib Reduced the Extent of Atherosclerosis in Apo E-/- Mice. Journal of Surgical Research 146:1, 135-142
CrossRef340
Warren A Katz, Robert L Barkin. (2008) Dilemmas in Chronic/Persistent Pain Management. American Journal of Therapeutics 15:3, 256-264
CrossRef341
Susanna M. Proudman, Leslie G. Cleland, Michael J. James. (2008) Dietary Omega-3 Fats for Treatment of Inflammatory Joint Disease: Efficacy and Utility. Rheumatic Disease Clinics of North America 34:2, 469-479
CrossRef342
Anthony Sebba. (2008) Efficacy and safety of etoricoxib in the treatment of osteoarthritis. Expert Review of Clinical Pharmacology 1:3, 345-355
CrossRef343
Marianna Alacqua, Gianluca Trifirò, Lorenzo Cavagna, Roberto Caporali, Carlo Maurizio Montecucco, Salvatore Moretti, Domenico Ugo Tari, Mariella Galdo, Achille P. Caputi, Vincenzo Arcoraci. (2008) Prescribing pattern of drugs in the treatment of osteoarthritis in italian general practice: The effect of rofecoxib withdrawal. Arthritis & Rheumatism 59:4, 568-574
CrossRef344
U. Kiltz, J. Zochling, W. E. Schmidt, J. Braun. (2008) Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know?. Rheumatology 47:9, 1342-1347
CrossRef345
Jenna G. Wooten, Anthony T. Blikslager, Kathleen A. Ryan, Steve L. Marks, J. Mac Law, B. Duncan X. Lascelles. (2008) Cyclooxygenase expression and prostanoid production in pyloric and duodenal mucosae in dogs after administration of nonsteroidal anti-inflammatory drugs. American Journal of Veterinary Research 69:4, 457-464
CrossRef346
Robert J Macfarlane, Boon Han Ng, Zakareya Gamie, Mohamed A El Masry, Stylianos Velonis, Constantin Schizas, Eleftherios Tsiridis. (2008) Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opinion on Pharmacotherapy 9:5, 767-786
CrossRef347
Gabrielle Velde, Sheilah Hogg-Johnson, Ahmed M. Bayoumi, J. David Cassidy, Pierre Côté, Eleanor Boyle, Hilary Llewellyn-Thomas, Stella Chan, Peter Subrata, Jan Lucas Hoving, Eric Hurwitz, Claire Bombardier, Murray Krahn. (2008) Identifying the Best Treatment Among Common Nonsurgical Neck Pain Treatments. European Spine Journal 17:S1, 184-191
CrossRef348
F.H. Klebl, J. Schölmerich. (2008) Future expectations in the prophylaxis of intestinal bleeding. Best Practice & Research Clinical Gastroenterology 22:2, 373-387
CrossRef349
Giorgio Talamini, Marina Tommasi, Valeria Amadei, Benedetta Pajusco, Anna Fratucello, Alessandro Lechi, Giovanna Scroccaro, Italo Vantini. (2008) Risk Factors of Peptic Ulcer in 4943 Inpatients. Journal of Clinical Gastroenterology 42:4, 373-380
CrossRef350
M.E. van Leerdam. (2008) Epidemiology of acute upper gastrointestinal bleeding. Best Practice & Research Clinical Gastroenterology 22:2, 209-224
CrossRef351
Laura E. Targownik, Colleen J. Metge, Stella Leung, Daniel G. Chateau. (2008) The Relative Efficacies of Gastroprotective Strategies in Chronic Users of Nonsteroidal Anti-inflammatory Drugs. Gastroenterology 134:4, 937-944.e1
CrossRef352
James D. Lewis, Brian L. Strom, A. Russell Localio, David C. Metz, John T. Farrar, Robert M. Weinrieb, Lisa Nessel, Colleen Brensinger, Stephen E. Kimmel. (2008) Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiology and Drug Safety 17:4, 328-335
CrossRef353
James M. Scheiman. (2008) Prevention of NSAID-induced ulcers. Current Treatment Options in Gastroenterology 11:2, 125-134
CrossRef354
Jason D. Burch, Michel Belley, Réjean Fortin, Denis Deschênes, Mario Girard, John Colucci, Julie Farand, Alex G. Therien, Marie-Claude Mathieu, Danielle Denis, Erika Vigneault, Jean-François Lévesque, Sébastien Gagné, Mark Wrona, Daigen Xu, Patsy Clark, Steve Rowland, Yongxin Han. (2008) Structure–activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP4 receptor. Bioorganic & Medicinal Chemistry Letters 18:6, 2048-2054
CrossRef355
Shaojun Shi, Ulrich Klotz. (2008) Clinical use and pharmacological properties of selective COX-2 inhibitors. European Journal of Clinical Pharmacology 64:3, 233-252
CrossRef356
Mark Greener. (2008) First do no harm. Improving drug safety through legislation and independent research. EMBO reports 9:3, 221-224
CrossRef357
Mathias B. Forrester. (2008) Impact of withdrawal from market on the pattern of cyclooxygenase-2 inhibitors reported to Texas poison control centers. Toxicological & Environmental Chemistry 90:2, 285-292
CrossRef358
Jay L. Goldstein, James Aisenberg, Salam F. Zakko, Manuela F. Berger, William E. Dodge. (2008) Endoscopic Ulcer Rates in Healthy Subjects Associated with Use of Aspirin (81 mg q.d.) Alone or Coadministered with Celecoxib or Naproxen: A randomized, 1-Week Trial. Digestive Diseases and Sciences 53:3, 647-656
CrossRef359
Takahisa Sato, Takehiko Yamaji, Hideyuki Inose, Yuko Sekino, Satoru Uchida, Shigeru Usuda, Kenji Takagishi, Kenji Shirakura, Hideomi Watanabe. (2008) Effect of a modified S-form hip brace, WISH type, for patients with painful osteoarthritis of the hip: a role in daily walking as a hip muscle exercise. Rheumatology International 28:5, 419-428
CrossRef360
Chuan-Ming Hao, Matthew D. Breyer. (2008) Physiological Regulation of Prostaglandins in the Kidney. Annual Review of Physiology 70:1, 357-377
CrossRef361
Debabrata Mukherjee. (2008) Nonsteroidal Anti-Inflammatory Drugs and the Heart: What Is the Danger?. Congestive Heart Failure 14:2, 75-82
CrossRef362
Carla R. Scanzello, Neal K. Moskowitz, Allan Gibofsky. (2008) The Post-NSAID Era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Current Rheumatology Reports 10:1, 49-56
CrossRef363
M.T. Arroyo, S. Mostacero, L. Cortés. (2008) Patología gastroduodenal causada por antiinflamatorios no esteroideos. Medicine - Programa de Formación Médica Continuada Acreditado 10:2, 95-100
CrossRef364
Cliff K. S. Ong, Robin A. Seymour. (2008) An evidence-based update of the use of analgesics in dentistry. Periodontology 2000 46:1, 143-164
CrossRef365
Shrinivas K. Kulkarni, Vijay Pal Singh. (2008) Licofelone: The answer to unmet needs in osteoarthritis therapy?. Current Rheumatology Reports 10:1, 43-48
CrossRef366
James M Brophy. (2008) Cardiovascular effects of cyclooxygenase-2 inhibitors. Current Opinion in Internal Medicine 7:1, 29-36
CrossRef367
Gabrielle van der Velde, Sheilah Hogg-Johnson, Ahmed M. Bayoumi, J David Cassidy, Pierre Côté, Eleanor Boyle, Hilary Llewellyn-Thomas, Stella Chan, Peter Subrata, Jan Lucas Hoving, Eric Hurwitz, Claire Bombardier, Murray Krahn. (2008) Identifying the Best Treatment Among Common Nonsurgical Neck Pain Treatments. Spine 33:Neck Pain Suppl, S184-S191
CrossRef368
Axel H Schönthal, Thomas C Chen, Florence M Hofman, Stan G Louie, Nicos A Petasis. (2008) Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opinion on Investigational Drugs 17:2, 197-208
CrossRef369
Silvio Garattini, Vittorio Bertele’. (2008) Do we learn the right things from clinical trials?. European Journal of Clinical Pharmacology 64:2, 115-125
CrossRef370
Margaret Ekstein, Doron Gavish, Tiberiu Ezri, Avi A Weinbroum. (2008) Monitored Anaesthesia Care in the Elderly. Drugs & Aging 25:6, 477-500
CrossRef371
Myrthe P. P. Sukel, Michiel W. van der Linden, Connie Chen, Joëlle A. Erkens, Ron M. C. Herings. (2008) Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiology and Drug Safety 17:1, 9-19
CrossRef372
Aishi Kimoto, Akiro Hanaoka, Masao Sasamata, Keiji Miyata. (2008) Pre-clinical and clinical profiles of celecoxib, a new specific cyclooxygenase-2 inhibitor. Folia Pharmacologica Japonica 131:2, 127-136
CrossRef373
G MALANGA, E WOLFF. (2008) Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics. The Spine Journal 8:1, 173-184
CrossRef374
Stefan Kaehler, Claudia Marsik, Birgit Heinisch, Christiane Thallinger, Robert Sauermann, Lili Kazemi-Shirazi, Oswald Wagner, Christian Joukhadar. (2008) S-Ibuprofen Effectively Inhibits Thromboxane B<sub>2</sub> Levels and Platelet Function in an Experimental Model of Lipopolysaccharide-Stimulated and Non-Stimulated Whole Blood. Pharmacology 81:2, 181-186
CrossRef375
Nobuo Nagai, Marc F. Hoylaerts, David J. Gallacher, Hua Rong Lu, H. Roger Lijnen. (2008) Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. Thrombosis Research 122:5, 668-673
CrossRef376
Domenico Motola, Antonio Vargiu, Roberto Leone, Anita Conforti, Ugo Moretti, Alberto Vaccheri, Giampaolo Velo, Nicola Montanaro. (2008) Influence of Regulatory Measures on the Rate of Spontaneous Adverse Drug Reaction Reporting in Italy. Drug Safety 31:7, 609-616
CrossRef377
Natalia Navas, Rocio Ureña, Luis-Fermin Capitan-Vallvey. (2008) Determination of Celecoxib, Rofecoxib, Sodium Diclofenac and Niflumic Acid in Human Serum Samples by HPLC with DAD Detection. Chromatographia 67:1-2, 55-61
CrossRef378
Silvio Garattini. (2008) Do Clinical Trials Always Benefit Patients?. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku 13:2, 95-109
CrossRef379
Shigeru Ushiyama, Tomoko Yamada, Yukiko Murakami, Sei-ichiro Kumakura, Shin-ichi Inoue, Keisuke Suzuki, Akira Nakao, Akihiro Kawara, Tomio Kimura. (2008) Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. European Journal of Pharmacology 578:1, 76-86
CrossRef380
Stefan Soltesz, Mark U Gerbershagen, Bernhard Pantke, Frank Eichler, Gerd Molter. (2008) Parecoxib versus Dipyrone (Metamizole) for Postoperative Pain??Relief after Hysterectomy. Clinical Drug Investigation 28:7, 421-428
CrossRef381
Asokumar Buvanendran, Scott S. Reuben. 2008. , 671.
CrossRef382
Chun Wei Choo. (2008) Organizational disasters: why they happen and how they may be prevented. Management Decision 46:1, 32-45
CrossRef383
(2008) CrossRef Listing of Deleted DOIs. CrossRef Listing of Deleted DOIs
CrossRef384
Miguel A. Iñiguez, Cristina Cacheiro-Llaguno, Natalia Cuesta, Manuel D. Díaz-Muñoz, Manuel Fresno. (2008) Prostanoid function and cardiovascular disease. Archives Of Physiology And Biochemistry 114:3, 201-209
CrossRef385
Elizabeth E Roughead, Emmae Ramsay, Nicole Pratt, Andrew L Gilbert. (2008) NSAID Use in Individuals at Risk of Renal Adverse Events. Drug Safety 31:11, 997-1003
CrossRef386
Ying Hong, Fran M Gengo, Michelle M Rainka, Vernice E Bates, Donald E Mager. (2008) Population Pharmacodynamic Modelling of Aspirin- and Ibuprofen-Induced Inhibition of Platelet Aggregation in Healthy Subjects. Clinical Pharmacokinetics 47:2, 129-137
CrossRef387
Michel Brazier, Patrice Fardellone, Johnny Moretto. 2008. Traitement de la polyarthrite rhumatoïde. , 367-385.
CrossRef388
Leobardo Terán Estrada. (2008) Cardiovascular Risk of Cyclooxigenase Selective Inhibitors. Reumatolog ía Cl ínica (English Edition) 4:3, 107-114
CrossRef389
Vibeke Strand. (2007) Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. The Lancet 370:9605, 2138-2151
CrossRef390
William B. White. (2007) Cardiovascular risk, hypertension, and NSAIDs. Current Pain and Headache Reports 11:6, 428-435
CrossRef391
Jennifer K. King, Bevra H. Hahn. (2007) Systemic lupus erythematosus: modern strategies for management – a moving target. Best Practice & Research Clinical Rheumatology 21:6, 971-987
CrossRef392
E Selg, C Buccellati, M Andersson, G E Rovati, M Ezinga, A Sala, A-K Larsson, E Ambrosio, L Låstbom, V Capra, B Dahlén, Ryrfeldt, G C Folco, S-E Dahlén. (2007) Antagonism of thromboxane receptors by diclofenac and lumiracoxib. British Journal of Pharmacology 152:8, 1185-1195
CrossRef393
Takashi Fujimura, Tetsuo Ohta, Katsunobu Oyama, Tomoharu Miyashita, Kochi Miwa. (2007) Cyclooxygenase-2 (COX-2) in Carcinogenesis and Selective COX-2 Inhibitors for Chemoprevention in Gastrointestinal Cancers. Journal of Gastrointestinal Cancer 38:2-4, 78-82
CrossRef394
Carla R. Scanzello, Neal K. Moskowitz, Allan Gibofsky. (2007) The post-NSAID era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Current Pain and Headache Reports 11:6, 415-422
CrossRef395
Gayle McKellar, Rajan Madhok, Gurkirpal Singh. (2007) The problem with NSAIDs: What data to believe?. Current Pain and Headache Reports 11:6, 423-427
CrossRef396
Girish P. Joshi, Ralph Gertler, Ruth Fricker. (2007) Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesthesia & Analgesia 105:6, 1793-1804
CrossRef397
Aruna V Krishnan, Jacqueline Moreno, Larisa Nonn, Srilatha Swami, Donna M Peehl, David Feldman. (2007) Calcitriol as a Chemopreventive and Therapeutic Agent in Prostate Cancer: Role of Anti-Inflammatory Activity. Journal of Bone and Mineral Research 22:S2, V74-V80
CrossRef398
John D. Bauer, Michael S. Foster, Jeffrey D. Hugdahl, Kristi L. Burns, Sheldon W. May, Stanley H. Pollock, Horace G. Cutler, Stephen J. Cutler. (2007) Synthesis and pharmacological evaluation of m-terphenyl amines as cyclooxygenase inhibitors. Medicinal Chemistry Research 16:3, 119-129
CrossRef399
S. Fiorucci, L. Santucci, E. Distrutti. (2007) NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: What lies beyond the horizon. Digestive and Liver Disease 39:12, 1043-1051
CrossRef400
Alejandro Escudero-Contreras, Janitzia Vazquez-Mellado Cervantes, Eduardo Collantes-Estevez. (2007) Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor. Future Rheumatology 2:6, 545-565
CrossRef401
J. GRAFF, C. SKARKE, U. KLINKHARDT, B. WATZER, S. HARDER, H. SEYBERTH, G. GEISSLINGER, R. M. NÜSING. (2007) Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. Journal of Thrombosis and Haemostasis 5:12, 2376-2385
CrossRef402
Kay Brune. (2007) Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Current Medical Research and Opinion 23:12, 2985-2995
CrossRef403
Samy Suissa, Edeltraut Garbe. (2007) Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages. Nature Clinical Practice Rheumatology 3:12, 725-732
CrossRef404
M MELOUN, S BORDOVSKA, L GALLA. (2007) The thermodynamic dissociation constants of four non-steroidal anti-inflammatory drugs by the least-squares nonlinear regression of multiwavelength spectrophotometric pH-titration data. Journal of Pharmaceutical and Biomedical Analysis 45:4, 552-564
CrossRef405
Susan S. Jick, James A. Kaye, Hershel Jick. (2007) Diclofenac and acute myocardial infarction in patients with no major risk factors. British Journal of Clinical Pharmacology 64:5, 662-667
CrossRef406
Alexander Lyon. (2007) “Putting Patients First”: Systematically Distorted Communication and Merck's Marketing of Vioxx. Journal of Applied Communication Research 35:4, 376-398
CrossRef407
Steven Mathis, Venkatakrishna R. Jala, Bodduluri Haribabu. (2007) Role of leukotriene B4 receptors in rheumatoid arthritis. Autoimmunity Reviews 7:1, 12-17
CrossRef408
E. RAHME, H. NEDJAR, A. BIZZI, S. MORIN. (2007) Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Alimentary Pharmacology & Therapeutics 26:10, 1387-1398
CrossRef409
Colin D Funk, Garret A FitzGerald. (2007) COX-2 Inhibitors and Cardiovascular Risk. Journal of Cardiovascular Pharmacology 50:5, 470-479
CrossRef410
Katriina Vuolteenaho, Teemu Moilanen, Eeva Moilanen. (2007) Non-Steroidal Anti-Inflammatory Drugs, Cyclooxygenase-2 and the Bone Healing Process. Basic & Clinical Pharmacology & Toxicology 0:0, 071031053307004-???
CrossRef411
Burkhard Hinz, Bertold Renner, Kay Brune. (2007) Drug Insight: cyclo-oxygenase-2 inhibitors—a critical appraisal. Nature Clinical Practice Rheumatology 3:10, 552-560
CrossRef412
Helena T.J.I. de Leest, Kirsti S.S. Steen, Willem F. Lems, Johannes W.J. Bijlsma, Mart A.F.J. van de Laar, A. Margriet Huisman, Harald E. Vonkeman, Harry H.M.L. Houben, Sylvana W. Kadir, Piet J. Kostense, Maurits W. van Tulder, Ernst J. Kuipers, Maarten Boers, Ben A.C. Dijkmans. (2007) Eradication of Helicobacter pylori Does Not Reduce the Incidence of Gastroduodenal Ulcers in Patients on Long-term NSAID Treatment: Double-Blind, Randomized, Placebo-Controlled Trial. Helicobacter 12:5, 477-485
CrossRef413
J L Wallace. (2007) Building a better aspirin: gaseous solutions to a century-old problem. British Journal of Pharmacology 152:4, 421-428
CrossRef414
Scott S Reuben. (2007) Update on the role of nonsteroidal anti-inflammatory drugs and coxibs in the management of acute pain. Current Opinion in Anaesthesiology 20:5, 440-450
CrossRef415
Jay L. Goldstein, Byron Cryer, Fouad Amer, Barbara Hunt. (2007) Celecoxib Plus Aspirin Versus Naproxen and Lansoprazole Plus Aspirin: A Randomized, Double-Blind, Endoscopic Trial. Clinical Gastroenterology and Hepatology 5:10, 1167-1174
CrossRef416
J. L. GOLDSTEIN, J. F. JOHANSON, C. J. HAWKEY, L. J. SUCHOWER, K. A. BROWN. (2007) Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole. Alimentary Pharmacology & Therapeutics 26:8, 1101-1111
CrossRef417
Patricia McGettigan, David Henry. (2007) COX-2, NSAIDs, and cardiovascular risk. Current Cardiovascular Risk Reports 1:4, 296-302
CrossRef418
Janet Woodcock, James Witter, Raymond A. Dionne. (2007) Stimulating the development of mechanism-based, individualized pain therapies. Nature Reviews Drug Discovery 6:9, 703-710
CrossRef419
George A. Gale, Kanyawim Kirtikara, Pattama Pittayakhajonwut, Somsak Sivichai, Yodhathai Thebtaranonth, Chawanee Thongpanchang, Vanicha Vichai. (2007) In search of cyclooxygenase inhibitors, anti-Mycobacterium tuberculosis and anti-malarial drugs from Thai flora and microbes. Pharmacology & Therapeutics 115:3, 307-351
CrossRef420
Alan Matsumoto, Agustin Melian, Arvind Shah, Sean P. Curtis. (2007) Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. Current Medical Research and Opinion 23:9, 2259-2268
CrossRef421
G. Jones, F. M. Cicuttini. (2007) Database research in Australia: time to dredge up some action. Internal Medicine Journal 37:9, 587-588
CrossRef422
Laurence Maiden, Bjarni Thjodleifsson, Anna Seigal, Ingvar Iain Bjarnason, David Scott, Sigurbjorn Birgisson, Ingvar Bjarnason. (2007) Long-Term Effects of Nonsteroidal Anti-Inflammatory Drugs and Cyclooxygenase-2 Selective Agents on the Small Bowel: A Cross-Sectional Capsule Enteroscopy Study. Clinical Gastroenterology and Hepatology 5:9, 1040-1045
CrossRef423
Jacek A. Kopec, Chris G. Richardson, Hilary Llewellyn-Thomas, Alice Klinkhoff, Anne Carswell, Andrew Chalmers. (2007) Probabilistic threshold technique showed that patients' preferences for specific trade-offs between pain relief and each side effect of treatment in osteoarthritis varied. Journal of Clinical Epidemiology 60:9, 929-938
CrossRef424
Richard A. Bond, Domenico Spina, Sergio Parra, Clive P. Page. (2007) Getting to the heart of asthma: Can “β blockers” be useful to treat asthma?. Pharmacology & Therapeutics 115:3, 360-374
CrossRef425
Wayne A. Ray, Cecilia P. Chung, C. Michael Stein, Walter E. Smalley, Kathi Hall, Patrick G. Arbogast, Marie R. Griffin. (2007) Risk of Peptic Ulcer Hospitalizations in Users of NSAIDs With Gastroprotective Cotherapy Versus Coxibs. Gastroenterology 133:3, 790-798
CrossRef426
M. J. James, R. J. Cook-Johnson, L. G. Cleland. (2007) Selective COX-2 Inhibitors, Eicosanoid Synthesis and Clinical Outcomes: A Case Study of System Failure. Lipids 42:9, 779-785
CrossRef427
David Feldman, Aruna Krishnan, Jacqueline Moreno, Srilatha Swami, Donna M. Peehl, Sandy Srinivas. (2007) Vitamin D Inhibition of the Prostaglandin Pathway as Therapy for Prostate Cancer. Nutrition Reviews 65, S113-S115
CrossRef428
Katerina Antoniou, Michael Malamas, Alexandros A Drosos. (2007) Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Expert Opinion on Pharmacotherapy 8:11, 1719-1732
CrossRef429
Claudia Vergelli, Maria Paola Giovannoni, Stefano Pieretti, Amalia Di Giannuario, Vittorio Dal Piaz, Pierfrancesco Biagini, Claudio Biancalani, Alessia Graziano, Nicoletta Cesari. (2007) 4-Amino-5-vinyl-3(2H)-pyridazinones and analogues as potent antinociceptive agents: Synthesis, SARs, and preliminary studies on the mechanism of action. Bioorganic & Medicinal Chemistry 15:16, 5563-5575
CrossRef430
F. Richy, V. Rabenda, A. Mawet, J.-Y. Reginster. (2007) Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative. International Journal of Clinical Practice 61:8, 1396-1406
CrossRef431
Marc P Pusztaszeri, Robert M Genta, Byron L Cryer. (2007) Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations. Nature Clinical Practice Gastroenterology & Hepatology 4:8, 442-453
CrossRef432
Jeffrey A. Kramer, John E. Sagartz, Dale L. Morris. (2007) The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nature Reviews Drug Discovery 6:8, 636-649
CrossRef433
F. Depont, A. Fourrier, Y. Merlière, C. Droz, M. Amouretti, B. Bégaud, J. Bénichou, Y. Moride, G. P. Velo, M. Sturkenboom, P. Blin, N. Moore, . (2007) Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiology and Drug Safety 16:8, 891-900
CrossRef434
Shawn X. Sun, Kwan Y. Lee, Carl T. Bertram, Jay L. Goldstein. (2007) Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization*. Current Medical Research and Opinion 23:8, 1859-1866
CrossRef435
Liliana García-Hernández, Myrna Déciga-Campos, Uriah Guevara-López, Francisco Javier López-Muñoz. (2007) Co-administration of rofecoxib and tramadol results in additive or sub-additive interaction during arthritic nociception in rat. Pharmacology Biochemistry and Behavior 87:3, 331-340
CrossRef436
R.W. Moskowitz, S.B. Abramson, F. Berenbaum, L.S. Simon, M. Hochberg. (2007) Coxibs and NSAIDs – Is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis and Cartilage 15:8, 849-856
CrossRef437
Elmar Friderichs, Thomas Christoph, Helmut Buschmann. 2007. Analgesics and Antipyretics. .
CrossRef438
Christopher J. Hawkey, Wilfred M. Weinstein, Walter Smalley, Xavier Gitton, Peter Sallstig, Kirstin Stricker, Gerhard Krammer, Bernhard Mellein, Dominik Richard, Patrice Matchaba. (2007) Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study. Gastroenterology 133:1, 57-64
CrossRef439
I. BJARNASON, C. SCARPIGNATO, K. TAKEUCHI, K. D. RAINSFORD. (2007) Determinants of the short-term gastric damage caused by NSAIDs in man. Alimentary Pharmacology & Therapeutics 26:1, 95-106
CrossRef440
Larissa Feldman, Beny Masella, Hyman Tannenbaum. (2007) A pharmacist's perspective: Proceedings from the Third Canadian Consensus Conference: An Evidence-Based Approach to Prescribing NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis. Canadian Pharmacists Journal 140:4, 244-253
CrossRef441
Scott S. Reuben, Evan F. Ekman, Derek Charron. (2007) Evaluating the Analgesic Efficacy of Administering Celecoxib as a Component of Multimodal Analgesia for Outpatient Anterior Cruciate Ligament Reconstruction Surgery. Anesthesia & Analgesia 105:1, 222-227
CrossRef442
Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Janet Joyce, Peter Tugwell, George W. Wells. (2007) Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review. Clinical Gastroenterology and Hepatology 5:7, 818-828.e5
CrossRef443
Elham Rahme, Alan N. Barkun, Youssef Toubouti, Alissa Scalera, Sophie Rochon, Jacques Lelorier. (2007) Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?. Arthritis & Rheumatism 57:5, 748-755
CrossRef444
Zuhre Tutuncu, Arthur Kavanaugh. (2007) Treatment of elderly rheumatoid arthritis. Future Rheumatology 2:3, 313-319
CrossRef445
C. J. PETERS, R. C. FITZGERALD. (2007) Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Alimentary Pharmacology & Therapeutics 25:11, 1253-1269
CrossRef446
Paul J Fortun, Christopher J Hawkey. (2007) Nonsteroidal antiinflammatory drugs and the small intestine. Current Opinion in Internal Medicine 6:3, 253-260
CrossRef447
V. KVATERNICK, M. POLLMEIER, J. FISCHER, P. D. HANSON. (2007) Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses. Journal of Veterinary Pharmacology and Therapeutics 30:3, 208-217
CrossRef448
Xiaoxia Wang, Takashi Uzu, Keiji Isshiki, Masami Kanasaki, Kunio Hirata, Mariko Soumura, Jun Nakazawa, Atsunori Kashiwagi, Kiho Takaya, Motohide Isono, Masataka Nishimura, Tsutomu Shikano, Toshiji Nishio, Kobin Tomita, Tetsuro Arimura, . (2007) Iron Status and the Use of Non-Steroidal Anti-Inflammatory Drugs in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 11:3, 215-219
CrossRef449
M. Lazzaroni, A. Battocchia, G. Bianchi Porro. (2007) COXIBs and non-selective NSAIDs in the gastroenterological setting: What should patients and physicians do?. Digestive and Liver Disease 39:6, 589-596
CrossRef450
A M Feldman, W J Koch, T L Force. (2007) Developing Strategies to Link Basic Cardiovascular Sciences with Clinical Drug Development: Another Opportunity for Translational Sciences. Clinical Pharmacology & Therapeutics 81:6, 887-892
CrossRef451
Cesare Gridelli, Ciro Gallo, Anna Ceribelli, Vittorio Gebbia, Teresa Gamucci, Fortunato Ciardiello, Francesco Carozza, Adolfo Favaretto, Bruno Daniele, Domenico Galetta, Santi Barbera, Francesco Rosetti, Antonio Rossi, Paolo Maione, Francesco Cognetti, Antonio Testa, Massimo Di Maio, Alessandro Morabito, Francesco Perrone. (2007) Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. The Lancet Oncology 8:6, 500-512
CrossRef452
C-M Hao, M D Breyer. (2007) Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney International 71:11, 1105-1115
CrossRef453
Julia Metzner, Laura Popp, Claudiu Marian, Ronald Schmidt, Christine Manderscheid, Christoph Renne, Beate Fisslthaler, Ingrid Fleming, Rudi Busse, Gerd Geisslinger, Ellen Niederberger. (2007) The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE−/− mice. Journal of Molecular Medicine 85:6, 623-633
CrossRef454
Frank Andersohn. (2007) Cerebrovascular Events After Discontinuation of Rofecoxib Treatment. Cardiovascular Drugs and Therapy 21:2, 77-79
CrossRef455
F. Depont, A. Fourrier, Y. Merlière, C. Droz, M. Amouretti, B. Bégaud, J. Bénichou, Y. Moride, P. Blin, N. Moore, . (2007) The CADEUS study: methods and logistics. Pharmacoepidemiology and Drug Safety 16:5, 571-580
CrossRef456
Andrea Morgner, Stephan Miehlke, Joachim Labenz. (2007) Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. Expert Opinion on Pharmacotherapy 8:7, 975-988
CrossRef457
Elham Rahme, Douglas J. Watson, Sheldon X. Kong, Youssef Toubouti, Jacques LeLorier. (2007) Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiology and Drug Safety 16:5, 493-503
CrossRef458
M. E. EYSTER, S. M. ASAAD, B. D. GOLD, S. E. COHN, J. J. GOEDERT, . (2007) Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs. Haemophilia 13:3, 279-286
CrossRef459
J. L. GOLDSTEIN, G. M. EISEN, B. LEWIS, I. M. GRALNEK, J. AISENBERG, P. BHADRA, M. F. BERGER. (2007) Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Alimentary Pharmacology & Therapeutics 25:10, 1211-1222
CrossRef460
Francis Ka Leung Chan, Vincent Wai Sun Wong, Bing Yee Suen, Justin Che Yuen Wu, Jessica Yuet Ling Ching, Lawrence Cheung Tsui Hung, Aric Josun Hui, Vincent King Sun Leung, Vivian Wing Yan Lee, Larry Hin Lai, Grace Lai Hung Wong, Dorothy Kai Lai Chow, Ka Fa To, Wai Keung Leung, Philip Wai Yan Chiu, Yuk Tong Lee, James Yun Wong Lau, Henry Lik Yuen Chan, Enders Kwok Wai Ng, Joseph Jao Yiu Sung. (2007) Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. The Lancet 369:9573, 1621-1626
CrossRef461
C MAN, I CHEUNG, P CAMERON, T RAINER. (2007) Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial. Annals of Emergency Medicine 49:5, 670-677
CrossRef462
Marie Hudson, Elham Rahme, Hugues Richard, Louise Pilote. (2007) Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: A class effect?. Arthritis & Rheumatism 57:3, 516-523
CrossRef463
Cara Usher, Kathleen Bennett, Mary Teeling, John Feely. (2007) Characterizing new users of NSAIDs before and after rofecoxib withdrawal. British Journal of Clinical Pharmacology 63:4, 494-497
CrossRef464
S. CHRISTENSEN, A. RIIS, M. NØRGAARD, R. W. THOMSEN, H. T. SØRENSEN. (2007) Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcer. Alimentary Pharmacology & Therapeutics 25:8, 907-912
CrossRef465
Anna Raber, Joan Heras, Joan Costa, Josep Fortea, Albert Cobos. (2007) Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. Therapeutics and Clinical Risk Management 3:2, 225-230
CrossRef466
Cristina Varas-Lorenzo, Andrew Maguire, Jordi Castellsague, Susana Perez-Gutthann. (2007) Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Pharmacoepidemiology and Drug Safety 16:4, 366-376
CrossRef467
N. S. ABRAHAM, H. B. EL-SERAG, C. HARTMAN, P. RICHARDSON, A. DESWAL. (2007) Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Alimentary Pharmacology & Therapeutics 25:8, 913-924
CrossRef468
William B. White. (2007) Cardiovascular risk, hypertension, and NSAIDs. Current Rheumatology Reports 9:1, 36-43
CrossRef469
L M Lichtenberger, J J Romero, E J Dial. (2007) Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. British Journal of Pharmacology 150:7, 913-919
CrossRef470
Wendy Rogers. (2007) A Book of Its Time. BioSocieties 2:1, 143-145
CrossRef471
Frank Ruschitzka. (2007) Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension. Current Hypertension Reports 9:1, 41-44
CrossRef472
Aruna V. Krishnan, Jacqueline Moreno, Larisa Nonn, Peter Malloy, Srilatha Swami, Lihong Peng, Donna M. Peehl, David Feldman. (2007) Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 694-702
CrossRef473
Michael Camilleri, Erin C. Dubnansky, Anil K. Rustgi. (2007) Conflicts of Interest and Disclosures in Publications. Gastroenterology 132:3, 841-847
CrossRef474
Chiara Cuccurullo, Andrea Mezzetti, Francesco Cipollone. (2007) COX-2 and the vasculature: Angel or evil?. Current Hypertension Reports 9:1, 73-80
CrossRef475
Xiao-Min Wang, Tian-Xia Wu, May Hamza, Edward S. Ramsay, Sharon M. Wahl, Raymond A. Dionne. (2007) Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain 128:1-2, 136-147
CrossRef476
Cristiana Griffoni, Enzo Spisni, Antonio Strillacci, Mattia Toni, Markus Michael Bachschmid, Vittorio Tomasi. (2007) Selective inhibition of prostacyclin synthase activity by rofecoxib. Journal of Cellular and Molecular Medicine 11:2, 327-338
CrossRef477
Michael Camilleri, Erin C. Dubnansky, Anil K. Rustgi. (2007) Conflicts of Interest and Disclosures in Publications. Clinical Gastroenterology and Hepatology 5:3, 268-273.e1
CrossRef478
N L P Barnes, F Warnberg, G Farnie, D White, W Jiang, E Anderson, N J Bundred. (2007) Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. British Journal of Cancer 96:4, 575-582
CrossRef479
Young Ho Lee, Jong Dae Ji, Gwan Gyu Song. (2007) Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatology International 27:5, 477-482
CrossRef480
A. Papadima, E. E. Lagoudianakis, P. T. Antonakis, M. Pattas, F. Kremastinou, V. Katergiannakis, A. Manouras, L. Georgiou. (2007) Parecoxib vs. lornoxicam in the treatment of postoperative pain after laparoscopic cholecystectomy: a prospective randomized placebo-controlled trial. European Journal of Anaesthesiology 24:2, 154-158
CrossRef481
John A. Cairns. (2007) The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks. Canadian Journal of Cardiology 23:2, 125-131
CrossRef482
Baris Karadas, Tijen Kaya, Sefa Gulturk, Ahmet Parlak, Sinan Gursoy, Ali Cetin, Ihsan Bagcivan. (2007) Additive interaction of intraperitoneal dexmedetomidine and topical nimesulide, celecoxib, and DFU for antinociception. European Journal of Pharmacology 556:1-3, 62-68
CrossRef483
Yong I. Cha, Raymond N. DuBois. (2007) NSAIDs and Cancer Prevention: Targets Downstream of COX-2. Annual Review of Medicine 58:1, 239-252
CrossRef484
Luis A. García Rodríguez, Laura Barreales Tolosa. (2007) Risk of Upper Gastrointestinal Complications Among Users of Traditional NSAIDs and COXIBs in the General Population. Gastroenterology 132:2, 498-506
CrossRef485
Loren Laine, Sean P Curtis, Byron Cryer, Amarjot Kaur, Christopher P Cannon. (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. The Lancet 369:9560, 465-473
CrossRef486
Arthur Kavanaugh. (2007) Rheumatic Diseases in the Elderly: A “Perfect Storm”. Rheumatic Disease Clinics of North America 33:1, xi-xiii
CrossRef487
Angel Lanas, John A. Baron, Robert S. Sandler, Kevin Horgan, Jim Bolognese, Bettina Oxenius, Hui Quan, Douglas Watson, Tomas J. Cook, Robert Schoen, Carol Burke, Susan Loftus, Yaron Niv, Robert Ridell, Dion Morton, Robert Bresalier. (2007) Peptic Ulcer and Bleeding Events Associated With Rofecoxib in a 3-Year Colorectal Adenoma Chemoprevention Trial. Gastroenterology 132:2, 490-497
CrossRef488
David Henry, Patricia McGettigan. (2007) Selective COX-2 Inhibitors: A Promise Unfulfilled?. Gastroenterology 132:2, 790-794
CrossRef489
Zuhre Tutuncu, Arthur Kavanaugh. (2007) Rheumatic Disease in the Elderly: Rheumatoid Arthritis. Rheumatic Disease Clinics of North America 33:1, 57-70
CrossRef490
Scott D Solomon. (2007) Cyclooxygenase-2 inhibitors and cardiovascular risk. Current Opinion in Internal Medicine 6:1, 26-30
CrossRef491
James B. Moberly, Stuart I. Harris, Dennis S. Riff, James Craig Dale, Tara Breese, Patrick McLaughlin, Janet Lawson, Yaping Wan, Jianbo Xu, Kenneth E. Truitt. (2007) A Randomized, Double-Blind, One-Week Study Comparing Effects of a Novel COX-2 Inhibitor and Naproxen on the Gastric Mucosa. Digestive Diseases and Sciences 52:2, 442-450
CrossRef492
Şerif Yılmaz, Kadim Bayan, Mehmet Dursun, Fikri Canoruç, Nihal Kılınç, Yekta Tüzün, Ramazan Danış, Meliksah Ertem. (2007) Does Adding Misoprostol to Standard Intravenous Proton Pump Inhibitor Protocol Improve the Outcome of Aspirin/NSAID-Induced Upper Gastrointestinal Bleeding?. Digestive Diseases and Sciences 52:1, 110-118
CrossRef493
Hanns Ulrich Zeilhofer. (2007) Prostanoids in nociception and pain. Biochemical Pharmacology 73:2, 165-174
CrossRef494
Douglas J Watson, Elham Rahme, Nancy C Santanello. (2007) Increase in Nonfatal Digestive Perforations and Haemorrhages following Introduction of Selective NSAIDs: a Public Health Concern. Drug Safety 30:1, 89-90
CrossRef495
B. Hinz, K. Brune. (2007) Schmerztherapie mit antipyretischen Analgetika. Der Orthopäde 36:1, 23-31
CrossRef496
B.H. Thiers. (2007) Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. Yearbook of Dermatology and Dermatologic Surgery 2007, 247-248
CrossRef497
Gerard M.P. Giblin, Rino A. Bit, Susan H. Brown, Hélène M. Chaignot, Anita Chowdhury, Iain P. Chessell, Nicholas M. Clayton, Tanya Coleman, Adrian Hall, Beverley Hammond, David N. Hurst, Anton D. Michel, Alan Naylor, Riccardo Novelli, Tiziana Scoccitti, David Spalding, Sac P. Tang, Alex W. Wilson, Rich Wilson. (2007) The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Bioorganic & Medicinal Chemistry Letters 17:2, 385-389
CrossRef498
Robert S Bresalier. (2007) Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story). Current Opinion in Gastroenterology 23:1, 44-47
CrossRef499
Franco Dallegri, Luciano Ottonello. (2007) Are there any Differences among Non-Steroidal Anti-Inflammatory Drugs? Focus on Nimesulide. Clinical Drug Investigation 27:Suppl 1, 15???22
CrossRef500
Nicholas Moore. (2007) Diclofenac Potassium 12.5mg Tablets for Mild to Moderate Pain and Fever. Clinical Drug Investigation 27:3, 163-195
CrossRef501
Justin Biddle. (2007) Lessons from the Vioxx Debacle: What the Privatization of Science Can Teach Us About Social Epistemology. Social Epistemology 21:1, 21-39
CrossRef502
Henry J. McQuay, Andrew Moore. 2007. AINE y Coxib. , 483-492.
CrossRef503
Todd A. Lee, Brian Bartle, Kevin B. Weiss. (2007) Impact of NSAIDS on Mortality and the Effect of Preexisting Coronary Artery Disease in US Veterans. The American Journal of Medicine 120:1, 98.e9-98.e16
CrossRef504
Roger Chou, Rongwei Fu, Susan Carson, Somnath Saha, Mark Helfand. (2007) Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions. Journal of Clinical Epidemiology 60:1, 18-28
CrossRef505
Daniel Mazanec, Anantha Reddy. (2007) MEDICAL MANAGEMENT OF CERVICAL SPONDYLOSIS. Neurosurgery 60:SUPPLEMENT, S1-43???S1-50
CrossRef506
Kay Brune, Hanns Ulrich Zeilhofer. 2007. Analgésicos antipiréticos. , 471-482.
CrossRef507
Gary Vorsanger, Jim Xiang, Donna Jordan, Jean Farrell. (2007) Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Efficacy and Tolerability Study of Tramadol Extended Release for the Treatment of Osteoarthritis Pain in Geriatric Patients. Clinical Therapeutics 29:11, 2520-2535
CrossRef508
l. bueno, f. de ponti, m. fried, g. a. kullak-ublick, m. a. kwiatek, d. pohl, e. m. m. quigley, j. tack, n. j. talley. (2007) Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterology & Motility 19:s1, 89-119
CrossRef509
A BUVANENDRAN, S REUBEN, J KROIN. (2007) Recent advances in nonopioid analgesics for acute pain management. Techniques in Regional Anesthesia and Pain Management 11:1, 19-26
CrossRef510
Josef G Grohs, Maximilian Schmidt, Axel Wanivenhaus. (2007) Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: A double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthopaedica 78:1, 95-98
CrossRef511
Huub J L Van Der Heide, Willard J Rijnberg, Adriaan Van Sorge, Albert Van Kampen, B Willem Schreurs. (2007) Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. Acta Orthopaedica 78:1, 90-94
CrossRef512
W.J. Elliott. (2007) Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. Yearbook of Cardiology 2007, 55-57
CrossRef513
Angelo Zullo, Cesare Hassan, Salvatore M A Campo, Sergio Morini. (2007) Bleeding Peptic Ulcer in the Elderly. Drugs & Aging 24:10, 815-828
CrossRef514
Rita K. Upmacis, Ruba S. Deeb, David P. Hajjar. (2007) Reprint of “Oxidative alterations of cyclooxygenase during atherogenesis” [Prostag. Oth. Lipid. M. 80 (2006) 1–14]. Prostaglandins & Other Lipid Mediators 82:1-4, I-XIV
CrossRef515
William B. White, Christine R. West, Jeffrey S. Borer, Philip B. Gorelick, Lisa Lavange, Sharon X. Pan, Ethan Weiner, Kenneth M. Verburg. (2007) Risk of Cardiovascular Events in Patients Receiving Celecoxib: A Meta-Analysis of Randomized Clinical Trials. The American Journal of Cardiology 99:1, 91-98
CrossRef516
Noori S. Al-Waili, Khelod Y. Saloom, Thia Al-Waili, Ali Al-Waili, Hamza Al-Waili. (2007) Modulation of prostaglandin activity, part 1: Prostaglandin inhibition in the management of nonrheumatologic diseases: Immunologic and hematologic aspects. Advances in Therapy 24:1, 189-222
CrossRef517
E. Viel, S. Jaber, J. Ripart, F. Navarro, J.-J. Eledjam. (2007) Analgesia postoperatoria nell’adulto (esclusa quella ambulatoriale). EMC - Anestesia-Rianimazione 12:2, 1-26
CrossRef518
Marta L. Capone, Stefania Tacconelli, Luigia Di Francesco, Andrea Sacchetti, Maria G. Sciulli, Paola Patrignani. (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins & Other Lipid Mediators 82:1-4, 85-94
CrossRef519
D.J.A. de Groot, E.G.E. de Vries, H.J.M. Groen, S. de Jong. (2007) Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic. Critical Reviews in Oncology/Hematology 61:1, 52-69
CrossRef520
Wally R. Smith. (2007) Pseudoevidence-based medicine: what it is, and what to do about it. Clinical Governance: An International Journal 12:1, 42-52
CrossRef521
William M Spalding, Mathew J Reeves, Andrew Whelton. (2007) Thromboembolic Cardiovascular Risk Among Arthritis Patients Using Cyclooxygenase-2-Selective Inhibitor or Nonselective Cyclooxygenase Inhibitor Nonsteroidal Anti-inflammatory Drugs. American Journal of Therapeutics 14:1, 3-12
CrossRef522
James E Frampton, Gillian M Keating. (2007) Celecoxib. Drugs 67:16, 2433-2472
CrossRef523
Josée Guindon, Jean-Sébastien Walczak, Pierre Beaulieu. (2007) Recent Advances in the Pharmacological Management of Pain. Drugs 67:15, 2121-2133
CrossRef524
Ignatius Gerardo E. Zarraga, Ernst R. Schwarz. (2007) Coxibs and Heart Disease. Journal of the American College of Cardiology 49:1, 1-14
CrossRef525
Harald E Vonkeman, Rogier M Klok, Maarten J Postma, Jacobus R B J Brouwers, Mart A F J van de Laar. (2007) Direct Medical Costs of Serious Gastrointestinal Ulcers among Users of NSAIDs. Drugs & Aging 24:8, 681-690
CrossRef526
Srinivas Pyati, Tong J Gan. (2007) Perioperative Pain Management. CNS Drugs 21:3, 185-211
CrossRef527
Shingo TSUJI. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:4, 213-218
CrossRef528
Kristine L. Clark. (2007) Nutritional Considerations in Joint Health. Clinics in Sports Medicine 26:1, 101-118
CrossRef529
Elliot V. Hersh, Andres Pinto, Paul A. Moore. (2007) Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clinical Therapeutics 29:11, 2477-2497
CrossRef530
Richard O Day, Kenneth M Williams. (2007) Open-Label Extension Studies. Drug Safety 30:2, 93-105
CrossRef531
Luis A. García Rodríguez, Antonio González-Péreza. (2007) Cardiovascular Safety of Non-Steroidal Anti-Inflammatory Drugs. Lights and Shadows. Reumatolog ía Cl ínica (English Edition) 3:3, 95-97
CrossRef532
Martijn G. H. Oijen, Robert J. F. Laheij, Marjolein Koetsier, Evelien Kleine, René H. M. Morsche, Lieke A. S. Kerkhoven, Jan B. M. J. Jansen, Joost P. H. Drenth. (2006) Effect of a Specific Cyclooxygenase-Gene Polymorphism (A-842G/C50T) on the Occurrence of Peptic Ulcer Hemorrhage. Digestive Diseases and Sciences 51:12, 2348-2352
CrossRef533
Manuel Castro Pazos, Alberto Raúl Juncal Fondevila. (2006) Evaluación de la calidad de la prescripción farmacéutica. Atención Primaria 38:10, 584-585
CrossRef534
L-C. Chen, D. M. Ashcroft. (2006) Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics 31:6, 565-576
CrossRef535
Maria Rosa Hernandez, Raul Tonda, Javier Pedreño, Eduardo Salas, Gemma Arderiu, Marc Pino, Mireia Serradell, Gines Escolar. (2006) Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity. Journal of Cardiovascular Medicine 7:12, 859-865
CrossRef536
Michel Lièvre. (2006) Evaluation of adverse treatment effects in controlled trials. Joint Bone Spine 73:6, 624-626
CrossRef537
Sean P. Curtis, Amy T. Ko, James A. Bolognese, Paul F. Cavanaugh, Alise S. Reicin. (2006) Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX‐2 selective Inhibitor etoricoxib*. Current Medical Research and Opinion 22:12, 2365-2374
CrossRef538
Samy Suissa. (2006) Contribution of pharmacoepidemiological studies to the evaluation of treatment-related adverse events. Joint Bone Spine 73:6, 627-628
CrossRef539
Marianne Ulcickas Yood, Emmeline Watkins, Karen Wells, Gena Kucera, Christine Cole Johnson, Eva Lydick. (2006) The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiology and Drug Safety 15:12, 852-860
CrossRef540
Hong Lu, David Y. Graham. (2006) New development in the mechanistic understanding of peptic ulcer diseases. Drug Discovery Today: Disease Mechanisms 3:4, 431-437
CrossRef541
Ivan P Uray, Powel H Brown. (2006) Prevention of breast cancer: current state of the science and future opportunities. Expert Opinion on Investigational Drugs 15:12, 1583-1600
CrossRef542
John A. Baron, Robert S. Sandler, Robert S. Bresalier, Hui Quan, Robert Riddell, Angel Lanas, James A. Bolognese, Bettina Oxenius, Kevin Horgan, Susan Loftus, Dion G. Morton. (2006) A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas. Gastroenterology 131:6, 1674-1682
CrossRef543
Félix M. Arellano, Marianne Ulcickas Yood, Charles E Wentworth, Susan A Oliveria, Elena Rivero, Anila Verma, Kenneth J Rothman. (2006) Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiology and Drug Safety 15:12, 861-872
CrossRef544
Laura E. Targownik, Alice Nabalamba. (2006) Trends in Management and Outcomes of Acute Nonvariceal Upper Gastrointestinal Bleeding: 1993–2003. Clinical Gastroenterology and Hepatology 4:12, 1459-1466.e1
CrossRef545
Viktorija Erdeljic, Igor Francetic, Viola Macolic Sarinic, Marinko Bilusic, Ksenija Makar Ausperger, Mirjana Huic, Iveta Mercep. (2006) Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study. Pharmacy World & Science 28:5, 318-325
CrossRef546
Steven Simoens, Sandra Coster, Bernard Ruyck, Petra Stutz, Gert Laekeman. (2006) Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDS. Pharmacy World & Science 28:5, 309-317
CrossRef547
Jeffery T. Fletcher, Nicole Graf, Anthony Scarman, Hamda Saleh, Stephen I. Alexander. (2006) Nephrotoxicity with cyclooxygenase 2 inhibitor use in children. Pediatric Nephrology 21:12, 1893-1897
CrossRef548
Sheikh Arshad Saeed, Sagheer Ahmed. (2006) Anti-ischemic effects of nimesulide, a cyclooxygenase-2 inhibitor on the ischemic model of rabbit induced by isoproterenol. Archives of Pharmacal Research 29:11, 977-983
CrossRef549
Neal M Davies, Jonathon K Reynolds, Megan R Undeberg, Brian J Gates, Yusuke Ohgami, Karina R Vega-Villa. (2006) Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal. Expert Review of Neurotherapeutics 6:11, 1643-1655
CrossRef550
Heather Mernitz, Donald E. Smith, Andrew X. Zhu, Xiang-Dong Wang. (2006) 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-β but no change in cyclooxygenase-2. Cancer Letters 244:1, 101-108
CrossRef551
Lenard M. Lichtenberger, Yong Zhou, Elizabeth J. Dial, Robert M. Raphael. (2006) NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. Journal of Pharmacy and Pharmacology 58:11, 1421-1428
CrossRef552
Christopher P Cannon, Sean P Curtis, Garret A FitzGerald, Henry Krum, Amarjot Kaur, James A Bolognese, Alise S Reicin, Claire Bombardier, Michael E Weinblatt, Désirée van der Heijde, Erland Erdmann, Loren Laine. (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. The Lancet 368:9549, 1771-1781
CrossRef553
Sebastian Schneeweiss, Daniel H. Solomon, Philip S. Wang, Jeremy Rassen, M. Alan Brookhart. (2006) Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysis. Arthritis & Rheumatism 54:11, 3390-3398
CrossRef554
Japie A Louw. (2006) Peptic ulcer disease. Current Opinion in Gastroenterology 22:6, 607-611
CrossRef555
James M Brophy. (2006) Vascular events with selective COX2 inhibitors and NSAIDs: analyzing the risks. Nature Clinical Practice Cardiovascular Medicine 3:11, 586-587
CrossRef556
N. D. YEOMANS, L-E SVEDBERG, J. NAESDAL. (2006) Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?. International Journal of Clinical Practice 60:11, 1401-1407
CrossRef557
Kathleen A. Sennello, Michael S. Leib. (2006) Effects of Deracoxib or Buffered Aspirin on the Gastric Mucosa of Healthy Dogs. Journal of Veterinary Internal Medicine 20:6, 1291-1296
CrossRef558
PATRICIA O'MALLEY. (2006) The Emerging Cardiovascular Risk Profile for Nonsteroidal Anti-inflammatory Drugs. Clinical Nurse Specialist 20:6, 277-265
CrossRef559
Jay L. Goldstein, Kimberly B. Howard, Surrey M. Walton, Trent P. Mclaughlin, Denise T. Kruzikas. (2006) Impact of Adherence to Concomitant Gastroprotective Therapy on Nonsteroidal-Related Gastroduodenal Ulcer Complications. Clinical Gastroenterology and Hepatology 4:11, 1337-1345.e1
CrossRef560
Alex Cahana, Alexandre Mauron. (2006) The story of Vioxx—no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry. Journal of Anesthesia 20:4, 348-351
CrossRef561
Dianne Volker, Peony Lee. 2006. Osteoarthritis. , 193-222.
CrossRef562
Daniel E. Furst, Dinesh Khanna, Harold E. Paulus. (2006) Cyclooxygenase 2 controversy: Thoughts on the process of discovery, development, and assessment of benefit and risk of therapies for chronic immunoinflammatory diseases of uncertain autoimmune etiology. Arthritis & Rheumatism 55:5, 683-686
CrossRef563
2006. Chronic Heart Failure. .
CrossRef564
Tai-Juan Aw, Danny Liew, Geoffrey H Tofler, Hans G Schneider, Marie-Christine Morel-Kopp, Baki Billah, Henry Krum. (2006) Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?. Journal of Hypertension 24:10, 1979-1984
CrossRef565
Francis KL Chan. (2006) Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. Nature Clinical Practice Gastroenterology & Hepatology 3:10, 563-573
CrossRef566
Sharon Bingham, Paul J. Beswick, David E. Blum, Norman M. Gray, Iain P. Chessell. (2006) The role of the cylooxygenase pathway in nociception and pain. Seminars in Cell & Developmental Biology 17:5, 544-554
CrossRef567
Mark Stafford-Smith. (2006) Hurry up and slow down: Lessons in drug development from the COX-2 inhibitors. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 53:10, 973-977
CrossRef568
Harald E. Vonkeman, Mart A.F.J. van de Laar, Job van der Palen, Jacobus R.B.J. Brouwers, Istvan Vermes. (2006) Allele variants of the cytochrome P450 2C9 genotype in white subjects from the netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clinical Therapeutics 28:10, 1670-1676
CrossRef569
Hershel Jick, James A Kaye, Stefan Russmann, Susan S Jick. (2006) Nonsteroidal Antiinflammatory Drugs and Acute Myocardial Infarction in Patients with No Major Risk Factors. Pharmacotherapy 26:10, 1379-1387
CrossRef570
Olga Cheremina, Kay Brune, Burkhard Hinz. (2006) A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. Biomedical Chromatography 20:10, 1033-1037
CrossRef571
K. R. Schmelzer, B. Inceoglu, L. Kubala, I.-H. Kim, S. L. Jinks, J. P. Eiserich, B. D. Hammock. (2006) Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proceedings of the National Academy of Sciences 103:37, 13646-13651
CrossRef572
Hao-Wei Wang, Chung-Tsen Hsueh, Chien-Fu Jeff Lin, Teh-Ying Chou, Wen-Hu Hsu, Liang-Shun Wang, Yu-Chung Wu. (2006) Clinical Implications of Microsomal Prostaglandin E Synthase-1 Overexpression in Human Non–Small-Cell Lung Cancer. Annals of Surgical Oncology 13:9, 1224-1234
CrossRef573
Priscilla Velentgas, William West, Carolyn C. Cannuscio, Douglas J. Watson, Alexander M. Walker. (2006) Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiology and Drug Safety 15:9, 641-652
CrossRef574
B. RATTRAY, D. J. NUGENT, G. YOUNG. (2006) Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 12:5, 514-517
CrossRef575
Melanie Maxwell, Michael Nathanson. (2006) Parecoxib - getting to the heart of the matter. Anaesthesia 61:9, 823-825
CrossRef576
Elena C. Lascano, Héctor F. Valle, Jorge A. Negroni. (2006) Role of the cyclooxygenase pathway in the protection against postischemic stunning in conscious sheep. Molecular and Cellular Biochemistry 289:1-2, 91-100
CrossRef577
Hanns Ulrich Zeilhofer, Kay Brune. (2006) Analgesic strategies beyond the inhibition of cyclooxygenases. Trends in Pharmacological Sciences 27:9, 467-474
CrossRef578
L. LAINE, R. SMITH, K. MIN, C. CHEN, R. W. DUBOIS. (2006) Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics 24:5, 751-767
CrossRef579
J. K. Aronson. (2006) The NSAID roller coaster: more about rofecoxib. British Journal of Clinical Pharmacology 62:3, 257-259
CrossRef580
Jeffrey D. Greenberg, Clifton O. Bingham, Steven B. Abramson, George Reed, Mitsumasa Kishimoto, Kim Hinkle, Joel Kremer, . (2006) Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis & Rheumatism 55:4, 543-550
CrossRef581
Georgio Mosis, Theo Stijnen, Jordi Castellsague, Jeanne P. Dieleman, Johan van der Lei, Bruno H. C. Stricker, Miriam C. J. M. Sturkenboom. (2006) Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs. Arthritis & Rheumatism 55:4, 537-542
CrossRef582
Samy Suissa, Sasha Bernatsky, Marie Hudson. (2006) Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis & Rheumatism 55:4, 531-536
CrossRef583
Jürgen Drews. (2006) Case histories, magic bullets and the state of drug discovery. Nature Reviews Drug Discovery 5:8, 635-640
CrossRef584
June M. Chan, Angela Feraco, Marc Shuman, Sonia Hernández-Díaz. (2006) The Epidemiology of Prostate Cancer—with a Focus on Nonsteroidal Anti-inflammatory Drugs. Hematology/Oncology Clinics of North America 20:4, 797-809
CrossRef585
R.M. Langford, V. Mehta. (2006) Selective cyclooxygenase inhibition: its role in pain and anaesthesia. Biomedicine & Pharmacotherapy 60:7, 323-328
CrossRef586
Birgitta Haglund, Inger Von Bültzingslöwen. (2006) Combining paracetamol with a selective cyclooxygenase-2 inhibitor for acute pain relief after third molar surgery: a randomized, double-blind, placebo-controlled study. European Journal of Oral Sciences 114:4, 293-301
CrossRef587
Piet Borgdorff, Geert Jan Tangelder, Walter J. Paulus. (2006) Cyclooxygenase-2 Inhibitors Enhance Shear Stress-Induced Platelet Aggregation. Journal of the American College of Cardiology 48:4, 817-823
CrossRef588
Stephen B. Miller. (2006) Prostaglandins in Health and Disease: An Overview. Seminars in Arthritis and Rheumatism 36:1, 37-49
CrossRef589
Stacy P Ardoin, John S Sundy. (2006) Update on nonsteriodal anti-inflammatory drugs. Current Opinion in Internal Medicine 5:4, 372-377
CrossRef590
Johannes W J Bijlsma. (2006) Celecoxib—fewer gastrointestinal adverse events in patients with osteoarthritis. Nature Clinical Practice Rheumatology 2:8, 414-415
CrossRef591
George N. Ziakas, Eleni A. Rekka, Antonios M. Gavalas, Phaedra T. Eleftheriou, Panos N. Kourounakis. (2006) New analogues of butylated hydroxytoluene as anti-inflammatory and antioxidant agents. Bioorganic & Medicinal Chemistry 14:16, 5616-5624
CrossRef592
Michael A. Fischer, Hailu Cheng, Sebastian Schneeweiss, Jerry Avorn, Daniel H. Solomon. (2006) Prior Authorization Policies for Selective Cyclooxygenase-2 Inhibitors in Medicaid. Medical Care 44:7, 658-663
CrossRef593
Steven S. Smugar, Thomas J. Schnitzer, Arthur L. Weaver, Bernard R. Rubin, Adam B. Polis, Andrew M. Tershakovec. (2006) Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies*. Current Medical Research and Opinion 22:7, 1353-1367
CrossRef594
Brian D. De Smet, A. Mark Fendrick, James G. Stevenson, Steven J. Bernstein. (2006) Over and Under-utilization of Cyclooxygenase-2 Selective Inhibitors by Primary Care Physicians and Specialists: The Tortoise and the Hare Revisited. Journal of General Internal Medicine 21:7, 694-697
CrossRef595
Zachary A Stacy, Paul P Dobesh, Toby C Trujillo. (2006) Cardiovascular Risks of Cyclooxygenase Inhibition. Pharmacotherapy 26:7, 919-938
CrossRef596
Almudena Gómez-Hernández, Jose Luis Martín-Ventura, Eva Sánchez-Galán, Cristina Vidal, Mónica Ortego, Luis Miguel Blanco-Colio, Luis Ortega, José Tuñón, Jesús Egido. (2006) Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB. Atherosclerosis 187:1, 139-149
CrossRef597
Rita K. Upmacis, Ruba S. Deeb, David P. Hajjar. (2006) Oxidative alterations of cyclooxygenase during atherogenesis. Prostaglandins & Other Lipid Mediators 80:1-2, 1-14
CrossRef598
Richard M. Langford. (2006) Pain management today—what have we learned?. Clinical Rheumatology 25:S1, 2-8
CrossRef599
Angel LANAS, Angel FERRANDEZ. (2006) NSAID-induced gastrointestinal damage: Current clinical management and recommendations for prevention. Chinese Journal of Digestive Diseases 7:3, 127-133
CrossRef600
Thomas J. Schnitzer. (2006) Update on guidelines for the treatment of chronic musculoskeletal pain. Clinical Rheumatology 25:S1, 22-29
CrossRef601
Sinead Toomey, Brendan Harhen, Helen M. Roche, Desmond Fitzgerald, Orina Belton. (2006) Profound resolution of early atherosclerosis with conjugated linoleic acid. Atherosclerosis 187:1, 40-49
CrossRef602
S. Grosch, T. J. Maier, S. Schiffmann, G. Geisslinger. (2006) Cyclooxygenase-2 (COX-2)-Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. JNCI Journal of the National Cancer Institute 98:11, 736-747
CrossRef603
P. O. KATZ, J. M. SCHEIMAN, A. N. BARKUN. (2006) Review article: acid-related disease - what are the unmet clinical needs?. Alimentary Pharmacology and Therapeutics 23:s2, 9-22
CrossRef604
C. J. Hawkey, G. M. Hawkey, S. Everitt, M. M. Skelly, W. A. Stack, D. Gray. (2006) Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 61:6, 730-737
CrossRef605
Hilal Maradit Kremers, Sherine E. Gabriel. (2006) Rheumatoid arthritis and the heart. Current Heart Failure Reports 3:2, 57-63
CrossRef606
SERDAR KAHVECIOGLU, KAMIL DILEK, IBRAHIM AKDAG, MUSTAFA GULLULU, CELALETTIN DEMIRCAN, ALPASLAN ERSOY, MUSTAFA YURTKURAN. (2006) Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis. Nephrology 11:3, 232-237
CrossRef607
Nurullah Akkoc, Sjef van der Linden, Muhammad Asim Khan. (2006) Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Practice & Research Clinical Rheumatology 20:3, 539-557
CrossRef608
Bhupesh Parashar, Bridget Shafit-Zagardo. (2006) Inhibition of human Neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor Nimesulide. Journal of Neuro-Oncology 78:2, 129-134
CrossRef609
S. Moncada. (2006) Adventures in vascular biology: a tale of two mediators. Philosophical Transactions of the Royal Society B: Biological Sciences 361:1469, 735-759
CrossRef610
S. K. MURTHY, S. KAULDHER, L. E. TARGOWNIK. (2006) Physicians' approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users. Alimentary Pharmacology and Therapeutics 23:9, 1365-1372
CrossRef611
Loren Laine. (2006) GI Risk and Risk Factors of NSAIDs. Journal of Cardiovascular Pharmacology 47:Supplement 1, S60-S66
CrossRef612
Arnold B. Alper, Holly Tomlin, Usha Sadhwani, Andrew Whelton, Jules Puschett. (2006) Effects of the Selective Cyclooxygenase-2 Inhibitor Analgesic Celecoxib on Renal Carbonic Anhydrase Enzyme Activity: A Randomized, Controlled Trial. American Journal of Therapeutics 13:3, 229-235
CrossRef613
José A. Páramo, Óscar Beloqui, Josune Orbe. (2006) Ciclooxigenasa 2: ¿una nueva diana terapéutica en la aterosclerosis?. Medicina Clínica 126:20, 782-786
CrossRef614
Jin Sheng Guo, Chi Hin Cho, Ji Yao Wang, Marcel Wing Leung Koo. (2006) Differential effects of selective and non-selective inhibition of nitric oxide synthase on the expression and activity of cyclooxygenase-2 during gastric ulcer healing. European Journal of Pharmacology 536:3, 301-308
CrossRef615
Daniel H. Solomon, Jerry Avorn, Til Stürmer, Robert J. Glynn, Helen Mogun, Sebastian Schneeweiss. (2006) Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk. Arthritis & Rheumatism 54:5, 1378-1389
CrossRef616
Jan Steffel, Thomas F. L??scher, Frank Ruschitzka, Felix C. Tanner. (2006) Cyclooxygenase-2 Inhibition and Coagulation. Journal of Cardiovascular Pharmacology 47:Supplement 1, S15-S20
CrossRef617
Francesco Cipollone, Maria Luigia Fazia. (2006) COX-2 and Atherosclerosis. Journal of Cardiovascular Pharmacology 47:Supplement 1, S26-S36
CrossRef618
Adrian Hall, Rino A. Bit, Susan H. Brown, Helene M. Chaignot, Iain P. Chessell, Tanya Coleman, Gerard M.P. Giblin, David N. Hurst, Ian R. Kilford, Xiao Q. Lewell, Anton D. Michel, Shiyam Mohamed, Alan Naylor, Riccardo Novelli, Lee Skinner, David J. Spalding, Sac P. Tang, Richard J. Wilson. (2006) Discovery of novel biaryl heterocyclic EP1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 16:10, 2666-2671
CrossRef619
J??rgen Sch??lmerich. (2006) Nonsteroidal Anti-inflammatory Drugs Versus Selective COX-2 Inhibitors in the Upper Gastrointestinal Tract. Journal of Cardiovascular Pharmacology 47:Supplement 1, S67-S71
CrossRef620
Vibeke Strand. (2006) Expectations From Patients With Rheumatoid Arthritis Regarding COX-2s: Cutting to the Heart of the Matter. Journal of Cardiovascular Pharmacology 47:Supplement 1, S55-S59
CrossRef621
Francesco Cipollone, Maria Luigia Fazia. (2006) Cyclooxygenase-2 inhibition: Vascular inflammation and cardiovascular risk. Current Atherosclerosis Reports 8:3, 245-251
CrossRef622
Andrew F Riley, Laura A Wakely, Hussain Y Patel, Bridget Neveldsen, Gordon L Purdie, Anthony P Wells. (2006) Use of a cyclo-oxygenase 2 inhibitor for prophylaxis of cystoid macular oedema following cataract surgery: a randomized placebo-controlled trial. Clinical and Experimental Ophthalmology 34:4, 299-304
CrossRef623
J. L. GOLDSTEIN, S. C. LOWRY, F. L. LANZA, H. I. SCHWARTZ, W. E. DODGE. (2006) The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Alimentary Pharmacology and Therapeutics 23:10, 1489-1498
CrossRef624
M Alan Brookhart, Philip S. Wang, Daniel H. Solomon, Sebastian Schneeweiss. (2006) Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental Variable. Epidemiology 17:3, 268-275
CrossRef625
Sebastian Schneeweiss. (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiology and Drug Safety 15:5, 291-303
CrossRef626
R. Preston Mason, Mary F. Walter, Hyesun P. McNulty, Samuel F. Lockwood, Jungsoo Byun, Charles A. Day, Robert F. Jacob. (2006) Rofecoxib Increases Susceptibility of Human LDL and Membrane Lipids to Oxidative Damage: A Mechanism of Cardiotoxicity. Journal of Cardiovascular Pharmacology 47:Supplement 1, S7-S14
CrossRef627
Matthias Hermann. (2006) Cyclooxygenase-2 and Nitric Oxide. Journal of Cardiovascular Pharmacology 47:Supplement 1, S21-S25
CrossRef628
C. Kneitz, H. P. Tony, K. Krüger. (2006) NSAR und Coxibe: aktueller Stand. Der Internist 47:5, 533-540
CrossRef629
N. Gitlin, A. L. Weaver. (2006) Response to: Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. International Journal of Clinical Practice 60:5, 609-610
CrossRef630
C. J. Hawkey. (2006) NSAIDs, Coxibs, and the Intestine. Journal of Cardiovascular Pharmacology 47:Supplement 1, S72-S75
CrossRef631
Irmgard Tegeder, Gerd Geisslinger. (2006) Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?. Naunyn-Schmiedeberg's Archives of Pharmacology 373:1, 1-17
CrossRef632
Byron Cryer. (2006) A COX-2-Specific Inhibitor Plus a Proton-Pump Inhibitor: Is This a Reasonable Approach to Reduction in NSAIDs' GI Toxicity?. The American Journal of Gastroenterology 101:4, 711-713
CrossRef633
Angel Lanas. (2006) Prevention and treatment of NSAID-induced gastroduodenal injury. Current Treatment Options in Gastroenterology 9:2, 147-156
CrossRef634
Ulrike Puhlmann, Dirk Schäfer, Christina Ziemann. (2006) Update on COX-2 inhibitor patents with a focus on optimised formulation and therapeutic scope of drug combinations making use of COX-2 inhibitors. Expert Opinion on Therapeutic Patents 16:4, 403-430
CrossRef635
F. Soriano, V. Campana, M. Moya, A. Gavotto, J. Simes, M. Soriano, R. Soriano, L. Spitale, J. Palma. (2006) Photobiomodulation of Pain and Inflammation in Microcrystalline Arthropathies: Experimental and Clinical Results. Photomedicine and Laser Surgery 24:2, 140-150
CrossRef636
Lise Lotte Gluud. (2006) Unravelling industry bias in clinical trials. Pain 121:3, 175-176
CrossRef637
John L. Wallace. (2006) Commonality of Defensive Roles of COX-2 in the Lung and Gut. The American Journal of Pathology 168:4, 1060-1063
CrossRef638
Christopher A. Church, Charles Stewart, T J. O-Lee, Desiree Wallace. (2006) Rofecoxib versus Hydrocodone/Acetaminophen for Postoperative Analgesia in Functional Endoscopic Sinus Surgery. The Laryngoscope 116:4, 602-606
CrossRef639
Steven Joseph Haas. (2006) Adverse Drug Reaction Reporting and Pharmacovigilance of New Therapeutic Agents. Southern Medical Journal 99:4, 325-326
CrossRef640
Ellen Niederberger, Christine Manderscheid, Gerd Geisslinger. (2006) Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Biochemical and Biophysical Research Communications 342:3, 940-948
CrossRef641
James M. Scheiman, Neville D. Yeomans, Nicholas J. Talley, Nimish Vakil, Francis K. L. Chan, Zsolt Tulassay, Jorge L. Rainoldi, Leszek Szczepanski, Kjell-Arne Ung, Dariusz Kleczkowski, Henrik Ahlbom, Jorgen Naesdal, Christopher Hawkey. (2006) Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors. The American Journal of Gastroenterology 101:4, 701-710
CrossRef642
Curfman, Gregory D., Morrissey, Stephen, Drazen, Jeffrey M., . (2006) Expression of Concern Reaffirmed. New England Journal of Medicine 354:11, 1193-1193
Full Text643
(2006) Response to Expression of Concern Regarding VIGOR Study. New England Journal of Medicine 354:11, 1196-1199
Full Text644
Jacek Spławiński, Jerzy Kuźniar, Krzysztof Filipiak, Waldemar Zieliński. (2006) Evaluation of drug toxicity in clinical trials. Science and Engineering Ethics 12:1, 139-145
CrossRef645
W. D. CHEY, S. ESWAREN, C. W. HOWDEN, J. M. INADOMI, A. M. FENDRICK, J. M. SCHEIMAN. (2006) Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. Alimentary Pharmacology and Therapeutics 23:5, 655-668
CrossRef646
Yong I. Cha, Raymond N. DuBois. (2006) Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E2 signaling: Recent advances in basic biology. Current Colorectal Cancer Reports 2:2, 60-65
CrossRef647
Stéphanie Lugardon, Henri Roussel, Robert Bourrel, Vincent Sciortino, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (2006) Profil des utilisateurs d'anti-inflammatoires non stéroïdiens. Thérapie 61:2, 109-114
CrossRef648
Jay L. Goldstein, James Aisenberg, Frank Lanza, Howard Schwartz, George H. Sands, Manuela F. Berger, Sharon Pan. (2006) A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years. Clinical Therapeutics 28:3, 340-351
CrossRef649
Michael J James, Leslie G Cleland. (2006) Cyclooxygenase-2 inhibitors: what went wrong?. Current Opinion in Clinical Nutrition and Metabolic Care 9:2, 89-94
CrossRef650
Angel Ferrández, Angel Lanas. (2006) The role of COX-2 in chemoprevention of colorectal cancer: A friend or an enemy?. Current Colorectal Cancer Reports 2:1, 5-12
CrossRef651
Michael A. Steinman, Kenneth R. McQuaid, Kenneth E. Covinsky. (2006) Age and Rising Rates of Cyclooxygenase-2 Inhibitor Use. Results from a National Survey. Journal of General Internal Medicine 21:3, 245-250
CrossRef652
Sonia Hernandez-Diaz, Cristina Varas-Lorenzo, Luis A. Garcia Rodriguez. (2006) Non-Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 98:3, 266-274
CrossRef653
Félix M. Arellano. (2006) Observational studies and the withdrawal of rofecoxib. Pharmacoepidemiology and Drug Safety 15:3, 203-205
CrossRef654
Liebson Philip R.. (2006) PERSPECTIVES. Muraglitazar and the FDA: What Constitutes Drug Safety?. Preventive Cardiology 9:2, 110-114
CrossRef655
Fumiaki Kojima, Mohit Kapoor, Shinichi Kawai, Leslie J Crofford. (2006) New insights into eicosanoid biosynthetic pathways: implications for arthritis. Expert Review of Clinical Immunology 2:2, 277-291
CrossRef656
Elham Rahme, Elke Hunsche, Youssef Toubouti, Isabelle Chabot. (2006) Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: What is the potential impact of the withdrawal of rofecoxib?. Arthritis & Rheumatism 55:1, 27-34
CrossRef657
D Mazhar, R Ang, J Waxman. (2006) COX inhibitors and breast cancer. British Journal of Cancer 94:3, 346-350
CrossRef658
Christopher J Hawkey, Paul J Fortun. (2006) Cyclooxygenase-2 inhibitors. Current Opinion in Internal Medicine 5:1, 106-110
CrossRef659
Silvano Adami. (2006) Anti-inflammatory therapy and cardiovascular risk: new insights. Future Rheumatology 1:1, 7-10
CrossRef660
Cornelia M. Ulrich, Jeannette Bigler, John D. Potter. (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Reviews Cancer 6:2, 130-140
CrossRef661
Arthur L. Weaver, Ronald P. Messner, William W. Storms, Adam B. Polis, Daryl K. Najarian, Richard A. Petruschke, Gregory P. Geba, Andrew M. Tershakovec. (2006) Treatment of Patients With Osteoarthritis With Rofecoxib Compared With Nabumetone. JCR: Journal of Clinical Rheumatology 12:1, 17-25
CrossRef662
M. Vieth. (2006) NSAR-Kolopathie. Der Pathologe 27:1, 65-72
CrossRef663
Omidreza Firuzi, Domenico Praticò. (2006) Coxibs and Alzheimer's disease: Should they stay or should they go?. Annals of Neurology 59:2, 219-228
CrossRef664
Mika Katagiri, Toru Ogasawara, Kazuto Hoshi, Daichi Chikazu, Aishi Kimoto, Masahiro Noguchi, Masao Sasamata, Shun-ichi Harada, Hideto Akama, Hatsue Tazaki, Ung-il Chung, Tsuyoshi Takato, Kozo Nakamura, Hiroshi Kawaguchi. (2006) Suppression of Adjuvant-Induced Arthritic Bone Destruction by Cyclooxygenase-2 Selective Agents With and Without Inhibitory Potency Against Carbonic Anhydrase II. Journal of Bone and Mineral Research 21:2, 219-227
CrossRef665
Yuhong Yuan, Ireneusz T Padol, Richard H Hunt. (2006) Peptic ulcer disease today. Nature Clinical Practice Gastroenterology & Hepatology 3:2, 80-89
CrossRef666
Alastair J.M. Watson. (2006) An overview of apoptosis and the prevention of colorectal cancer. Critical Reviews in Oncology/Hematology 57:2, 107-121
CrossRef667
Ray, Wayne A., Stein, C. Michael, . (2006) Reform of Drug Regulation — Beyond an Independent Drug-Safety Board. New England Journal of Medicine 354:2, 194-201
Full Text668
Gim Gee Teng, Raj Nair, Kenneth G Saag. (2006) Pathophysiology, Clinical Presentation and Treatment of Gout. Drugs 66:12, 1547-1563
CrossRef669
Clive H. Wilder-Smith, Bror Jonzon, Bodil Fornstedt-Wallin, Ann Hedman, Pär Karlsson. (2006) Dose–effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. Scandinavian Journal of Gastroenterology 41:3, 264-273
CrossRef670
W.J. Elliott. (2006) Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure. Yearbook of Cardiology 2006, 50-51
CrossRef671
G. TREIBER, T. WEX, A. LINK, M. VIETH, S. LAUFER, P. MALFERTHEINER. (2006) The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa. Alimentary Pharmacology and Therapeutics 23:1, 155-167
CrossRef672
Jane A. Mitchell, Timothy D. Warner. (2006) COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nature Reviews Drug Discovery 5:1, 75-86
CrossRef673
Reynold Spector, Elliot S. Vesell. (2006) The Power of Pharmacological Sciences: The Example of Proton Pump Inhibitors. Pharmacology 76:3, 148-156
CrossRef674
Marc Maillard, Michel Burnier. (2006) Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opinion on Drug Safety 5:1, 83-94
CrossRef675
Louise Barnard, Dominic Lavoie, Nancy Lajeunesse. (2006) Increase in Nonfatal Digestive Perforations and Haemorrhages Following Introduction of Selective NSAIDs. Drug Safety 29:7, 613-620
CrossRef676
Hadas Dvory-Sobol, Diana Kazanov, Eliezer Liberman, Shlomo Birkenfeld, Benny Bulvik, Pauline Luk, Moshe Leshno, Nadir Arber. (2006) MF tricyclic and sulindac retard tumor formation in an animal model. International Journal of Cancer 118:1, 11-16
CrossRef677
I. HILMI, KL GOH. (2006) Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs. Chinese Journal of Digestive Diseases 7:1, 1-6
CrossRef678
Burkhard Hinz, Harald Dormann, Kay Brune. (2006) More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis & Rheumatism 54:1, 282-291
CrossRef679
Lars Sl??rdal, Olav Spigset. (2006) Heart Failure Induced by Non-Cardiac Drugs. Drug Safety 29:7, 567-586
CrossRef680
FAYEZ KOTOB, MARK J. LEMA. 2006. Nonopioid Analgesics. , 253-303.
CrossRef681
Angela M. Meyer, Nizar N. Ramzan, Russell I. Heigh, Jonathan A. Leighton. (2006) Relapse of Inflammatory Bowel Disease Associated With Use of Nonsteroidal Anti-Inflammatory Drugs. Digestive Diseases and Sciences 51:1, 168-172
CrossRef682
2006. COX-2 inhibitors. , 1000-1015.
CrossRef683
Bin Zhang, Xiao-Li He, Yi Ding, Guan-Hua Du. (2006) Gaultherin, a natural salicylate derivative from Gaultheria yunnanensis: Towards a better non-steroidal anti-inflammatory drug. European Journal of Pharmacology 530:1-2, 166-171
CrossRef684
Judy T. Chen, Frank Pucino, Beth H. Resman-Targoff. (2006) Celecoxib versus a Non-Selective NSAID Plus Proton-Pump Inhibitor. Journal of Pain and Palliative Care Pharmacotherapy 20:4, 11-32
CrossRef685
C. Birbara, G. Ruoff, E. Sheldon, C. Valenzuela, A. Rodgers, R. A. Petruschke, D. J. Chang, A. M. Tershakovec. (2006) Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current Medical Research and Opinion 22:1, 199-210
CrossRef686
William K. Sietsema. (2006) Product Pipelines and Pharmaceutical Risk Management in the New Era of Strict Regulatory Scrutiny. International Journal of Pharmaceutical Medicine 20:2, 99-106
CrossRef687
Maurits W. Tulder, Bart Koes, Antti Malmivaara. (2006) Outcome of non-invasive treatment modalities on back pain: an evidence-based review. European Spine Journal 15:S1, S64-S81
CrossRef688
James M Scheiman. (2006) Unmet Needs in Non-steroidal Anti-inflammatory Drug-induced Upper Gastrointestinal Diseases. Drugs 66:Suppl 1, 15???21
CrossRef689
John E. Madias, Nicolaos E. Madias. (2006) Reversible Attenuation of the ECG Voltage Due to Peripheral Edema Associated With Treatment With a COX-2 Inhibitor. Congestive Heart Failure 12:1, 46-50
CrossRef690
Hasan Fehmi Kucuk, Sadık Mehmet Bingul, Necmi Kurt, Levent Kaptanoglu, Huseyin Akyol, Oguzhan Aziz Torlak, Elif Colak. (2006) Effect of a Selective Cyclooxygenase-2 Inhibitor on Renal Scarring. European Surgical Research 38:5, 451-457
CrossRef691
J??rgen N??sdal, Kurt Brown. (2006) NSAID-Associated Adverse Effects and Acid Control Aids to Prevent Them. Drug Safety 29:2, 119-132
CrossRef692
(2006) News In Brief. Nature Reviews Drug Discovery 5:1, 10-11
CrossRef693
Christopher J. Hawkey, Xavier Gitton, Godehard Hoexter, Dominik Richard, Wilfred M. Weinstein. (2006) Gastrointestinal Tolerability of Lumiracoxib in Patients With Osteoarthritis and Rheumatoid Arthritis. Clinical Gastroenterology and Hepatology 4:1, 57-66
CrossRef694
Ðngel Lanas, Carmelo Scarpignato. (2006) Microbial Flora in NSAID-Induced Intestinal Damage: A Role for Antibiotics?. Digestion 73:1, 136-150
CrossRef695
Lorne J. Hofseth, Lei Ying. (2006) Identifying and defusing weapons of mass inflammation in carcinogenesis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1765:1, 74-84
CrossRef696
Curfman, Gregory D., Morrissey, Stephen, Drazen, Jeffrey M., . (2005) Expression of Concern: Bombardier et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” N Engl J Med 2000;343:1520-8.. New England Journal of Medicine 353:26, 2813-2814
Full Text697
Lauren A. Trepanier. (2005) Potential interactions between non-steroidal anti-inflammatory drugs and other drugs. Journal of Veterinary Emergency and Critical Care 15:4, 248-253
CrossRef698
Mansoor Ahmed, Dinesh Khanna, Daniel E Furst. (2005) Meloxicam in rheumatoid arthritis. Expert Opinion on Drug Metabolism & Toxicology 1:4, 739-751
CrossRef699
Neena S Abraham, David Y Graham. (2005) NSAIDs and gastrointestinal complications: new clinical challenges. Expert Opinion on Pharmacotherapy 6:15, 2681-2689
CrossRef700
Anwar ARSHAD, Mohammed Shahdan SHAHID. (2005) Mortality in rheumatoid arthritis: time to take it seriously. APLAR Journal of Rheumatology 8:3, 154-158
CrossRef701
S. Nitschmann, J. Mössner. (2005) ASS oder Clopidogrel plus Esomeprazol bei Patienten nach Ulkusblutungen. Der Internist 46:12, 1405-1408
CrossRef702
H. B. J. Fischer, C. J. P. Simanski, . (2005) A procedure-specific systematic review and consensus recommendations for analgesia after total hip replacement. Anaesthesia 60:12, 1189-1202
CrossRef703
James D. Lewis, Stephen E. Kimmel, A. Russell Localio, David C. Metz, John T. Farrar, Lisa Nessel, Colleen Brensinger, Karen McGibney, Brian L. Strom. (2005) Risk of Serious Upper Gastrointestinal Toxicity With Over-the-Counter Nonaspirin Nonsteroidal Anti-inflammatory Drugs. Gastroenterology 129:6, 1865-1874
CrossRef704
C. Zerbini, Z. E. Ozturk, J. Grifka, M. Maini, S. Nilganuwong, R. Morales, M. Hupli, M. Shivaprakash, H. Giezek. (2005) Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4‐week, multinational, randomized, double-blind study. Current Medical Research and Opinion 21:12, 2037-2049
CrossRef705
Gary W. Williams. (2005) An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. Current Pain and Headache Reports 9:6, 377-389
CrossRef706
(2005) More bad news about anti-inflammatory agents. Journal of Medical Toxicology 1:1, 36-37
CrossRef707
Qiao-Hong Chen, P.N. Praveen Rao, Edward E. Knaus. (2005) Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: A novel class of cyclooxygenase-2 inhibitors. Bioorganic & Medicinal Chemistry 13:23, 6425-6434
CrossRef708
Ichiro Kudo, Makoto Murakami. (2005) Prostaglandin E Synthase, a Terminal Enzyme for Prostaglandin E 2 Biosynthesis. Journal of Biochemistry and molecular biology 38:6, 633-638
CrossRef709
P.N. Praveen Rao, Qiao-Hong Chen, Edward E. Knaus. (2005) Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorganic & Medicinal Chemistry Letters 15:21, 4842-4845
CrossRef710
James M Brophy. (2005) Celecoxib and cardiovascular risks. Expert Opinion on Drug Safety 4:6, 1005-1015
CrossRef711
Tsui-Yao Chen, Ming-Shi Shiao, Bonnie Sun Pan. (2005) Inhibition of 12- and 15-lipoxygenase activities and protection of human and tilapia low density lipoprotein oxidation by I-Tiao-Gung (Glycine tomentella). Lipids 40:11, 1171-1177
CrossRef712
Danny Liew, Henry Krum. (2005) The cardiovascular safety of celecoxib. Future Cardiology 1:6, 709-722
CrossRef713
Barry Bowen, Yuhong Yuan, Cindy James, Ferid Rashid, Richard H. Hunt. (2005) Time Course and Pattern of Blood Loss With Ibuprofen Treatment in Healthy Subjects. Clinical Gastroenterology and Hepatology 3:11, 1075-1082
CrossRef714
Jin Sheng Guo, Fung Ling Chau, Chi Hin Cho, Marcel Wing Leung Koo. (2005) Worsening effect of partial sleep deprivation on indomethacin-induced gastric mucosal damage. Pharmacology Biochemistry and Behavior 82:3, 515-521
CrossRef715
S. MEHTA, I. T. JOHNSON, M. RHODES. (2005) Systematic review: the chemoprevention of oesophageal adenocarcinoma. Alimentary Pharmacology and Therapeutics 22:9, 759-768
CrossRef716
Denis M. McCarthy. (2005) Occult GI Bleeding in NSAID Users—The Base of the Iceberg!. Clinical Gastroenterology and Hepatology 3:11, 1071-1074
CrossRef717
Trevor Penning, Lawrence Szewczuk. 2005. Resveratrol and Prostaglandin Biosynthesis. , 215-232.
CrossRef718
Robert J. Kaplan. (2005) Current Status of NonsteroidalAnti-Inflammatory Drugsin Physiatry. American Journal of Physical Medicine & Rehabilitation 84:11, 885-894
CrossRef719
Gregory E. Simon, Bruce M. Psaty, Jennifer Berg Hrachovec, Marc Mora. (2005) Principles For Evidence-Based Drug Formulary Policy. Journal of General Internal Medicine 20:10, 964-968
CrossRef720
G. Singh, G. Triadafilopoulos. (2005) Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. International Journal of Clinical Practice 59:10, 1210-1217
CrossRef721
Christianne L. Roumie, Patrick G. Arbogast, Edward F. Mitchel, Marie R. Griffin. (2005) Prescriptions for Chronic High-Dose Cyclooxygenase-2 Inhibitors are Often Inappropriate and Potentially Dangerous. Journal of General Internal Medicine 20:10, 879-883
CrossRef722
I. A. Scott, P. B. Greenberg. (2005) Cautionary tales in the clinical interpretation of therapeutic trial reports. Internal Medicine Journal 35:10, 611-621
CrossRef723
M MODICA, P VANHEMS, J TEBIB. (2005) Comparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients. Joint Bone Spine 72:5, 397-402
CrossRef724
N. L. P. Barnes, N. J. Bundred. (2005) COX-2 inhibitors in breast cancer. Breast Cancer Online 8:10,
CrossRef725
Lisa K. Stamp, Michael J. James, Leslie G. Cleland. (2005) Diet and Rheumatoid Arthritis: A Review of the Literature. Seminars in Arthritis and Rheumatism 35:2, 77-94
CrossRef726
Fadia T Shaya, Navendu Samant, Richard Skolasky, Elijah Saunders. (2005) Modeling risk of gastrointestinal events among Medicaid NSAID users using propensity scores. Expert Review of Pharmacoeconomics & Outcomes Research 5:5, 625-632
CrossRef727
Neena S. Abraham, Hashem B. El–Serag, Michael L. Johnson, Christine Hartman, Peter Richardson, Wayne A. Ray, Walter Smalley. (2005) National Adherence to Evidence-Based Guidelines for the Prescription of Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology 129:4, 1171-1178
CrossRef728
Werner Kiefer, Gerd Dannhardt. (2005) COX-2 inhibition and pain management: a review summary. Expert Review of Clinical Immunology 1:3, 431-442
CrossRef729
F. CIPOLLONE, M. FAZIA, A. MEZZETTI. (2005) Novel determinants of plaque instability. Journal of Thrombosis and Haemostasis 3:9, 1962-1975
CrossRef730
G. Durrieu, P. Olivier, J. L. Montastruc, . (2005) COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database. European Journal of Clinical Pharmacology 61:8, 611-614
CrossRef731
J.J. Grau de Castro. (2005) Inhibidores de la ciclooxigenasa-2 en la prevención del cáncer. Revista Clínica Española 205:9, 446-456
CrossRef732
J. BONNET. (2005) Review article: a cardiologist's view of the risks and benefits of cyclo-oxygenase-2 inhibitors, aspirin and other non-steroidal anti-inflammatory drugs. Alimentary Pharmacology & Therapeutics Symposium Series 1:1, 11-15
CrossRef733
Boris Sapoznikov, Alex Vilkin, Marcella Hershkovici, Michal Fishman, Rami Eliakim, Yaron Niv. (2005) Minidose Aspirin and Gastrointestinal Bleeding—A Retrospective, Case–Control Study in Hospitalized Patients. Digestive Diseases and Sciences 50:9, 1621-1624
CrossRef734
A. LANAS. (2005) Review article: recommendations for the clinical management of patients taking non-steroidal anti-inflammatory drugs - a gastroenterologist's perspective. Alimentary Pharmacology & Therapeutics Symposium Series 1:1, 16-19
CrossRef735
Mary Sarah Bergh, Steven C. Budsberg. (2005) The Coxib NSAIDs: Potential Clinical and Pharmacologic Importance in Veterinary Medicine. Journal of Veterinary Internal Medicine 19:5, 633-643
CrossRef736
Stefan R. Florentinus, Eibert R. Heerdink, Antonius de Boer, Liset van Dijk, Hubert G.M. Leufkens. (2005) The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiology and Drug Safety 14:9, 669-669
CrossRef737
D. J. Dickson. (2005) Who's failing who in pain relief?. International Journal of Clinical Practice 59:9, 1109-1111
CrossRef738
A. L. WEAVER. (2005) Review article: aspirin, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-1 sparing agents. Alimentary Pharmacology & Therapeutics Symposium Series 1:1, 2-5
CrossRef739
Angel Lanas, Maria Angeles Perez-Aisa, Faust Feu, Julio Ponce, Esteban Saperas, Santos Santolaria, Luis Rodrigo, Joaquim Balanzo, Eduardo Bajador, Pedro Almela, Jose M. Navarro, Fernando Carballo, Manuel Castro, Enrique Quintero, . (2005) A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use. The American Journal of Gastroenterology 100:8, 1685-1693
CrossRef740
Piercarlo Sarzi-Puttini, Marco A. Cimmino, Raffaele Scarpa, Roberto Caporali, Fabio Parazzini, Augusto Zaninelli, Fabiola Atzeni, Bianca Canesi. (2005) Osteoarthritis: An Overview of the Disease and Its Treatment Strategies. Seminars in Arthritis and Rheumatism 35:1, 1-10
CrossRef741
Brigitta M. Peskar. (2005) Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing. InflammoPharmacology 13:1-3, 15-26
CrossRef742
Peter Tugwell, Maria G. Judd, Jim F. Fries, Gurkirpal Singh, George A. Wells. (2005) Powering our way to the elusive side effect: A composite outcome ‘basket’ of predefined designated endpoints in each organ system should be included in all controlled trials. Journal of Clinical Epidemiology 58:8, 785-790
CrossRef743
Elliot V. Hersh, Edward T. Lally, Paul A. Moore. (2005) Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?*. Current Medical Research and Opinion 21:8, 1217-1226
CrossRef744
Dirk Duppen. (2005) Wetenschapsfilosofie en commerciële belangen in het debat over evidence-based geneeskunde. Huisarts en Wetenschap 48:8, 451-454
CrossRef745
Marta L Capone, Stefania Tacconelli, Paola Patrignani. (2005) Clinical pharmacology of etoricoxib. Expert Opinion on Drug Metabolism & Toxicology 1:2, 269-282
CrossRef746
D. PEREG, M. LISHNER. (2005) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. Journal of Internal Medicine 258:2, 115-123
CrossRef747
Rosaria Ottanà, Rosanna Maccari, Maria Letizia Barreca, Giuseppe Bruno, Archimede Rotondo, Antonietta Rossi, Giuseppa Chiricosta, Rosanna Di Paola, Lidia Sautebin, Salvatore Cuzzocrea, Maria Gabriella Vigorita. (2005) 5-Arylidene-2-imino-4-thiazolidinones: Design and synthesis of novel anti-inflammatory agents. Bioorganic & Medicinal Chemistry 13:13, 4243-4252
CrossRef748
Margaret E. McCann, Eric L. Rickes, Donald F. Hora, Paul K. Cunningham, Donghui Zhang, Christine Brideau, W. Cameron Black, Gerard J. Hickey. (2005) In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. American Journal of Veterinary Research 66:7, 1278-1284
CrossRef749
Patrick P. Gleason, Clint Williams, Sally Hrdy, Steven C. Hartwig, David Lassen. (2005) Medical and Pharmacy Expenditures After Implementation of a Cyclooxygenase-2 Inhibitor Prior Authorization Program. Pharmacotherapy 25:7, 924-934
CrossRef750
Tong Wu. (2005) Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1755:2, 135-150
CrossRef751
Daniel H. Solomon. (2005) Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis & Rheumatism 52:7, 1968-1978
CrossRef752
Sherrie L. Aspinall, Chester B. Good, Peter A. Glassman, Michael A. Valentino. (2005) The Evolving Use of Cost-Effectiveness Analysis in Formulary Management Within the Department of Veterans Affairs. Medical Care 43:Supplement, II-20-II-26
CrossRef753
Stefan R. Florentinus, Eibert R. Heerdink, Antonius de Boer, Liset van Dijk, Hubert G. M. Leufkens. (2005) The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiology and Drug Safety 14:7, 437-441
CrossRef754
Matthew Wagner, James Loos, Nicole Weksler, Marin Gantner, Christopher L. Corless, John M. Barry, Tomasz M. Beer, Mark Garzotto. (2005) Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochemical and Biophysical Research Communications 332:3, 800-807
CrossRef755
Ming-hui LI, Lin-lin YIN, Mao-jun CAI, Wei-yu ZHANG, Yue HUANG, Xin WANG, Xing-zu ZHU, Jing-kang SHEN. (2005) Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives. Acta Pharmacologica Sinica 26:7, 865-872
CrossRef756
Kenneth Khamly, Michael Jefford, Michael Michael, John Zalcberg. (2005) Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opinion on Investigational Drugs 14:6, 607-628
CrossRef757
John L Wallace, Pallavi R Devchand. (2005) Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. British Journal of Pharmacology 145:3, 275-282
CrossRef758
Gary Spektor, Valentin Fuster. (2005) Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?. Nature Clinical Practice Cardiovascular Medicine 2:6, 290-300
CrossRef759
Lee S. Simon, Vibeke Strand. (2005) Perception of risk: The state of COX-2 selective inhibitors. Current Rheumatology Reports 7:3, 163-166
CrossRef760
Maureen P. Flattery, Leigh Anne Hylton Gravatt. (2005) COX-2 Inhibitors and Cardiovascular Risk. Progress in Cardiovascular Nursing 20:3, 123-125
CrossRef761
Leon J Thal, Steven H Ferris, Louis Kirby, Gilbert A Block, Christopher R Lines, Eric Yuen, Christopher Assaid, Michael L Nessly, Barbara A Norman, Christine C Baranak, Scott A Reines. (2005) A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment. Neuropsychopharmacology 30:6, 1204-1215
CrossRef762
Michel Burnier. (2005) The safety of rofecoxib. Expert Opinion on Drug Safety 4:3, 491-499
CrossRef763
Laurence Maiden, Bjarni Thjodleifsson, Asgeir Theodors, Juan Gonzalez, Ingvar Bjarnason. (2005) A Quantitative Analysis of NSAID-Induced Small Bowel Pathology by Capsule Enteroscopy. Gastroenterology 128:5, 1172-1178
CrossRef764
Paul J. Desjardins, Donald R. Mehlisch, David J. Chang, David Krupa, Adam B. Polis, Richard A. Petruschke, Kerstin Malmstrom, Gregory P. Geba. (2005) The Time to Onset and Overall Analgesic Efficacy of Rofecoxib 50 mg. The Clinical Journal of Pain 21:3, 241-250
CrossRef765
Grant D. Innes, Peter J. Zed. (2005) Basic Pharmacology and Advances in Emergency Medicine. Emergency Medicine Clinics of North America 23:2, 433-465
CrossRef766
Dena R. Ramey, Douglas J. Watson, Chang Yu, James A. Bolognese, Sean P. Curtis, Alise S. Reicin. (2005) The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis* * Some of the material included in this manuscript was presented at the American College of Rheumatology 2003 Annual Meeting (Orlando, FL, 23–26 November 2003) and at the 2004 European League Against Rheumatism meeting (Berlin, Germany, 9–12 June 2004). Current Medical Research and Opinion 21:5, 715-722
CrossRef767
S. Straube, S. Derry, H. J. McQuay, R. A. Moore. (2005) Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: A systematic review of randomized studies. Acta Anaesthesiologica Scandinavica 49:5, 601-613
CrossRef768
Dingzhi Wang, Jason R. Mann, Raymond N. Dubois. (2005) The Role of Prostaglandins and Other Eicosanoids in the Gastrointestinal Tract. Gastroenterology 128:5, 1445-1461
CrossRef769
Rosemarie A Reiter, Bernd Jilma. (2005) Platelets and new antiplatelet drugs. Therapy 2:3, 465-502
CrossRef770
Robert J MacFadyen, Thomas M MacDonald. (2005) Cardiovascular safety of COX-2 inhibition: time to inform systems of postmarketing surveillance?. Therapy 2:3, 325-328
CrossRef771
Alaa Rostom, Lawrence Goldkind, Loren Laine. (2005) Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients. Clinical Gastroenterology and Hepatology 3:5, 489-498
CrossRef772
Chris Hawkey, Nicholas J Talley, Neville D Yeomans, Roger Jones, Joseph J.Y. Sung, Goran Langstrom, Jorgen Naesdal, James M Scheiman, . (2005) Improvements with Esomeprazole in Patients with Upper Gastrointestinal Symptoms Taking Non-Steroidal Antiinflammatory Drugs, Including Selective COX-2 Inhibitors. The American Journal of Gastroenterology 100:5, 1028-1036
CrossRef773
Linda Rabeneck, Jay L. Goldstein, An Vu, Tracy J. Mayne, Dale A. Rublee. (2005) Valdecoxib Is Associated with Improved Dyspepsia-Related Health Compared with Nonspecific NSAIDs in Patients with Osteoarthritis or Rheumatoid Arthritis. The American Journal of Gastroenterology 100:5, 1043-1050
CrossRef774
Bertrand Naveau. (2005) Dual Inhibition of Cyclo-oxygenases and 5-Lipoxygenase: a Novel Therapeutic Approach to Inflammation?. Joint Bone Spine 72:3, 199-201
CrossRef775
Steven Gabardi, Stuart Abramson. (2005) Drug Dosing in Chronic Kidney Disease. Medical Clinics of North America 89:3, 649-687
CrossRef776
Farid E Ahmed. (2005) Molecular markers that predict response to colon cancer therapy. Expert Review of Molecular Diagnostics 5:3, 353-375
CrossRef777
B. Rattray, D. J. Nugent, G. Young. (2005) Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia 11:3, 240-244
CrossRef778
J.L. Pablos Álvarez. (2005) Antiinflamatorios no esteroideos y analgésicos en las enfermedades articulares. Medicine - Programa de Formación Médica Continuada Acreditado 9:32, 2117-2123
CrossRef779
JORDAN BAKER, JAMES D. COTTER, DAVID F. GERRARD, MELANIE L. BELL, ROBERT J. WALKER. (2005) Effects of Indomethacin and Celecoxib on Renal Function in Athletes. Medicine & Science in Sports & Exercise 37:5, 712-717
CrossRef780
Muhammad Mamdani. (2005) Are rates of gastrointestinal bleeding higher following the introduction of COX-2 inhibitors?. Expert Opinion on Drug Safety 4:3, 591-598
CrossRef781
Brennan M. R. Spiegel, Chiun-Fang Chiou, Joshua J. Ofman. (2005) Minimizing complications from nonsteroidal antiinflammatory drugs: Cost-effectiveness of competing strategies in varying risk groups. Arthritis & Rheumatism 53:2, 185-197
CrossRef782
S ZELCER, Y KOLESNIKOV, I KOVALYSHYN, D PASTERNAK, G PASTERNAK. (2005) Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs. Brain Research 1040:1-2, 151-156
CrossRef783
Jason R Mann, Michael G Backlund, Raymond N DuBois. (2005) Mechanisms of Disease: inflammatory mediators and cancer prevention. Nature Clinical Practice Oncology 2:4, 202-210
CrossRef784
Paola Patrignani, Stefania Tacconelli, Maria Gina Sciulli, Marta L. Capone. (2005) New insights into COX-2 biology and inhibition. Brain Research Reviews 48:2, 352-359
CrossRef785
Marta L. Capone, Maria G. Sciulli, Stefania Tacconelli, Marilena Grana, Emanuela Ricciotti, Giulia Renda, Patrizia Di Gregorio, Gabriele Merciaro, Paola Patrignani. (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. Journal of the American College of Cardiology 45:8, 1295-1301
CrossRef786
Steven R. Steinhubl. (2005) The use of anti-inflammatory analgesics in the patient with cardiovascular disease. Journal of the American College of Cardiology 45:8, 1302-1303
CrossRef787
Reiner Lehmann, Marek Brzosko, Petr Kopsa, Ruth Nischik, Andreas Kreiss, Helen Thurston, Stephane Litschig, Victor S. Sloan. (2005) Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Current Medical Research and Opinion 21:4, 517-526
CrossRef788
Lorenz M. Fischer, Raymond G. Schlienger, Christian M. Matter, Hershel Jick, Christoph R. Meier. (2005) Current Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction. Pharmacotherapy 25:4, 503-510
CrossRef789
Warren A. Katz, Russell Rothenberg. (2005) Section 4. JCR: Journal of Clinical Rheumatology 11:Supplement, S16-S28
CrossRef790
Okie, Susan, . (2005) Raising the Safety Bar — The FDA's Coxib Meeting. New England Journal of Medicine 352:13, 1283-1285
Full Text791
Psaty, Bruce M., Furberg, Curt D., . (2005) COX-2 Inhibitors — Lessons in Drug Safety. New England Journal of Medicine 352:11, 1133-1135
Full Text792
Bresalier, Robert S., Sandler, Robert S., Quan, Hui, Bolognese, James A., Oxenius, Bettina, Horgan, Kevin, Lines, Christopher, Riddell, Robert, Morton, Dion, Lanas, Angel, Konstam, Marvin A., Baron, John A., . (2005) Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. New England Journal of Medicine 352:11, 1092-1102
Full Text793
Solomon, Scott D., McMurray, John J.V., Pfeffer, Marc A., Wittes, Janet, Fowler, Robert, Finn, Peter, Anderson, William F., Zauber, Ann, Hawk, Ernest, Bertagnolli, Monica, . (2005) Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. New England Journal of Medicine 352:11, 1071-1080
Full Text794
Drazen, Jeffrey M., . (2005) COX-2 Inhibitors — A Lesson in Unexpected Problems. New England Journal of Medicine 352:11, 1131-1132
Full Text795
F. K. L. CHAN. (2005) Non-steroidal anti-inflammatory drugs and proton-pump inhibitors vs. cyclo-oxygenase-2 selective inhibitors in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Alimentary Pharmacology and Therapeutics 21:s1, 5-6
CrossRef796
G. M. Eisen, J. L. Goldstein, D. B. Hanna, D. A. Rublee. (2005) Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Alimentary Pharmacology and Therapeutics 21:5, 591-598
CrossRef797
Arantxa Catalán. (2005) Rofecoxib y riesgo de toxicidad cardiovascular: ¿hubieran justificado las evidencias acumuladas disponibles en cada momento una retirada más temprana del mercado?. FMC - Formación Médica Continuada en Atención Primaria 12:3, 195
CrossRef798
F
lix M. Arellano. (2005) The withdrawal of rofecoxib. Pharmacoepidemiology and Drug Safety 14:3, 213-217
CrossRef799
J.H. Fielder. (2005) The Vioxx debacle. IEEE Engineering in Medicine and Biology Magazine 24:2, 106-109
CrossRef800
A. LANAS. (2005) The appropriate use of proton-pump inhibitor co-therapy with non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors. Alimentary Pharmacology and Therapeutics 21:s1, 2-4
CrossRef801
Frank A Beebe, Robert L Barkin, Stacie Barkin. (2005) A Clinical and Pharmacologic Review of Skeletal Muscle Relaxants for Musculoskeletal Conditions. American Journal of Therapeutics 12:2, 151-171
CrossRef802
Heiko Reinold, Seifollah Ahmadi, Ulrike B. Depner, Beate Layh, Cornelia Heindl, May Hamza, Andreas Pahl, Kay Brune, Shuh Narumiya, Ulrike Müller, Hanns Ulrich Zeilhofer. (2005) Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. Journal of Clinical Investigation 115:3, 673-679
CrossRef803
Andreas Kopf, Anne Banzhaf, Christoph Stein. (2005) Perioperative management of the chronic pain patient. Best Practice & Research Clinical Anaesthesiology 19:1, 59-76
CrossRef804
Paul James Fortun, Christopher John Hawkey. (2005) Nonsteroidal antiinflammatory drugs and the small intestine. Current Opinion in Gastroenterology 21:2, 169-175
CrossRef805
Jeffrey D. Greenberg, Clifton O. Bingham, Steven B. Abramson, George Reed, Rolf J. Sebaldt, Joel Kremer. (2005) Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis & Rheumatism 53:1, 12-17
CrossRef806
Sheila A Doggrell. (2005) The safety of lumiracoxib when used in the treatment of arthritis. Expert Opinion on Pharmacotherapy 6:2, 347-350
CrossRef807
Adrian Cristian, Jodi Thomas, Michelle Nisenbaum, LilyAnn Jeu. (2005) Practical considerations in the assessment and treatment of pain in adults with physical disabilities. Physical Medicine and Rehabilitation Clinics of North America 16:1, 57-90
CrossRef808
E LIMARODRIGUEZ, J CALVOROMERO. (2005) Toxicidad gastrointestinal del rofecoxib. Atención Primaria 35:2, 110-111
CrossRef809
Xavier Carn
CrossRef810
Jay L. Goldstein, Glenn M. Eisen, Blair Lewis, Ian M. Gralnek, Steve Zlotnick, John G. Fort. (2005) Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clinical Gastroenterology and Hepatology 3:2, 133-141
CrossRef811
Simon RJ Maxwell, David J Webb. (2005) COX-2 selective inhibitors—important lessons learned. The Lancet 365:9458, 449-451
CrossRef812
David J Graham, David Campen, Rita Hui, Michele Spence, Craig Cheetham, Gerald Levy, Stanford Shoor, Wayne A Ray. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. The Lancet 365:9458, 475-481
CrossRef813
Ronald Esser, Carol Berry, Zhengming Du, Janet Dawson, Alyson Fox, Roger A Fujimoto, William Haston, Earl F Kimble, Julie Koehler, Jane Peppard, Elizabeth Quadros, Joseph Quintavalla, Karen Toscano, Laszlo Urban, John Duzer, Xiaoli Zhang, Siyuan Zhou, Paul J Marshall. (2005) Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. British Journal of Pharmacology 144:4, 538-550
CrossRef814
David Chantry, Laurence E Burgess. (2005) Inflammation Research Association: 12th international conference. Expert Opinion on Emerging Drugs 10:1, 219-224
CrossRef815
T. Jaworski, I. Sarosiek, S. Sostarich, K. Roeser, M. Connor, S. Brotze, G. Wallner, J. Sarosiek. (2005) Restorative Impact of Rabeprazole on Gastric Mucus and Mucin Production Impairment During Naproxen Administration: Its Potential Clinical Significance. Digestive Diseases and Sciences 50:2, 357-365
CrossRef816
Sarah E Garner, Dogan Fidan, Ruth R Frankish, Maria Judd, Tanveer Towheed, Peter Tugwell, George A Wells, Sarah E Garner. 2005. Rofecoxib for rheumatoid arthritis. .
CrossRef817
Eric Sheldon, Andre Beaulieu, Zorba Paster, Dipen Dutta, Sue Yu, Victor S. Sloan. (2005) Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo. Clinical Therapeutics 27:1, 64-77
CrossRef818
Francis K L Chan. (2005) NSAID-Induced Peptic Ulcers and Helicobacter pylori Infection. Drug Safety 28:4, 287-300
CrossRef819
James L. Ellis, Michael E. Augustyniak, Edward D. Cochran, Richard A. Earl, David S. Garvey, Laura J. Gordon, David R. Janero, Subhash P. Khanapure, L. Gordon Letts, Terry L. Melim, Madhavi G. Murty, David J. Schwalb, Matthew J. Shumway, William M. Selig, A. Mark Trocha, Delano V. Young, Irina S. Zemtseva. (2005) NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. InflammoPharmacology 12:5-6, 521-534
CrossRef820
Ken Shinmura. (2005) Possible mechanisms of cyclooxygenase (COX)-2 hazard: Is COX-2 in the cardiovascular system a friend or a foe?. Ensho Saisei 25:6, 517-524
CrossRef821
Shinichi Kawai, Fumiaki Kojima, Natsuko Kusunoki. (2005) Recent Advances in Nonsteroidal Anti-Inflammatory Drugs. Allergology International 54:2, 209-215
CrossRef822
Sebastian Schneeweiss, Robert J. Glynn, Elizabeth H. Tsai, Jerry Avorn, Daniel H. Solomon. (2005) Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using External Information. Epidemiology 16:1, 17-24
CrossRef823
Ian Gilron, Elizabeth Orr, Dongsheng Tu, J. Peter O'Neill, Jorge E. Zamora, Allan C. Bell. (2005) A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. Pain 113:1-2, 191-200
CrossRef824
Matthias Hermann, Frank Enseleit, Frank T. Ruschitzka. (2005) Anti-inflammatory strategies in hypertension: Focus on COX-1 and COX-2. Current Hypertension Reports 7:1, 52-60
CrossRef825
Thomas J. Schnitzer, James R. Fricke, Xavier Gitton, Sumedha Jayawardene, Victor S. Sloan. (2005) Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies. Current Medical Research and Opinion 21:1, 151-161
CrossRef826
Peter Jüni, Stephan Reichenbach, Paul A Dieppe, Matthias Egger. (2005) Discontinuation of Vioxx. The Lancet 365:9453, 26-27
CrossRef827
Michel Lièvre, Eric Abadie. (2005) Discontinuation of Vioxx. The Lancet 365:9453, 23-24
CrossRef828
Jack Nyberg. (2005) Discontinuation of Vioxx. The Lancet 365:9453, 24-25
CrossRef829
Carsten H. Meyer, Jörg C. Schmidt, Eduardo B. Rodrigues, Stefan Mennel. (2005) Risk of Retinal Vein Occlusions in Patients Treated with Rofecoxib (Vioxx). Ophthalmologica 219:4, 243-247
CrossRef830
Monica Schaefer, Melissa DeLattre, Xin Gao, Jennifer Stephens, Marc Botteman, Anthony Morreale. (2005) Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Current Medical Research and Opinion 21:1, 47-60
CrossRef831
Arrigo F G Cicero, Giuseppe Derosa, Antonio Gaddi. (2005) Combined Lipoxygenase/Cyclo-oxygenase Inhibition in the Elderly. Drugs & Aging 22:5, 393-403
CrossRef832
Andreas Stang, Hans-Werner Hense, Karl-Heinz Jöckel, Erick H. Turner, Martin R. Tramèr. (2005) Is It Always Unethical to Use a Placebo in a Clinical Trial?. PLoS Medicine 2:3, e72
CrossRef833
??ric Toussirot, Daniel Wendling. (2005) Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies. Drugs & Aging 22:6, 451-469
CrossRef834
Yaron Niv, Alex Battler, Galia Abuksis, Eyal Gal, Boris Sapoznikov, Alex Vilkin. (2005) Endoscopy in Asymptomatic Minidose Aspirin Consumers. Digestive Diseases and Sciences 50:1, 78-80
CrossRef835
Hiltrud Liedgens, Mark J C Nuijten, Barbara Poulsen Nautrup. (2005) Economic Evaluation of Tramadol/Paracetamol Combination Tablets for??Osteoarthritis Pain in The Netherlands. Clinical Drug Investigation 25:12, 785-802
CrossRef836
Sebastian Schneeweiss, Robert J. Glynn, Jerry Avorn, Daniel H. Solomon. (2005) A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. Journal of Clinical Epidemiology 58:1, 98-102
CrossRef837
Li-Xiong Shao, Min Shi. (2005) Facile synthesis of multisubstituted buta-1,3-dienes via Suzuki–Miyaura and Kumada cross-coupling strategy of 2,4-diiodo-buta-1-enes with arylboronic acids and Grignard reagents. Organic & Biomolecular Chemistry 3:10, 1828
CrossRef838
Jaspreet S Sandhu, E Darracott Vaughan. (2005) Combination Therapy for the Pharmacological Management of Benign Prostatic Hyperplasia. Drugs & Aging 22:11, 901-912
CrossRef839
Girish P Joshi. (2005) Valdecoxib for the management of chronic and acute pain. Expert Review of Neurotherapeutics 5:1, 11-24
CrossRef840
Lisa Stamp, Martin Searle, John O???Donnell, Peter Chapman. (2005) Gout in Solid Organ Transplantation. Drugs 65:18, 2593-2611
CrossRef841
Fadia T. Shaya, Steven Blume. (2005) Prescriptions for Cyclooxygenase-2 Inhibitors and Other Nonsteroidal Anti-inflammatory Agents in a Medicaid Managed Care Population: African Americans Versus Caucasians. Pain Medicine 6:1, 11-17
CrossRef842
M Hassan-Alin, J Naesdal, C Nilsson-Pieschl, G L??ngstr??m, T Andersson. (2005) Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Clinical Drug Investigation 25:11, 731-740
CrossRef843
Erick Turner, Martin Tramèr. (2005) Authors' Reply. PLoS Medicine 2:6, e187
CrossRef844
Mira Harrison-Woolrych, Peter Herbison, Rachael McLean, Janelle Ashton, Jim Slattery. (2005) Incidence of Thrombotic Cardiovascular Events in Patients Taking Celecoxib Compared with Those Taking Rofecoxib. Drug Safety 28:5, 435-442
CrossRef845
Florian Krötz, Thomas M. Schiele, Volker Klauss, Hae-Young Sohn. (2005) Selective COX-2 Inhibitors and Risk of Myocardial Infarction. Journal of Vascular Research 42:4, 312-324
CrossRef846
M LABETOULLE. (2005) Le retrait du Vioxx™ : des leçons pour tous. Journal Français d'Ophtalmologie 28:1, 126-127
CrossRef847
Takuji Machida, Miho Hiramatsu, Naoya Hamaue, Masaru Minami, Masahiko Hirafuji. (2005) Docosahexaenoic Acid Enhances Cyclooxygenase-2 Induction by Facilitating p44/42, but Not p38, Mitogen-Activated Protein Kinase Activation in Rat Vascular Smooth Muscle Cells. Journal of Pharmacological Sciences 99:1, 113-116
CrossRef848
Stuart J Warden. (2005) Cyclo-Oxygenase-2 Inhibitors. Sports Medicine 35:4, 271-283
CrossRef849
Peter S Kim, Alise S Reicin. (2005) Discontinuation of Vioxx. The Lancet 365:9453, 23
CrossRef850
Jonathan A Rosenberg, Jay L Goldstein. (2005) Safety and efficacy of lumiracoxib compared with NSAIDs. Nature Clinical Practice Gastroenterology & Hepatology 2:1, 14-15
CrossRef851
Francis Berenbaum. (2005) VIOXX and cardiovascular events: a class effect?. Joint Bone Spine 72:1, 1-3
CrossRef852
Shin Chung, Kyung Min Lim, Song Seok Shin. (2005) Profiles of COX-2 inhibitors: present and future. Expert Opinion on Therapeutic Patents 15:1, 9-32
CrossRef853
Thomas R McLean. (2005) Discontinuation of Vioxx. The Lancet 365:9453, 25
CrossRef854
Eustachio Nettis, Maria C. Colanardi, Antonio Ferrannini, Alfredo Tursi. (2005) Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Annals of Allergy, Asthma & Immunology 94:1, 29-33
CrossRef855
(2004) Rofecoxib, Merck, and the FDA. New England Journal of Medicine 351:27, 2875-2878
Full Text856
D. J. Watson, J. A. Bolognese, C. Yu, D. Krupa, S. Curtis. (2004) Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs*. Current Medical Research and Opinion 20:12, 1899-1908
CrossRef857
Mary F. Walter, Robert F. Jacob, Charles A. Day, Rachel Dahlborg, Yujia Weng, R. Preston Mason. (2004) Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 177:2, 235-243
CrossRef858
U. Grundmann, J. U. Schreiber. (2004) Selektive Zyklooxygenase-2-Inhibitoren zur postoperativen Schmerztherapie. Der Anaesthesist 53:12, 1211-1218
CrossRef859
Jan C. Becker, Wolfram Domschke, Thorsten Pohle. (2004) Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond. British Journal of Clinical Pharmacology 58:6, 587-600
CrossRef860
Jennifer M. Stephens, Chris L. Pashos, Seema Haider, Josephine M. Wong. (2004) Making Progress in the Management of Postoperative Pain: A Review of the Cyclooxygenase 2–Specific Inhibitors. Pharmacotherapy 24:12, 1714-1731
CrossRef861
Xuemei Luo, Ricardo Pietrobon, Lesley H. Curtis, Lloyd A. Hey. (2004) Prescription of Nonsteroidal Anti-inflammatory Drugs and Muscle Relaxants for Back Pain in the United States. Spine 29:23, E531-E537
CrossRef862
Stephen Y. Chang, Colin W. Howden. (2004) Is no NSAID a good NSAID? approaches to NSAID-associated upper gastrointestinal disease. Current Gastroenterology Reports 6:6, 447-453
CrossRef863
Steven A. Mazzuca, Kenneth D. Brandt, Barry P. Katz, Linda R. Ragozzino, Patricia M. G??Sell. (2004) Can a Nurse-Directed Intervention Reduce the Exposure of Patients With Knee Osteoarthritis to Nonsteroidal Antiinflammatory Drugs?. JCR: Journal of Clinical Rheumatology 10:6, 315-322
CrossRef864
Fischer, Michael A., Schneeweiss, Sebastian, Avorn, Jerry, Solomon, Daniel H., . (2004) Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors. New England Journal of Medicine 351:21, 2187-2194
Full Text865
Francis Berenbaum. (2004) COX-3: Fact or fancy?. Joint Bone Spine 71:6, 451-453
CrossRef866
Dieter Steinbilber, Stefan Laufer. (2004) Vioxx
CrossRef867
A. M. Blaicher, H. T. Landsteiner, J. Zwerina, U. Leitgeb, I. Volf, K. Hoerauf. (2004) Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time. Anaesthesia 59:11, 1100-1103
CrossRef868
J.B. Tuynman, M.P. Peppelenbosch, D.J. Richel. (2004) COX-2 inhibition as a tool to treat and prevent colorectal cancer. Critical Reviews in Oncology/Hematology 52:2, 81-101
CrossRef869
Susana Sánchez-Fidalgo, Inés Martín-Lacave, Matilde Illanes, Virginia Motilva. (2004) Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. European Journal of Pharmacology 505:1-3, 187-194
CrossRef870
Philip Schoenfeld. (2004) Evidence Based Medicine (EBM) in Practice: Applying Relative Risk and Relative Risk Reduction. The American Journal of Gastroenterology 99:11, 2084-2085
CrossRef871
E. J. Begg. (2004) Individualizing drug therapy, and 'men behaving badly'. British Journal of Clinical Pharmacology 58:5, 449-451
CrossRef872
Anthony N. DeMaria. (2004) The fallout from Vioxx. Journal of the American College of Cardiology 44:10, 2080-2081
CrossRef873
S. Lugardon, M. Lapeyre-Mestre, J. L. Montastruc, . (2004) Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. European Journal of Clinical Pharmacology 60:9, 673-677
CrossRef874
Rick A. Weideman, Kevin C. Kelly, Salahuddin Kazi, Anh Cung, Kevin W. Roberts, Herbert J. Smith, George A. Sarosi, Bertis B. Little, Byron Cryer. (2004) Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: A historical cohort analysis. Gastroenterology 127:5, 1322-1328
CrossRef875
Hyon K. Choi, John D. Seeger. (2004) Observational research in rheumatic disorders. Rheumatic Disease Clinics of North America 30:4, 685-699
CrossRef876
K. Arnold Chan, Sonia Hernandez-Diaz. (2004) Pharmacoepidemiology and rheumatic disorders. Rheumatic Disease Clinics of North America 30:4, 835-850
CrossRef877
P. Geusens, R. Alten, J. Rovensky, V.S. Sloan, G. Krammer, G. Kralidis, P. Richardson. (2004) Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. International Journal of Clinical Practice 58:11, 1033-1041
CrossRef878
Philippe Bertin. (2004) Should gastroprotective agents be given with COX-2 inhibitors? A question worthy of scrutiny. Joint Bone Spine 71:6, 454-456
CrossRef879
G. C. Fenn, M. Grobler, D. Schaffer. (2004) Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. Internal Medicine Journal 34:11, 647-649
CrossRef880
Topol, Eric J., . (2004) Failing the Public Health — Rofecoxib, Merck, and the FDA. New England Journal of Medicine 351:17, 1707-1709
Full Text881
Chin Lee, Walter L. Straus, Robert Balshaw, Suna Barlas, Suzanne Vogel, Thomas J. Schnitzer. (2004) A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: A meta-analysis. Arthritis & Rheumatism 51:5, 746-754
CrossRef882
C. Hartel, J. von Puttkamer, F. Gallner, T. Strunk, C. Schultz. (2004) Dose-dependent Immunomodulatory Effects of Acetylsalicylic Acid and Indomethacin in Human Whole Blood: Potential Role of Cyclooxygenase-2 Inhibition. Scandinavian Journal of Immunology 60:4, 412-420
CrossRef883
Byron Cryer. (2004) COX-2–specific inhibitor or proton pump inhibitor plus traditional NSAID: Is either approach sufficient for patients at highest risk of NSAID-induced ulcers?. Gastroenterology 127:4, 1256-1258
CrossRef884
Erbil Dogan, Uğur Saygili, Cemal Posaci, Burcin Tuna, Sezer Caliskan, Sabahattin Altunyurt, Bahadir Saatli. (2004) Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertility and Sterility 82, 1115-1120
CrossRef885
Karel PAVELKA. (2004) Symptomatic treatment of osteoarthritis: paracetamol or NSAIDs?. International Journal of Clinical Practice 58, 5-12
CrossRef886
Joaquín Quiralte, Julio Delgado, Blanca Sáenz de San Pedro, Esperanza López-Pascual, Maria A. Nieto, Nancy Ortega, Jose Fernando Florido, José Conde. (2004) Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Annals of Allergy, Asthma & Immunology 93:4, 360-364
CrossRef887
Paul J. Desjardins, Peter M. Black, Steven Daniels, Steven R. Bird, Brian J. Fitzgerald, Richard A. Petruschke, Andrew Tershakovec, David J. Chang. (2004) A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain. Current Medical Research and Opinion 20:10, 1523-1537
CrossRef888
George E EHRLICH. (2004) A benefit/risk assessment of existing therapeutic alternatives for the treatment of painful inflammatory conditions. International Journal of Clinical Practice 58, 20-26
CrossRef889
Francis K.L. Chan, Lawrence C.T. Hung, Bing Y. Suen, Vincent W.S. Wong, Aric J. Hui, Justin C.Y. Wu, Wai K. Leung, Yuk T. Lee, Ka F. To, S.C. Sydney Chung, Joseph J.Y. Sung. (2004) Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial. Gastroenterology 127:4, 1038-1043
CrossRef890
B. Witjes. (2004) Risico van selectieve COX-2-remmers. MFM 42:10, 278-279
CrossRef891
Anwar Umar, Michel Boisseau, Abdiryim Yusup, Halmurat Upur, Bernard Begaud, Nicholas Moore. (2004) Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Fundamental and Clinical Pharmacology 18:5, 559-563
CrossRef892
Jayne E. Edwards, Henry J. McQuay, R. Andrew Moore. (2004) Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Pain 111:3, 286-296
CrossRef893
Douglas J. Watson, Qinfen Yu, James A. Bolognese, Alise S. Reicin, Thomas J. Simon. (2004) The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis*. Current Medical Research and Opinion 20:10, 1539-1548
CrossRef894
T. J. Gan, G. P. Joshi, S. Z. Zhao, D. B. Hanna, R. Y. Cheung, C. Chen. (2004) Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. Acta Anaesthesiologica Scandinavica 48:9, 1194-1207
CrossRef895
Maryam Asgari, Emily White, Mary-Margaret Chren. (2004) Nonsteroidal Anti-inflammatory Drug Use in the Prevention and Treatment of Squamous Cell Carcinoma. Dermatologic Surgery 30:10, 1335-1342
CrossRef896
Helene Francois, Thomas M. Coffman. (2004) Prostanoids and blood pressure: which way is up?. Journal of Clinical Investigation 114:6, 757-759
CrossRef897
J. L. Goldstein, G. M. Eisen, N. Agrawal, W. F. Stenson, J. D. Kent, K. M. Verburg. (2004) Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Alimentary Pharmacology and Therapeutics 20:5, 527-538
CrossRef898
Tobias Kurth, Charles H. Hennekens, Julie E. Buring, J. Michael Gaziano. (2004) Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: Possible interactions and implications for treatment of rheumatoid arthritis. Current Rheumatology Reports 6:5, 351-356
CrossRef899
Thomas J. Schnitzer, Jannie Beier, Piet Geusens, Paul Hasler, Sanjay K. Patel, Ingo Senftleber, Xavier Gitton, Alan Moore, Victor S. Sloan, Gyula Poór. (2004) Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 51:4, 549-557
CrossRef900
Michael E Farkouh, Howard Kirshner, Robert A Harrington, Sean Ruland, Freek WA Verheugt, Thomas J Schnitzer, Gerd R Burmester, Eduardo Mysler, Marc C Hochberg, Michael Doherty, Elena Ehrsam, Xavier Gitton, Gerhard Krammer, Bernhard Mellein, Alberto Gimona, Patrice Matchaba, Christopher J Hawkey, James H Chesebro. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. The Lancet 364:9435, 675-684
CrossRef901
James M. Scheiman, A Mark Fendrick. (2004) Informed Choices in Anti-Inflammatory Drug Therapy. JCR: Journal of Clinical Rheumatology 10:4, 157-159
CrossRef902
Thomas J Schnitzer, Gerd R Burmester, Eduardo Mysler, Marc C Hochberg, Michael Doherty, Elena Ehrsam, Xavier Gitton, Gerhard Krammer, Bernhard Mellein, Patrice Matchaba, Alberto Gimona, Christopher J Hawkey. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. The Lancet 364:9435, 665-674
CrossRef903
Jennifer M Stephens, Christopher F Bell, Josephine M Wong, Beatriz M Peña, Seema Haider, Chris L Pashos. (2004) Value of cyclooxygenase-2 specific inhibitors in the management of osteoarthritis. Expert Review of Pharmacoeconomics & Outcomes Research 4:4, 441-455
CrossRef904
Eric J Topol, Gary W Falk. (2004) A coxib a day won't keep the doctor away. The Lancet 364:9435, 639-640
CrossRef905
Robert W. Dubois, Gil Y. Melmed, James M. Henning, Myriam Bernal. (2004) Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy. JCR: Journal of Clinical Rheumatology 10:4, 178-189
CrossRef906
James F. Fries, Kirsten N. Murtagh, Mihoko Bennett, Ernesto Zatarain, Bharathi Lingala, Bonnie Bruce. (2004) The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis & Rheumatism 50:8, 2433-2440
CrossRef907
A. Lanas. (2004) Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Alimentary Pharmacology and Therapeutics 20:3, 321-331
CrossRef908
Loren Laine, Eric S. Maller, Chang Yu, Hui Quan, Thomas Simon. (2004) Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial. Gastroenterology 127:2, 395-402
CrossRef909
Stuart I Harris, Randall R Stoltz, Dianne LeComte, Richard C Hubbard. (2004) Parecoxib Sodium Demonstrates Gastrointestinal Safety Comparable to Placebo in Healthy Subjects. Journal of Clinical Gastroenterology 38:7, 575-580
CrossRef910
S H Gardner, G Hawcroft, M A Hull. (2004) Effect of nonsteroidal anti-inflammatory drugs on β-catenin protein levels and catenin-related transcription in human colorectal cancer cells. British Journal of Cancer 91:1, 153-163
CrossRef911
C. J. Hawkey, M. Farkouh, X. Gitton, E. Ehrsam, J. Huels, P. Richardson. (2004) Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib - study design and patient demographics. Alimentary Pharmacology and Therapeutics 20:1, 51-63
CrossRef912
M. Lazzaroni, G. Bianchi Porro. (2004) Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Alimentary Pharmacology and Therapeutics 20:s2, 48-58
CrossRef913
James D Clark, Steve Tam. (2004) Potential therapeutic uses of phospholipase A 2 inhibitors. Expert Opinion on Therapeutic Patents 14:7, 937-950
CrossRef914
Jodi L. Mann, Tamara S. Evans. (2004) Gastrointestinal-Related Complications in a Long-Term Care Population Taking NSAIDs Versus COX-2 Inhibitor Therapy. The Consultant Pharmacist 19:7, 602-613
CrossRef915
Andrzej S. Tarnawski, Thomas C. Caves. (2004) Aspirin in the XXI century: its major clinical impact, novel mechanisms of action, and new safer formulations. Gastroenterology 127:1, 341-343
CrossRef916
P. Vergne-Salle, R.-M. Grilo, P. Bertin, C. Bonnet, D. Coyral, S. Perrot, R. Trèves. (2004) Douleurs en rhumatologie, aspects physiopathologiques, moyens d'évaluation, moyens thérapeutiques. EMC - Rhumatologie-Orthopédie 1:4, 266-294
CrossRef917
Rebecca L. Darling, Jimmy J. Romero, Elizabeth J. Dial, Jacqueline K. Akunda, Robert Langenbach, Lenard M. Lichtenberger. (2004) The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology 127:1, 94-104
CrossRef918
Andreas Otto Reiff. (2004) Developments in the treatment of juvenile arthritis. Expert Opinion on Pharmacotherapy 5:7, 1485-1496
CrossRef919
P.W. Sheeran, J.B. Rose, L.M. Fazi, R. Chiavacci, L. McCormick. (2004) Rofecoxib administration to paediatric patients undergoing adenotonsillectomy. Pediatric Anesthesia 14:7, 579-583
CrossRef920
C. J. Hawkey. (2004) Non-steroidal anti-inflammatory drugs: who should receive prophylaxis?. Alimentary Pharmacology and Therapeutics 20:s2, 59-64
CrossRef921
Robert Petrella, Evan F. Ekman, Reinhard Schuller, John G. Fort. (2004) Efficacy of Celecoxib, a COX-2–Specific Inhibitor, and Naproxen in the Management of Acute Ankle Sprain. Clinical Journal of Sport Medicine 14:4, 225-231
CrossRef922
Robin Matuk, Jonathan Crawford, Maria T. Abreu, Stephan R. Targan, Eric A. Vasiliauskas, Konstantinos A. Papadakis. (2004) The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 10:4, 352-356
CrossRef923
Wood, Alastair J.J., , O'Dell, James R., . (2004) Therapeutic Strategies for Rheumatoid Arthritis. New England Journal of Medicine 350:25, 2591-2602
Full Text924
Kenneth G. Saag, Jason J. Olivieri, Fausto Patino, Ted R. Mikuls, Jeroan J. Allison, Catherine H. MacLean. (2004) Measuring quality in arthritis care: The Arthritis Foundation's quality indicator set for analgesics. Arthritis & Rheumatism 51:3, 337-349
CrossRef925
L.-C. Chen, R. A. Elliott, D. M. Ashcroft. (2004) Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control. Journal of Clinical Pharmacy and Therapeutics 29:3, 215-229
CrossRef926
E. Mysler. (2004) Lumiracoxib (Prexige®): a new selective cox-2 inhibitor. International Journal of Clinical Practice 58:6, 606-611
CrossRef927
A. J. Kivitz, S. Nayiager, T. Schimansky, A. Gimona, H. J. Thurston, C. Hawkey. (2004) Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Alimentary Pharmacology and Therapeutics 19:11, 1189-1198
CrossRef928
Avril Melissa Houston, Stephen J. Teach. (2004) COX-2 Inhibitors. Pediatric Emergency Care 20:6, 396-399
CrossRef929
Garret A. FitzGerald. (2004) Prostaglandins. JCR: Journal of Clinical Rheumatology 10:Supplement, S12-S17
CrossRef930
Nathaniel Katz, Diana B. Rodgers, David Krupa, Alise Reicin. (2004) Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials*. Current Medical Research and Opinion 20:5, 651-658
CrossRef931
Keri L. Fakata. (2004) Anti-inflammatory agents for the treatment of musculoskeletal pain and arthritis. Current Pain and Headache Reports 8:3, 173-177
CrossRef932
Muhammad Mamdani, David N Juurlink, Douglas S Lee, Paula A Rochon, Alex Kopp, Gary Naglie, Peter C Austin, Andreas Laupacis, Therese A Stukel. (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. The Lancet 363:9423, 1751-1756
CrossRef933
F. K. L. Chan, D. Y. Graham. (2004) Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. Alimentary Pharmacology and Therapeutics 19:10, 1051-1061
CrossRef934
Scott Korn, Theodore C Vassil, Paul N.-A Kotey, James R Fricke. (2004) Comparison of rofecoxib and oxycodone plus acetaminophen in the treatment of acute pain: A randomized, double-blind, placebo-controlled study in patients with moderate to severe postoperative pain in the third molar extraction model. Clinical Therapeutics 26:5, 769-778
CrossRef935
B. Fautrel. (2004) Pharmacoepidemiology: lessons from real life. Joint Bone Spine 71:3, 175-177
CrossRef936
S BOUEE. (2004) Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era?concomitant gastroprotective therapy. Joint Bone Spine 71:3, 214-220
CrossRef937
Kim L. Isaacs. (2004) DOES STEROID USE INCREASE FRACTURE RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?. Evidence-Based Gastroenterology 5:2, 56-57
CrossRef938
Michalis V Karamouzis, Athanasios G Papavassiliou. (2004) COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?. Expert Opinion on Investigational Drugs 13:4, 359-372
CrossRef939
M. R. Hernandez, R. Tonda, M. Pino, M. Serradell, G. Arderiu, G. Escolar. (2004) Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. European Journal of Clinical Investigation 34:4, 297-302
CrossRef940
Margaret E. McCann, Donald R., Donghui Zhang, Christine Brideau, W. Cameron Black, Peter D. Hanson, Gerard J. Hickey. (2004) In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. American Journal of Veterinary Research 65:4, 503-512
CrossRef941
L. Biancone, C. Tosti, A. Geremia, D. Fina, C. Petruzziello, S. Emerenziani, F. Pallone. (2004) Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Alimentary Pharmacology and Therapeutics 19:7, 755-764
CrossRef942
N. D. Yeomans. (2004) Impact of cyclooxygenase-2 inhibitors: are they fulfilling their promises?. Internal Medicine Journal 34:4, 145-147
CrossRef943
B. Norgard, L. Pedersen, S. P. Johnsen, R. E. Tarone, J. K. McLaughlin, S. Friis, H. T. Sorensen. (2004) COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Alimentary Pharmacology and Therapeutics 19:7, 817-825
CrossRef944
Md.Jashim Uddin, P. N. Praveen Rao, Edward E Knaus. (2004) Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & Medicinal Chemistry Letters 14:8, 1953-1956
CrossRef945
James M. Scheiman, Byron Cryer, Michael B. Kimmey, Richard I. Rothstein, Dennis S. Riff, Michael M. Wolfe. (2004) A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury. Clinical Gastroenterology and Hepatology 2:4, 290-295
CrossRef946
F. F. Joshua, S. P. Oakley, G. A. Major. (2004) Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. Internal Medicine Journal 34:4, 153-161
CrossRef947
Alex M. Blaicher, Harald T. Landsteiner, Olga Al-Falaki, Jochen Zwerina, Ivo Volf, Diego Gruber, Michael Zimpfer, Klaus Hoerauf. (2004) Acetylsalicylic Acid, Diclofenac, and Lornoxicam, but Not Rofecoxib, Affect Platelet CD 62 Expression. Anesthesia & Analgesia1082-1085
CrossRef948
Anthony S Dalpiaz, Dave Peterson. (2004) Parecoxib: a shift in pain management?. Expert Review of Neurotherapeutics 4:2, 165-177
CrossRef949
D. Kellstein, D. Ott, S. Jayawardene, J. Fricke. (2004) Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. International Journal of Clinical Practice 58:3, 244-250
CrossRef950
K. Zelenakas, J. R. Fricke, S. Jayawardene, D. Kellstein. (2004) Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. International Journal of Clinical Practice 58:3, 251-256
CrossRef951
Peter Honig. (2004) Merck Sharp and Dohme versus Laporte. The Lancet 363:9414, 1079-1080
CrossRef952
Henry Krum, Danny Liew, Juan Aw, Steven Haas. (2004) Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Expert Review of Cardiovascular Therapy 2:2, 265-270
CrossRef953
Brian J. Anderson. (2004) Comparing the efficacy of NSAIDs and paracetamol in children. Pediatric Anesthesia 14:3, 201-217
CrossRef954
Stephen E Kimmel, Jesse A Berlin, Muredach Reilly, Jane Jaskowiak, Lori Kishel, Jesse Chittams, Brian L Strom. (2004) The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. Journal of the American College of Cardiology 43:6, 985-990
CrossRef955
Yaron Niv. (2004) Ethics of Sample Collecting in Gastrointestinal Endoscopy-based Research. Journal of Clinical Gastroenterology 38:3, 206-208
CrossRef956
Devashish Kothapalli, Ilia Fuki, Kamilah Ali, Sheryl A. Stewart, Liang Zhao, Ron Yahil, David Kwiatkowski, Elizabeth A. Hawthorne, Garret A. FitzGerald, Michael C. Phillips, Sissel Lund-Katz, Ellen Puré, Daniel J. Rader, Richard K. Assoian. (2004) Antimitogenic effects of HDL and APOE mediated by Cox-2–dependent IP activation. Journal of Clinical Investigation 113:4, 609-618
CrossRef957
M. B. Kimmey, A. Lanas. (2004) Appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Alimentary Pharmacology and Therapeutics 19:s1, 60-65
CrossRef958
Patricia A Howard, Patrice Delafontaine. (2004) Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk. Journal of the American College of Cardiology 43:4, 519-525
CrossRef959
David J Exon, S.C Sydney Chung. (2004) Endoscopic therapy for upper gastrointestinal bleeding. Best Practice & Research Clinical Gastroenterology 18:1, 77-98
CrossRef960
R. H. Hunt, F. Bazzoli. (2004) Should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Alimentary Pharmacology and Therapeutics 19:s1, 9-16
CrossRef961
Bulent Sivri. (2004) Trends in peptic ulcer pharmacotherapy. Fundamental and Clinical Pharmacology 18:1, 23-31
CrossRef962
Tanya Wilton. (2004) Cyclooxygenase-2 inhibitors: Do they have a role in emergency department prescribing?. Emergency Medicine Australasia 16:1, 65-73
CrossRef963
Dae Sik Jang, Muriel Cuendet, Alison D Pawlus, Leonardus B.S Kardono, Kazuko Kawanishi, Norman R Farnsworth, Harry H.S Fong, John M Pezzuto, A.Douglas Kinghorn. (2004) Potential cancer chemopreventive constituents of the leaves of Macaranga triloba. Phytochemistry 65:3, 345-350
CrossRef964
M. Arroyo Villarino, J. Alcedo González, A. Lanas Arbeloa. (2004) Gastropatía por antiinflamatorios no esteroideos. Medicine - Programa de Formación Médica Continuada Acreditado 9:2, 75-83
CrossRef965
Brennan M.R. Spiegel. (2004) HOW MUCH DO COXIBS COST?. Evidence-Based Gastroenterology 5:1, 10-11
CrossRef966
Bernard Bannwarth. (2004) Is licofelone, a dual inhibitor of cyclo-oxygenase and 5-lipoxygenase, a promising alternative in anti-inflammatory therapy?. Fundamental and Clinical Pharmacology 18:1, 125-130
CrossRef967
Bernard R. Rubin, Robert Burton, Sandra Navarra, Joseph Antigua, John Londo
CrossRef968
Andrew M. Wilson, Lehana Thabane, Anne Holbrook. (2004) Application of data mining techniques in pharmacovigilance. British Journal of Clinical Pharmacology 57:2, 127-134
CrossRef969
Randal L. Von Seggern, Lisa K. Mannix, James U. Adelman. (2004) Rofecoxib in the Prevention of Perimenstrual Migraine: An Open-Label Pilot Trial. Headache: The Journal of Head and Face Pain 44:2, 160-165
CrossRef970
Clare Atherton, John Jones, Brian McKaig, James Bebb, Rob Cunliffe, Jake Burdsall, Joanne Brough, Diane Stevenson, Johanne Bonner, Christiane Rordorf, Graham Scott, Janice Branson, Christopher J Hawkey. (2004) Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clinical Gastroenterology and Hepatology 2:2, 113-120
CrossRef971
R.M. Francis. (2004) Acute and long-term management of patients with vertebral fractures. QJM 97:2, 63-74
CrossRef972
Thérèse Dupin-Spriet, Alain Spriet. (2004) Chapitre 7. Conduite des essais sous placebo et responsabilité du promoteur. Journal International de Bioéthique 15:4, 93
CrossRef973
Hyman Tannenbaum. (2004) Lumiracoxib. Drugs 64:19, 2247-2248
CrossRef974
R. W. Dubois, G. Y. Melmed, J. M. Henning, L. Laine. (2004) Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Alimentary Pharmacology and Therapeutics 19:2, 197-208
CrossRef975
Allen Brinker, Lawrence Goldkind, Renan Bonnel, Julie Beitz. (2004) Spontaneous Reports of Hypertension Leading to Hospitalisation in Association with Rofecoxib, Celecoxib, Nabumetone and Oxaprozin. Drugs & Aging 21:7, 479-484
CrossRef976
Sean P. Curtis, Jennifer Ng, Qinfen Yu, Sumiko Shingo, Gina Bergman, Calogera L. McCormick, Alise S. Reicin. (2004) Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clinical Therapeutics 26:1, 70-83
CrossRef977
William B White, Vibeke Strand, Richard Roberts, Andrew Whelton. (2004) Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis. American Journal of Therapeutics 11:4, 244-250
CrossRef978
Joan-Ramon Laporte, Luisa Ib????ez, Xavier Vidal, Lourdes Vendrell, Roberto Leone. (2004) Upper Gastrointestinal Bleeding Associated with the Use of NSAIDs. Drug Safety 27:6, 411-420
CrossRef979
Salahuddin Kazi. 2004. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). , 737-739.
CrossRef980
V.W.S Wong, R.W.L Leong, F.K.L Chan. (2004) Upper gastrointestinal complications related to non-steroidal anti-inflammatory drugs—what have we achieved so far?. Digestive and Liver Disease 36:1, 1-3
CrossRef981
Byron Cryer. 2004. NSAID-Induced Injury. , 744-747.
CrossRef982
David W J Clark, Deborah Layton, Saad A W Shakir. (2004) Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?. Drug Safety 27:7, 427-456
CrossRef983
Ming Fock Kwong. (2004) Have Cox2 inhibitors lived up to expectations?. Best Practice & Research Clinical Gastroenterology 18, 13-16
CrossRef984
Elham Rahme, Alan N Barkun, Viviane Adam, Marc Bardou. (2004) Treatment Costs to Prevent or Treat Upper Gastrointestinal Adverse Events Associated with NSAIDs. Drug Safety 27:13, 1019-1042
CrossRef985
Perry G. Fine. (2004) Pharmacological Management of Persistent Pain in Older Patients. The Clinical Journal of Pain 20:4, 220-226
CrossRef986
Thorsten Nikolaus, Andrej Zeyfang. (2004) Pharmacological Treatments for Persistent Non-Malignant Pain in Older Persons. Drugs & Aging 21:1, 19-41
CrossRef987
C Romanò. (2004) Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. The Journal of Arthroplasty 19:1, 14-18
CrossRef988
Bror Jonzon, Ingvar Bjarnason, Chris Hawkey, John Jones, Andrew Goddard, Urban Fagerholm, Pär Karlsson. (2003) The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. InflammoPharmacology 11:4-6, 437-444
CrossRef989
Byron Cryer. (2003) The role of cyclooxygenase selective inhibitors in the gastrointestinal tract. Current Gastroenterology Reports 5:6, 453-458
CrossRef990
Sara Jane Andersen. (2003) Cyclooxygenase-2 inhibitor treatment of older osteoarthritis patients. Comprehensive Therapy 29:4, 215-223
CrossRef991
Andrew J Dannenberg, Kotha Subbaramaiah. (2003) Targeting cyclooxygenase-2 in human neoplasia. Cancer Cell 4:6, 431-436
CrossRef992
William F Anderson, Asad Umar, Ernest T Hawk. (2003) Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opinion on Pharmacotherapy 4:12, 2193-2204
CrossRef993
Nicholas Moore. (2003) Place of OTC analgesics and NSAIDs in osteoarthritis. InflammoPharmacology 11:4-6, 355-362
CrossRef994
Frederick Wolfe, Kaleb Michaud, Sean Z. Zhao. (2003) Patient Perception of the Burden of Weight Gain and Blood Pressure Increase Among RA Patients Using Celecoxib, Rofecoxib, and Non-specific NSAIDs. JCR: Journal of Clinical Rheumatology 9:6, 344-353
CrossRef995
Robert B. Zurier. (2003) Prostaglandins: then and now and next. Seminars in Arthritis and Rheumatism 33:3, 137-139
CrossRef996
Thomas J. Schnitzer, Sheldon X. Kong, Jeffrey H. Mitchell, Panagiotis Mavros, Douglas J. Watson, James M. Pellissier, Walter L. Straus. (2003) An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clinical Therapeutics 25:12, 3162-3172
CrossRef997
Uri Ladabaum. (2003) Potential cost-effectiveness of colorectal cancer chemoprevention with nonsteroidal anti-inflammatory drugs. Expert Review of Pharmacoeconomics & Outcomes Research 3:6, 757-771
CrossRef998
Florian Strasser, Larry C. Driver, Allen W. Burton. (2003) Update on Adjuvant Medications for Chronic Nonmalignant Pain. Pain Practice 3:4, 282-297
CrossRef999
Yuhong Yuan, Richard H. Hunt. (2003) Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?. InflammoPharmacology 11:4-6, 337-354
CrossRef1000
Jay L. Goldstein. (2003) YET ANOTHER MODEL LOOKING AT THE COST-EFFECTIVENESS OF COX-2 SELECTIVE INHIBITORS. Evidence-Based Gastroenterology 4:4, 133-134
CrossRef1001
Paul J. Nietert, Steven M. Ornstein, Lori M. Dickerson, Ralph J. Rothenberg. (2003) Comparison of Changes in Blood Pressure Measurements and Antihypertensive Therapy in Older, Hypertensive, Ambulatory Care Patients Prescribed Celecoxib or Rofecoxib. Pharmacotherapy 23:11, 1416-1423
CrossRef1002
Jaime A Oviedo, M.Michael Wolfe. (2003) Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?. Rheumatic Disease Clinics of North America 29:4, 769-788
CrossRef1003
Ian Gilron, Brian Milne, Murray Hong. (2003) Cyclooxygenase-2 Inhibitors in Postoperative Pain Management. Anesthesiology 99:5, 1198-1208
CrossRef1004
Sean M. Fahey, Richard M. Silver. (2003) Use of NSAIDs and COX-2 Inhibitors in Children With Musculoskeletal Disorders. Journal of Pediatric Orthopaedics794-799
CrossRef1005
Sean M. Fahey, Richard M. Silver. (2003) Use of NSAIDs and COX-2 Inhibitors in Children With Musculoskeletal Disorders. Journal of Pediatric Orthopaedics 23:6, 794-799
CrossRef1006
Allan Gibofsky, Gary W. Williams, Frank McKenna, John G. Fort. (2003) Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis & Rheumatism 48:11, 3102-3111
CrossRef1007
Japie A. Louw, I.N. (Solly) Marks. (2003) The management of peptic ulcer disease. Current Opinion in Gastroenterology 19:6, 533-539
CrossRef1008
Nicholas J. Shaheen. (2003) NSAIDs IN BARRETT'S ESOPHAGUS: AN ASPIRIN A DAY KEEPS THE SURGEON AWAY?. Evidence-Based Gastroenterology 4:4, 124-125
CrossRef1009
Manfred Gogol. (2003) Osteoarthritis and Rheumatoid Arthritis: Will New Data Clarify the Risk:Benefit Ratio of Cyclooxygenase-2 Inhibitors?. Journal of the American Geriatrics Society 51:11, 1675-1676
CrossRef1010
Subodh Verma, Paul E Szmitko. (2003) Coxibs and the endothelium**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 42:10, 1754-1756
CrossRef1011
Paul Dieppe, Kenneth D Brandt. (2003) What is important in treating osteoarthritis? Whom should we treat and how should we treat them?. Rheumatic Disease Clinics of North America 29:4, 687-716
CrossRef1012
Garret A. FitzGerald. (2003) COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Reviews Drug Discovery 2:11, 879-890
CrossRef1013
Susan Jung-Ah Lee, Arthur Kavanaugh. (2003) Pharmacological treatment of established rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 17:5, 811-829
CrossRef1014
Robert B Raffa, Rachel Clark-Vetri, Ronald J Tallarida, Albert I Wertheimer. (2003) Combination strategies for pain management. Expert Opinion on Pharmacotherapy 4:10, 1697-1708
CrossRef1015
F. J. Munoz-Bellido, M. Terron, A. Leon. (2003) Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance. Allergy 58:10, 1072-1075
CrossRef1016
Ted R Mikuls. (2003) Co-morbidity in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 17:5, 729-752
CrossRef1017
Paolo Ricchi, Sandro Pignata, Rosario Vincenzo Iaffaioli, Bruno Daniele. (2003) Cyclo-Oxygenase Inhibition in Colorectal Adenomas and Cancer. Journal of Clinical Gastroenterology 37:4, 281-287
CrossRef1018
Giampietro Gasparini, Raffaele Longo, Roberta Sarmiento, Alessandro Morabito. (2003) Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. The Lancet Oncology 4:10, 605-615
CrossRef1019
John A Collins. (2003) How does the WHI study alter the risk–benefit ratio of HT?. Fertility and Sterility 80, 19-26
CrossRef1020
Noor M. Gajraj. (2003) The Effect of Cyclooxygenase-2 Inhibitors on Bone Healing. Regional Anesthesia and Pain Medicine 28:5, 456-465
CrossRef1021
C. Rordorf, N. Kellett, S. Mair, M. Ford, S. Milosavljev, J. Branson, G. Scott. (2003) Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. Alimentary Pharmacology and Therapeutics 18:5, 533-541
CrossRef1022
Stephen W. Fenwick, Giles J. Toogood, J.Peter A. Lodge, Mark A. Hull. (2003) The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125:3, 716-729
CrossRef1023
Juan F. Herrero, E. Alfonso Romero-Sandoval, Gema Gaitan, Javier Mazario. (2003) Antinociception and the New COX Inhibitors: Research Approaches and Clinical Perspectives. CNS Drug Reviews 9:3, 227-252
CrossRef1024
R. D. Church, J. W. Fleshman, H. L. McLeod. (2003) Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. British Journal of Surgery 90:9, 1055-1067
CrossRef1025
Jeannie Cho, Catherine E. Cooke, Woody Proveaux. (2003) A Retrospective Review of the Effect of COX-2 Inhibitors on Blood Pressure Change. American Journal of Therapeutics 10:5, 311-317
CrossRef1026
Milo Engoren. (2003) Cost-effectiveness of different postoperative analgesic treatments. Expert Opinion on Pharmacotherapy 4:9, 1507-1519
CrossRef1027
Carl-Olav Stiller, Paul Hjemdahl. (2003) Endothelial COX-2 inhibition. Journal of Hypertension 21:9, 1615-1618
CrossRef1028
Michael J. S. Langman. (2003) Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract. Fundamental and Clinical Pharmacology 17:4, 393-403
CrossRef1029
Christopher J. Sweeney. (2003) Why Cyclooxygenase-2 Inhibition Plus Chemotherapy?. American Journal of Clinical Oncology 26:Supplement 2, S122-S125
CrossRef1030
O Phan. (2003) Are cyclooxygenase-2-selective inhibitors safe for the kidneys?. Joint Bone Spine 70:4, 237-241
CrossRef1031
Martin W. James, Christopher J. Hawkey. (2003) Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. British Journal of Clinical Pharmacology 56:2, 146-155
CrossRef1032
Loren Laine, Jenifer Wogen, Holly Yu. (2003) Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.. Gastroenterology 125:2, 389-395
CrossRef1033
Marjorie M. Walker, Brendan J. R. Whittle. (2003) British Journal of Clinical Pharmacology review series Clinical research methods in gastroenterology. British Journal of Clinical Pharmacology 56:2, 143-145
CrossRef1034
Inmaculada del Rincón, Agustín Escalante. (2003) Atherosclerotic cardiovascular disease in rheumatoid arthritis. Current Rheumatology Reports 5:4, 278-286
CrossRef1035
Gurpreet Singh Ranger, Kefah Mokbel. (2003) COX-2 inhibitors and breast cancer. ANZ Journal of Surgery 73:8, 565-566
CrossRef1036
R FERNER. (2003) Adverse Drug Reactions. Medicine 31:8, 20-24
CrossRef1037
Rachel Clarke, Sheena Derry, R Andrew Moore, Henry J McQuay, Maura Moore. 2003. Single dose oral etoricoxib for postoperative pain. .
CrossRef1038
Carlos R. Becerra, Eugene P. Frenkel, Raheela Ashfaq, Richard B. Gaynor. (2003) Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. International Journal of Cancer 105:6, 868-872
CrossRef1039
Keith Gottesdiener, Nancy Agrawal, Arturo Porras, Peggy Wong, J. Douglas Rogers, Barry J. Gertz, Jan S. Redfern, Thomas Marbury. (2003) Effects of Renal Insufficiency and Hemodialysis on the Pharmacokinetics of Rofecoxib. American Journal of Therapeutics 10:4, 252-258
CrossRef1040
J. L. Goldstein, A. J. Kivitz, K. M. Verburg, D. P. Recker, R. C. Palmer, J. D. Kent. (2003) A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Alimentary Pharmacology and Therapeutics 18:1, 125-132
CrossRef1041
M.E. Leerdam, E. M. Vreeburg, E.A.J. Rauws, A.A.M. Geraedts, J.G.P. Tijssen, J.B. Reitsma, G.N.J. Tytgat. (2003) Acute upper GI bleeding: did anything change?. Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. The American Journal of Gastroenterology 98:7, 1494-1499
CrossRef1042
Fabio Celotti, Thierry Durand. (2003) The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins & Other Lipid Mediators 71:3-4, 147-162
CrossRef1043
Richard Makins, Anne Ballinger. (2003) Gastrointestinal side effects of drugs. Expert Opinion on Drug Safety 2:4, 421-429
CrossRef1044
E.A.J. Knijff-Dutmer. (2003) The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users. QJM 96:7, 513-520
CrossRef1045
Andreas Maetzel, Murray Krahn, Gary Naglie. (2003) The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis & Rheumatism 49:3, 283-292
CrossRef1046
E Kankuri. (2003) Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. Thrombosis Research 110:5-6, 299-303
CrossRef1047
J Vane. (2003) The mechanism of action of aspirin. Thrombosis Research 110:5-6, 255-258
CrossRef1048
A Szczeklik. (2003) Aspirin and thrombinogenesis. Thrombosis Research 110:5-6, 345-347
CrossRef1049
(2003) Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding. New England Journal of Medicine 348:24, 2464-2466
Full Text1050
Brendan J. R. Whittle. (2003) Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundamental & Clinical Pharmacology 17:3, 301-313
CrossRef1051
Jeroen C. F. De Jong, Paul B. Van Den Berg, Hilde Tobi, Lolkje T. W. De Jong, - Van Den Berg. (2003) Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. British Journal of Clinical Pharmacology 55:6, 591-595
CrossRef1052
J. M. Scheiman, J. K. Greenson, J. Lee, B. Cryer. (2003) Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention. Alimentary Pharmacology and Therapeutics 17:12, 1535-1543
CrossRef1053
P Goupille. (2003) Naturalistic survey on nonsteroidal antiinflammatory treatment in patients with musculoskeletal pain. Joint Bone Spine 70:3, 219-225
CrossRef1054
Mark A. Perazella. (2003) Drug-Induced Renal Failure: Update on New Medications and Unique Mechanisms of Nephrotoxicity. The American Journal of the Medical Sciences 325:6, 349-362
CrossRef1055
Noor M. Gajraj. (2003) Cyclooxygenase-2 Inhibitors. Anesthesia & Analgesia1720-1738
CrossRef1056
W. Reinisch, W. Miehsler, C. Dejaco, M. Harrer, T. Waldhoer, C. Lichtenberger, H. Vogelsang. (2003) An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Alimentary Pharmacology and Therapeutics 17:11, 1371-1380
CrossRef1057
A. Ng. (2003) Analgesic effects of parecoxib following total abdominal hysterectomydaggerddagger. British Journal of Anaesthesia 90:6, 746-749
CrossRef1058
Keri L. Fakata, Arthur G. Lipman. (2003) Pharmacotherapy for pain in rheumatologic conditions: The neuropathic component. Current Pain and Headache Reports 7:3, 197-205
CrossRef1059
Pamela L Cross. (2003) Effect of ibuprofen on cardioprotective effect of aspirin. The Lancet 361:9368, 1560-1561
CrossRef1060
Keith Beard. (2003) Are drugs really toxic for older people?. Expert Opinion on Drug Safety 2:3, 211-213
CrossRef1061
Michael F. Byrne, Naurang M. Agrawal. (2003) A RATIONALE FOR APPROPRIATE USE OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS INSTEAD OF NSAIDs BASED ON RISK FACTORS FOR ADVERSE GASTROINTESTINAL EVENTS. Evidence-Based Gastroenterology 4:2, 39-40
CrossRef1062
Lutz Bräutigam, Jens U. Nefflen, Gerd Geisslinger. (2003) Determination of etoricoxib in human plasma by liquid chromatography–tandem mass spectrometry with electrospray ionisation. Journal of Chromatography B 788:2, 309-315
CrossRef1063
Giovanni de Gaetano, Maria Benedetta Donati, Chiara Cerletti. (2003) Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends in Pharmacological Sciences 24:5, 245-252
CrossRef1064
Orina Belton, Desmond Fitzgerald. (2003) Cyclooxygenase-2 inhibitors and atherosclerosis**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 41:10, 1820-1822
CrossRef1065
Lars Köehler, Jens G. Kuipers, Henning Zeidler. (2003) Rationale for the use of cyclooxygenase-2-specific nonsteroidal antiinflammatory drugs in ankylosing spondylitis: the available evidence. Current Rheumatology Reports 5:3, 178-180
CrossRef1066
Colin G Crosby, Raymond N DuBois. (2003) The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. Expert Opinion on Emerging Drugs 8:1, 1-7
CrossRef1067
Nathaniel Katz, William D. Ju, David A. Krupa, Rhoda S. Sperling, Diana Bozalis Rodgers, Barry J. Gertz, Joseph Gimbel, Spencer Coleman, Chester Fisher, Shahriar Nabizadeh, David Borenstein. (2003) Efficacy and Safety of Rofecoxib in Patients with Chronic Low Back Pain. Spine 28:9, 851-858
CrossRef1068
Jay L. Goldstein. (2003) IS THERE A DIFFERENCE BETWEEN A COXIB VERSUS A PPI PLUS AN NSAID IN THE RISK OF RECURRENT ULCER BLEEDING IN PATIENTS WITH ARTHRITIS?. Evidence-Based Gastroenterology 4:2, 41-43
CrossRef1069
David Rott, Jianhui Zhu, Mary Susan Burnett, Y.i F.u Zhou, Alexandra Zalles-Ganley, Jibike Ogunmakinwa, Stephen E Epstein. (2003) Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. Journal of the American College of Cardiology 41:10, 1812-1819
CrossRef1070
Munir Pirmohamed, B. Kevin Park. (2003) Adverse drug reactions: back to the future. British Journal of Clinical Pharmacology 55:5, 486-492
CrossRef1071
Geoff Norman. (2003) The paradox of evidence-based medicine. Commentary on Gupta (2003), A critical appraisal of evidence-based medicine: some ethical considerations. Journal of Evaluation in Clinical Practice 9, 111-121. Journal of Evaluation in Clinical Practice 9:2, 129-132
CrossRef1072
Stephan K.W. Schwarz. (2003) COX-2 Inhibition for Postoperative Analgesia. Anesthesia & Analgesia1235
CrossRef1073
F Berenbaum. (2003) NSAIDs and aspirin: friends or foes?. Joint Bone Spine 70:2, 89-90
CrossRef1074
T. Philip Malan, Gregory Marsh, Sam I. Hakki, Evie Grossman, Louise Traylor, Richard C. Hubbard. (2003) Parecoxib Sodium, a Parenteral Cyclooxygenase 2 Selective Inhibitor, Improves Morphine Analgesia and Is Opioid-sparing following Total Hip Arthroplasty. Anesthesiology 98:4, 950-956
CrossRef1075
Ken Shinmura, Eitaro Kodani, Y.u-Ting Xuan, Buddhadeb Dawn, Xian-Liang Tang, Roberto Bolli. (2003) Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. Journal of the American College of Cardiology 41:7, 1183-1194
CrossRef1076
Daniel H. Solomon, Jerry Avorn. (2003) Pharmacoepidemiology and rheumatic diseases: 2001–2002. Current Opinion in Rheumatology 15:2, 122-126
CrossRef1077
Mary L. Chavez, Carrie J. DeKorte. (2003) Valdecoxib: A review. Clinical Therapeutics 25:3, 817-851
CrossRef1078
Francesco Cosentino, Pietro Francia, Massimo Volpe. (2003) Do COX-2 inhibitors really prevent hypertension and proteinuria? Another brick in the wall for the COX-2 inhibition and cardiovascular disease controversy. Journal of Hypertension 21:3, 501-503
CrossRef1079
Jan M Schwab, Hermann J Schluesener, Stefan Laufer. (2003) COX-3: just another COX or the solitary elusive target of paracetamol?. The Lancet 361:9362, 981-982
CrossRef1080
Celia C. Kamath, Hilal Maradit Kremers, David J. Vanness, W. Michael O'Fallon, Rosa L. Cabanela, Sherine E. Gabriel. (2003) The Cost-Effectiveness of Acetaminophen, NSAIDs, and Selective COX-2 Inhibitors in the Treatment of Symptomatic Knee Osteoarthritis. Value in Health 6:2, 144-157
CrossRef1081
K. C. Lai, C. S. Lau, W. Y. Ip, B. C. Y. Wong, W. M. Hui, W. H. C. Hu, R. W. M. Wong, S. K. Lam. (2003) Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Alimentary Pharmacology and Therapeutics 17:6, 799-805
CrossRef1082
Luigi Gatta, Nimish Vakil. (2003) Nsaids: Can We Stomach the Risk?. Laine L, Bombardier C, Hawkey CJ, et al., Stratifying the Risk of NSAID-Related Upper Gastrointestinal Clinical Events: Results of a Double-Blind Outcomes Study in Patients With Rheumatoid Arthritis, Gastroenterology 2002;123:1006-12. The American Journal of Gastroenterology 98:3, 694-695
CrossRef1083
Lars Noah. (2003) Challenges in the Federal Regulation of Pain Management Technologies. The Journal of Law, Medicine & Ethics 31:1, 55-74
CrossRef1084
T CONROZIER, R FLIPO. (2003) La prise en charge thérapeutique de l'arthrose en ce début de 3e millénaire.1re partie : le traitement pharmacologiqueCurrent management of osteoarthritis.Part 1: pharmacological strategies. La Revue de Médecine Interne 24:3, 183-188
CrossRef1085
S. Alsalameh, M. Burian, G. Mahr, B. G. Woodcock, G. Geisslinger. (2003) The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Alimentary Pharmacology and Therapeutics 17:4, 489-501
CrossRef1086
Franz F Immer, Alexsandra S Immer-Bansi, Nathalie Trachsel, Pascal A Berdat, Verena Eigenmann, Michele Curatolo, Thierry P Carrel. (2003) Pain treatment with a COX-2 inhibitor after coronary artery bypass operation: a randomized trial. The Annals of Thoracic Surgery 75:2, 490-495
CrossRef1087
Deborah Layton, Jane Riley, Lynda V. Wilton, Saad A. W. Shakir. (2003) Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. British Journal of Clinical Pharmacology 55:2, 166-174
CrossRef1088
R. Micklewright, S. Lane, W. Linley, C. McQuade, F. Thompson, N. Maskrey. (2003) NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors*. Alimentary Pharmacology and Therapeutics 17:3, 321-332
CrossRef1089
Paola Patrignani, Marta L Capone, Stefania Tacconelli. (2003) Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitor. Expert Opinion on Pharmacotherapy 4:2, 265-284
CrossRef1090
Louis Kuritzky, Arthur Weaver. (2003) Advances in Rheumatology. Journal of Pain and Symptom Management 25:2, 6-20
CrossRef1091
Margo L. Schilling. (2003) Pain management in older adults. Current Psychiatry Reports 5:1, 55-61
CrossRef1092
Glenn Eisen. (2003) THE RISK OF UPPER GASTROINTESTINAL HEMORRHAGE FOR PATIENTS TAKING COX-2 SELECTIVE AGENTS VERSUS NONSELECTIVE NSAIDS. Evidence-Based Gastroenterology 4:1, 9-10
CrossRef1093
John L. Wallace, Piero Del Soldato. (2003) The therapeutic potential of NO-NSAIDs. Fundamental and Clinical Pharmacology 17:1, 11-20
CrossRef1094
Tore K Kvien, Kirsten Viktil. (2003) Pharmacotherapy for regional musculoskeletal pain. Best Practice & Research Clinical Rheumatology 17:1, 137-150
CrossRef1095
A DEMARIA. (2003) Coxibs?Beyond the GI TractRenal and Cardiovascular Issues. Journal of Pain and Symptom Management 25:2, 41-49
CrossRef1096
L LAINE. (2003) Gastrointestinal Effects of NSAIDs and Coxibs. Journal of Pain and Symptom Management 25:2, 32-40
CrossRef1097
Jules I Schwartz, Patrick J Larson, Arturo G Porras, Kala-Jyoti Viswanathan-Aiyer, Nancy G B Agrawal, Kenneth C Lasseter, Ralph S Mazenko, Sheila A Merschman, Barry J Gertz. (2003) Pharmacokinetic Evaluation of Rofecoxib. Clinical Drug Investigation 23:8, 503-509
CrossRef1098
Emma A Meagher. (2003) Balancing Gastroprotection and Cardioprotection with Selective Cyclo-Oxygenase-2 Inhibitors. Drug Safety 26:13, 913-924
CrossRef1099
Eduardo Collantes-Estevez, Cristina Fernandez-Perez. (2003) Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Current Medical Research and Opinion 19:5, 402-410
CrossRef1100
Luis R. Arboleya, Enrique de la Figuera, María Soledad García, Belén Aragón. (2003) Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of Coxibs. Current Medical Research and Opinion 19:4, 278-287
CrossRef1101
Wayne A. Ray, Thomas M. MacDonald, Daniel H. Solomon, David J. Graham, Jerry Avorn. (2003) COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Pharmacoepidemiology and Drug Safety 12:1, 67-70
CrossRef1102
Myrna Déciga-Campos, Uriah Guevara López, Ma.Irene Dı́az Reval, Francisco J López-Muñoz. (2003) Enhancement of antinociception by co-administration of an opioid drug (morphine) and a preferential cyclooxygenase-2 inhibitor (rofecoxib) in rats. European Journal of Pharmacology 460:2-3, 99-107
CrossRef1103
Bernard Bannwarth, Richard Tr??ves, Liana Euller-Ziegler, Denis Rolland, Philippe Ravaud, Maxime Dougados. (2003) Adverse Events Associated with Rofecoxib Therapy. Drug Safety 26:1, 49-54
CrossRef1104
J. Zacher, D. Feldman, R. Gerli, D. Scott, S.-M. Hou, D. Uebelhart, I. W. Rodger, Z. E. Ozturk. (2003) A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Current Medical Research and Opinion 19:8, 725-736
CrossRef1105
Gys??le S Bleumink, Johannes Feenstra, Miriam C J M Sturkenboom, Bruno H Ch Stricker. (2003) Nonsteroidal Anti-Inflammatory Drugs and Heart Failure. Drugs 63:6, 525-534
CrossRef1106
Archibald McNicol, Sara J. Israels. (2003) Platelets and Anti-platelet Therapy. Journal of Pharmacological Sciences 93:4, 381-396
CrossRef1107
Kenneth Brandt. (2003) Paracetamol in the Treatment of Osteoarthritis Pain. Drugs 63:Special Issue 2, 23-38
CrossRef1108
Philip Schoenfeld, James Scheiman. (2003) An evidence-based approach to studies of gastrointestinal therapies. Clinical Gastroenterology and Hepatology 1:1, 57-63
CrossRef1109
Myung Chul Lee, Seokhyun Lee, Dong-Churl Suh, Jeeyeon Kim, Sheldon X Kong. (2003) A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea. Current Medical Research and Opinion 19:7, 597-602
CrossRef1110
Chiara Cerletti, Giuseppe Dell???Elba, Stefano Manarini, Romina Pecce, Augusto Di Castelnuovo, Nicola Scorpiglione, Vincenzo Feliziani, Giovanni de Gaetano. (2003) Pharmacokinetic and Pharmacodynamic Differences Between Two Low Dosages of Aspirin May Affect Therapeutic Outcomes. Clinical Pharmacokinetics 42:12, 1059-1070
CrossRef1111
Deanna Sanchez Yamamoto, Pamela Hallquist Viale. (2003) Cyclooxygenase-2: From Arthritis Treatment to New Indications for the Prevention and Treatment of Cancer. Clinical Journal of Oncology Nursing 7:1, 21-29
CrossRef1112
Robert E. Fowles. (2003) Potential Cardiovascular Effects of COX-2 Selective Nonsteroidal Antiinflammatory Drugs. Journal of Pain and Palliative Care Pharmacotherapy 17:2, 27-50
CrossRef1113
Suphat Subongkot, David Frame, William Leslie, Deborah Drajer. (2003) Selective Cyclooxygenase-2 Inhibition: A Target in Cancer Prevention and Treatment. Pharmacotherapy 23:1, 9-28
CrossRef1114
R. H. Hunt, S. Harper, P. Callegari, C. Yu, H. Quan, J. Evans, C. James, B. Bowen, F. Rashid. (2003) Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Alimentary Pharmacology and Therapeutics 17:2, 201-210
CrossRef1115
J. D. Belsey. (2003) Non-steroidal anti-inflammatory induced upper gastrointestinal event rates in patients awaiting joint replacement in the United Kingdom. An epidemiologically-based burden of disease model. Current Medical Research and Opinion 19:4, 306-312
CrossRef1116
Ernest T. Hawk, Jaye L. Viner, Asad Umar, William F. Anderson, Caroline C. Sigman, Kate Z. Guyton. (2003) Cancer and the Cyclo-oxygenase Enzyme. American Journal of Cancer 2:1, 27-55
CrossRef1117
John L Morris, David A Rosen, Kathleen R Rosen. (2003) Nonsteroidal Anti-Inflammatory Agents in Neonates. Pediatric Drugs 5:6, 385-405
CrossRef1118
Hui-Fang Cheng, Raymond C. Harris. (2003) Does cyclooxygenase-2 affect blood pressure?. Current Hypertension Reports 5:1, 87-92
CrossRef1119
Norbert Griessinger, Reinhard Sittl, Robert Jost, Michael Schaefer, Rudolf Likar. (2003) The Role of Opioid Analgesics in Rheumatoid Disease in the Elderly Population. Drugs & Aging 20:8, 571-583
CrossRef1120
Luis R. Arboleya, Enrique de la Figuera, María Soledad García, Belén Aragón. (2003) Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain:results of phase 2 of theVICOXX study. Current Medical Research and Opinion 19:4, 288-297
CrossRef1121
Dirk O. Stichtenoth, J??rgen C. Fr??lich. (2003) The Second Generation of COX-2 Inhibitors. Drugs 63:1, 33-45
CrossRef1122
Chan, Francis K.L., Hung, Lawrence C.T., Suen, Bing Y., Wu, Justin C.Y., Lee, Kenneth C., Leung, Vincent K.S., Hui, Aric J., To, Ka F., Leung, Wai K., Wong, Vincent W.S., Chung, S.C. Sydney, Sung, Joseph J.Y., . (2002) Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis. New England Journal of Medicine 347:26, 2104-2110
Full Text1123
Elham Rahme, Michael A. Marentette, Sheldon X. Kong, Jacques Lelorier. (2002) Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis & Rheumatism 47:6, 595-602
CrossRef1124
J. H. S. You, K. K. C. Lee, T. Y. K. Chan, W. H. Lau, F. K. L. Chan. (2002) Arthritis treatment in Hong Kong - cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Alimentary Pharmacology and Therapeutics 16:12, 2089-2096
CrossRef1125
Natsuko Kusunoki, Ryuta Yamazaki, Shinichi Kawai. (2002) Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis & Rheumatism 46:12, 3159-3167
CrossRef1126
Wahid Wassef. (2002) Interventional endoscopy. Current Opinion in Gastroenterology 18:6, 669-677
CrossRef1127
Christopher Cutts, Adam LaCaze, Susan Tett. (2002) A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. British Journal of Clinical Pharmacology 54:5, 522-527
CrossRef1128
Japie A. Louw, I.N. (Solly) Marks. (2002) Peptic ulcer disease. Current Opinion in Gastroenterology 18:6, 663-668
CrossRef1129
Asma A. Khan, Raymond A. Dionne. (2002) COX-2 inhibitors for endodontic pain. Endodontic Topics 3:1, 31-40
CrossRef1130
Marissa Lassere, Kent Johnson. (2002) The power of the protocol. The Lancet 360:9346, 1620-1622
CrossRef1131
Jos
CrossRef1132
M. Brian Fennerty. (2002) Clinical trials report. Current Gastroenterology Reports 4:6, 445-447
CrossRef1133
Jayshree Aiyar Gerken. (2002) The Data Dilemma in Formulary Design: Should the NIH Step In?. Biotechnology Law Report 21:5, 415-425
CrossRef1134
Carsten H Meyer, Renate Gähler. (2002) Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib. The Lancet 360:9339, 1100
CrossRef1135
Enid Morales, Jeffrey J. Mucksavage. (2002) Cyclooxygenase-2 Inhibitor–Associated Acute Renal Failure: Case Report with Rofecoxib and Review of the Literature. Pharmacotherapy 22:10, 1317-1321
CrossRef1136
Wayne A Ray, C Michael Stein, James R Daugherty, Kathi Hall, Patrick G Arbogast, Marie R Griffin. (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. The Lancet 360:9339, 1071-1073
CrossRef1137
Roy Fleischmann, Imran Iqbal, Gleb Slobodin. (2002) Meloxicam. Expert Opinion on Pharmacotherapy 3:10, 1501-1512
CrossRef1138
MacRae F. Linton, Sergio Fazio. (2002) Cyclooxygenase-2 and atherosclerosis. Current Opinion in Lipidology 13:5, 497-504
CrossRef1139
G. Singh-Ranger, K. Mokbel. (2002) Current concepts in cyclooxygenase inhibition in breast cancer. Journal of Clinical Pharmacy and Therapeutics 27:5, 321-327
CrossRef1140
Eija Kalso, Jayne Edwards, Henry J. McQuay, R. Andrew Moore. (2002) Five easy pieces on evidence based medicine (5). Trading benefit against harm—pain relief vs. adverse effects. European Journal of Pain 6:5, 409-412
CrossRef1141
Marcus, Aaron J., , Broekman, M. Johan, , Pinsky, David J., . (2002) COX Inhibitors and Thromboregulation. New England Journal of Medicine 347:13, 1025-1026
Full Text1142
Francis KL Chan, WK Leung. (2002) Peptic-ulcer disease. The Lancet 360:9337, 933-941
CrossRef1143
Ronald W. Jubb. (2002) Oral and intra-articular remedies: Review of papers published from March 2001 to February 2002. Current Opinion in Rheumatology 14:5, 597-602
CrossRef1144
Jennifer M. McCoy, Joan R. Wicks, Laurent P. Audoly. (2002) The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. Journal of Clinical Investigation 110:5, 651-658
CrossRef1145
Ian Milsom, Milos Minic, M.Yusoff Dawood, Mark D. Akin, June Spann, Nona F. Niland, R.Anne Squire. (2002) Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clinical Therapeutics 24:9, 1384-1400
CrossRef1146
Laurence J. Hirsch. (2002) Conflicts of interest in drug development: The practices of Merck & Co., Inc.. Science and Engineering Ethics 8:3, 429-442
CrossRef1147
Masaki Inada, Stephen M. Krane. (2002) Targeting rheumatoid inflammation and joint destruction in the mouse. Journal of Clinical Investigation 110:5, 611-612
CrossRef1148
Bruce A. Ferrell. (2002) Reply. Journal of the American Geriatrics Society 50:9, 1602-1603
CrossRef1149
Angel Ferrández, Angel Lanas. (2002) Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert Opinion on Drug Safety 1:3, 245-252
CrossRef1150
Raymond G. Schlienger, Hershel Jick, Christoph R. Meier. (2002) Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. British Journal of Clinical Pharmacology 54:3, 327-332
CrossRef1151
Vibeke Strand, Marc C. Hochberg. (2002) The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis & Rheumatism 47:4, 349-355
CrossRef1152
Turid Heiberg, Tore K. Kvien. (2002) Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: Pain has highest priority. Arthritis & Rheumatism 47:4, 391-397
CrossRef1153
William B White. (2002) Cyclooxygenase-2 inhibitors and cardiovascular thromboembolic events. Journal of the American College of Cardiology 40:3, 577-578
CrossRef1154
Ikuo Morita. (2002) Distinct functions of COX-1 and COX-2. Prostaglandins & Other Lipid Mediators 68-69, 165-175
CrossRef1155
Walter Smalley, C. Michael Stein, Patrick G. Arbogast, Glenn Eisen, Wayne A. Ray, Marie Griffin. (2002) Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis & Rheumatism 46:8, 2195-2200
CrossRef1156
Peng Thim FAN. (2002) The Feng Pao Hsii Lecture. APLAR Journal of Rheumatology 5:1, 41-47
CrossRef1157
Walter F. Kean, Robert Kean, W. Watson Buchanan. (2002) A critical assessment of oxaprozin clinical profile in rheumatic diseases. InflammoPharmacology 10:3, 241-284
CrossRef1158
Luis M. Ruilope, Antonio Coca, José R. Banegas, Jose Luis Pablos, Manuel Luque. (2002) Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity. Current Hypertension Reports 4:4, 261-264
CrossRef1159
Makoto Murakami, Yoshihito Nakatani, Toshihiro Tanioka, Ichiro Kudo. (2002) Prostaglandin E synthase. Prostaglandins & Other Lipid Mediators 68-69, 383-399
CrossRef1160
Lawrence J Marnett. (2002) Recent developments in cyclooxygenase inhibition. Prostaglandins & Other Lipid Mediators 68-69, 153-164
CrossRef1161
S Garner, D Fidan, R Frankish, M Judd, T Towheed, G Wells, P Tugwell. 2002. Rofecoxib for rheumatoid arthritis. .
CrossRef1162
Joaquín Quiralte, Blanca Sáenz de San Pedro, J. José Fernando Florido. (2002) Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Annals of Allergy, Asthma & Immunology 89:1, 63-66
CrossRef1163
Maarten Boers. (2002) Seminal pharmaceutical trials: maintaining masking in analysis. The Lancet 360:9327, 100-101
CrossRef1164
Jennifer Hamilton, Vadivelu Saravanan. (2002) Advances in the treatment of rheumatoid arthritis: old versus new therapies. Expert Opinion on Pharmacotherapy 3:7, 845-856
CrossRef1165
Daniel H Solomon, Robert J Glynn, Jerry Avorn. (2002) Non-steroidal antiinflammatory drugs and risk of serious coronary heart disease. The Lancet 360:9326, 90
CrossRef1166
G.A. FitzGerald. (2002) The choreography of cyclooxygenases in the kidney. Journal of Clinical Investigation 110:1, 33-34
CrossRef1167
Connail R. McCrory, Sten G. E. Lindahl. (2002) Cyclooxygenase Inhibition for Postoperative Analgesia. Anesthesia & Analgesia 95:1, 169-176
CrossRef1168
R SINATRA. (2002) Role of COX-2 Inhibitors in the Evolution of Acute Pain Management. Journal of Pain and Symptom Management 24:1, S18-S27
CrossRef1169
Larry W Moreland, Richard J Misischia. (2002) Rheumatoid arthritis: developing pharmacological therapies. Expert Opinion on Investigational Drugs 11:7, 927-935
CrossRef1170
S. V. Morant, Michael J. Shield, P. G. Davey, T. M. MacDonald. (2002) A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac. Pharmacoepidemiology and Drug Safety 11:5, 393-400
CrossRef1171
N KATZ. (2002) The Impact of Pain Management on Quality of Life. Journal of Pain and Symptom Management 24:1, S38-S47
CrossRef1172
Doruk Erkan, Yusuf Yazici, Melanie J. Harrison, Stephen A. Paget. (2002) Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy. Arthritis & Rheumatism 47:3, 285-290
CrossRef1173
Ivar Sønbø Kristiansen, Tore Kristian Kvien. (2002) Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis. Expert Review of Pharmacoeconomics & Outcomes Research 2:3, 229-241
CrossRef1174
JR Boulton-Jones, CJ Hawkey. (2002) Helicobacter pylori and peptic-ulcer disease. The Lancet 359:9321, 1943
CrossRef1175
(2002) The Management of Persistent Pain in Older Persons. Journal of the American Geriatrics Society 50:S6, 205-224
CrossRef1176
Lisa A. Greisman, Philip A. Mackowiak. (2002) Fever: beneficial and detrimental effects of antipyretics. Current Opinion in Infectious Diseases 15:3, 241-245
CrossRef1177
Arnaud Chiolero, Michel Burnier, Marc P Maillard. (2002) Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?. Expert Opinion on Drug Safety 1:1, 45-52
CrossRef1178
W. Stewart Hillis. (2002) Areas of Emerging Interest in Analgesia: Cardiovascular Complications. American Journal of Therapeutics 9:3, 259-269
CrossRef1179
Johannes W.J. Bijlsma. (2002) Analgesia and the Patient With Osteoarthritis. American Journal of Therapeutics 9:3, 189-197
CrossRef1180
Mark A Perazella. (2002) COX-2 selective inhibitors: analysis of the renal effects. Expert Opinion on Drug Safety 1:1, 53-64
CrossRef1181
AV Krymchantowski, JS Barbosa. (2002) Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22:4, 309-312
CrossRef1182
Leslie J. Crofford. (2002) Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?. Current Opinion in Rheumatology 14:3, 225-230
CrossRef1183
Andrew Szczeklik, Ewa Nizankowska, Lucyna Mastalerz, Zsuzsanna Szabo. (2002) Analgesics and Asthma. American Journal of Therapeutics 9:3, 233-243
CrossRef1184
S. Van Doornum, G. McColl, I. P. Wicks. (2002) Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis?. Arthritis & Rheumatism 46:4, 862-873
CrossRef1185
H.Ralph Schumacher. (2002) Introduction The Promise of Coxibs. Journal of Pain and Symptom Management 23:4, S1-S4
CrossRef1186
Thomas J Schnitzer. (2002) Update of ACR Guidelines for Osteoarthritis. Journal of Pain and Symptom Management 23:4, S24-S30
CrossRef1187
Tatsuo Yamamoto, Natsuko Nozaki-Taguchi. (2002) The Role of Cyclooxygenase-1 and -2 in the Rat Formalin Test. Anesthesia & Analgesia 94:4, 962-967
CrossRef1188
Navtej S. Buttar, Kenneth K. Wang, Olga Leontovich, Jay Y. Westgott, Rodney J. Pacifico, Marlys A. Anderson, Krishnawatie K. Krishnadath, Lori S. Lutzke, Lawrence J. Bijrgart. (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122:4, 1101-1112
CrossRef1189
Robert W. McMurray, Kenneth J. Hardy. (2002) Cox-2 Inhibitors:. The American Journal of the Medical Sciences 323:4, 181-189
CrossRef1190
David J Bjorkman. (2002) Commentary. Journal of Pain and Symptom Management 23:4, S11-S14
CrossRef1191
Miriam C. J. M. Sturkenboom, Ferdinando Romano, Giorgio Simon, Maria L. Correa-Leite, Marco Villa, Alfredo Nicolosi, Giulio Borgnolo, Gabriele Bianchi-Porro, Salvatore Mannino. (2002) The iatrogenic costs of NSAID therapy: A population study. Arthritis & Rheumatism 47:2, 132-140
CrossRef1192
Neville D Yeomans. (2002) Management of peptic ulcer disease not related to Helicobacter. Journal of Gastroenterology and Hepatology 17:4, 488-494
CrossRef1193
Lawrence J. Marnett, Raymond N. DuBois. (2002) COX-2: A Target for Colon Cancer Prevention. Annual Review of Pharmacology and Toxicology 42:1, 55-80
CrossRef1194
L LAINE. (2002) Gastrointestinal Safety of Coxibs and Outcomes StudiesWhat's the Verdict?. Journal of Pain and Symptom Management 23:4, S5-S10
CrossRef1195
João Freitas, Vitor Farricha, Isabel Nascimento, Paula Borralho, António Paramés. (2002) Rofecoxib. Journal of Clinical Gastroenterology 34:4, 451-453
CrossRef1196
J. L. Goldstein, G. M. Eisen, T. A. Burke, B. M. Pena, J. Lefkowith, G. S. Geis. (2002) Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Alimentary Pharmacology and Therapeutics 16:4, 819-827
CrossRef1197
A WEAVER. (2002) CommentaryUpdate of ACR Guidelines for Osteoarthritis: Role of the COX-2-Specific Inhibitors. Journal of Pain and Symptom Management 23:4, S31-S34
CrossRef1198
M. Brian Fennerty. (2002) Barrett's-related esophageal cancer: Has the final hurdle been cleared, now paving the way for human chemoprevention trials?. Gastroenterology 122:4, 1172-1175
CrossRef1199
Giuseppe Rossoni, Marcelo N Muscara, Giuseppe Cirino, John L Wallace. (2002) Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. British Journal of Pharmacology 135:6, 1540-1546
CrossRef1200
W. A. Stack, J. C. Atherton, G. M. Hawkey, R. F. A. Logan, C. J. Hawkey. (2002) Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Alimentary Pharmacology and Therapeutics 16:3, 497-506
CrossRef1201
Thomas M MacDonald, Christopher L Sheen. (2002) Gastrointestinal side effects of NSAIDs – pharmacoeconomic implications. Expert Opinion on Pharmacotherapy 3:3, 265-269
CrossRef1202
M. E. Van Leerdam, G. N. J. Tytgat. (2002) Helicobacter pylori infection in peptic ulcer haemorrhage. Alimentary Pharmacology and Therapeutics 16:s1, 66-78
CrossRef1203
Hubert Blain, Christelle Boileau, Françoise Lapicque, Emmanuelle Nédélec, Damien Lœuille, Cécile Guillaume, Alain Gaucher, Claude Jeandel, Patrick Netter, Jean-Yves Jouzeau. (2002) Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. British Journal of Clinical Pharmacology 53:3, 255-265
CrossRef1204
Pamela A. Foral, Amy F. Wilson, Kelly K. Nystrom. (2002) Gastrointestinal Bleeds Associated with Rofecoxib. Pharmacotherapy 22:3, 384-386
CrossRef1205
Helmut Schmidt, Gerd Geißlinger. (2002) Wirkungen und Nebenwirkungen der Coxibe: Kenntnisstand nach Markteinführung. Pharmazie in unserer Zeit 31:2, 180-187
CrossRef1206
R. Wigand. (2002) Kriterien für den Einsatz von COX-2-Inhibitoren: Spezifität, Wirkung, Indikation und Sicherheit. Pharmazie in unserer Zeit 31:2, 190-198
CrossRef1207
Ravinder K. Wali, William L. Henrich. (2002) Recent developments in toxic nephropathy. Current Opinion in Nephrology and Hypertension 11:2, 155-163
CrossRef1208
Holger Ulbrich, Gerd Dannhardt. (2002) NSAR: Klassifizierung und Wirkspektrum: Eine heterogene Arzneistoffklasse. Pharmazie in unserer Zeit 31:2, 146-154
CrossRef1209
Wolfgang W. Bolten. (2002) Kosten der NSAR-Therapie: Können wir uns moderne Antirheumatika leisten?. Pharmazie in unserer Zeit 31:2, 206-215
CrossRef1210
A. Szczeklik, M. Sanak. (2002) The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 32:3, 339-342
CrossRef1211
Stephen E. Kimmel, Jesse A. Berlin, Judith L. Kinman, Sean Hennessy, Harold Feldman, Jeffrey L. Carson, Brian L. Strom. (2002) Parenteral ketorolac and risk of myocardial infarction. Pharmacoepidemiology and Drug Safety 11:2, 113-119
CrossRef1212
M. J. Thun. (2002) Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. CancerSpectrum Knowledge Environment 94:4, 252-266
CrossRef1213
D. Aletaha, J. S. Smolen. (2002) Advances in Anti-Inflammatory Therapy. Acta Medica Austriaca 29:1, 1-6
CrossRef1214
Marta López-Parra, Joan Clària, Anna Planagumà, Esther Titos, Jaime L Masferrer, B Mark Woerner, Alane T Koki, Wladimiro Jiménez, Rosario Altuna, Vicente Arroyo, Francisca Rivera, Joan Rodés. (2002) Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. British Journal of Pharmacology 135:4, 891-900
CrossRef1215
(2002) Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis & Rheumatism 46:2, 328-346
CrossRef1216
W. W. Buchanan, W. F. Kean. (2002) Osteoarthritis IV: Clinical therapeutic trials and treatment. InflammoPharmacology 10:1-2, 79-155
CrossRef1217
J.L. Wallace. (2002) Selective cyclooxygenase-2 inhibitors: after the smoke has cleared. Digestive and Liver Disease 34:2, 89-94
CrossRef1218
&NA;. (2002) Rofecoxib: a selective and effective COX-2 inhibitor. Drugs & Therapy Perspectives 18:2, 1-3
CrossRef1219
Marco E. Turini, Raymond N. DuBois. (2002) C
YCLOOXYGENASE -2: A Therapeutic Target. Annual Review of Medicine 53:1, 35-57
CrossRef1220
A. Mark Fendrick, Rajesh R. Bandekar, Michael E. Chernew, James M. Scheiman. (2002) Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: A decision analysis. Arthritis & Rheumatism 47:1, 36-43
CrossRef1221
Brian Crichton, Martin Green. (2002) GP and Patient Perspectives on Treatment with Non-steroidal Anti-inflammatory Drugs for the Treatment of Pain in Osteoarthritis. Current Medical Research and Opinion 18:2, 92-96
CrossRef1222
Syed R. Ahmad, Cindy Kortepeter, Allen Brinker, Min Chen, Julie Beitz. (2002) Renal Failure Associated with the Use of Celecoxib and Rofecoxib. Drug Safety 25:7, 537-544
CrossRef1223
Josef Zacher, Manfred Schattenkirchner. (2002) Patient and Physician Satisfaction with Rofecoxib in Osteoarthritis: Results of a Post-marketing Surveillance Study in Primary Care in Germany. Current Medical Research and Opinion 18:4, 229-236
CrossRef1224
Judith Jacobi, Gilles L. Fraser, Douglas B. Coursin, Richard R. Riker, Dorrie Fontaine, Eric T. Wittbrodt, Donald B. Chalfin, Michael F. Masica, H. Scott Bjerke, William M. Coplin, David W. Crippen, Barry D. Fuchs, Ruth M. Kelleher, Paul E. Marik, Stanley A. Nasraway, Michael J. Murray, William T. Peruzzi, Philip D. Lumb. (2002) Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Critical Care Medicine 30:1, 119-141
CrossRef1225
J.A. Desmeules, C. Cedraschi, V. Piguet, A.-F. Allaz, Pierre Dayer. (2002) Advances with analgesics and NSAIDs for the treatment of spinal disorders. Best Practice & Research Clinical Rheumatology 16:1, 105-121
CrossRef1226
Stefania Tacconelli, Marta L. Capone, Maria G. Sciulli, Emanuela Ricciotti, Paola Patrignani. (2002) The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme Activity. Current Medical Research and Opinion 18:8, 503-511
CrossRef1227
Barry J. Gertz, David Krupa, James A. Bolognese, Rhoda S. Sperling, Alise Reicin. (2002) A Comparison of Adverse Renovascular Experiences Among Osteoarthritis Patients Treated with Rofecoxib and Comparator Non-selective Non-steroidal Anti-inflammatory Agents. Current Medical Research and Opinion 18:2, 82-91
CrossRef1228
John GF Cleland. (2002) No reduction in cardiovascular risk with NSAIDs—including aspirin?. The Lancet 359:9301, 92-93
CrossRef1229
Mette Olesen, Elizabeth Kwong, Arguello Meztli, Frederic Kontny, Ingebjörg Seljeflot, Harald Arnesen, Line Lyngdorf, Erling Falk. (2002) No Effect of Cyclooxygenase Inhibition on Plaque Size in Atherosclerosis-prone Mice. Scandinavian Cardiovascular Journal 36:6, 362-367
CrossRef1230
Wayne A Ray, C Michael Stein, Kathi Hall, James R Daugherty, Marie R Griffin. (2002) Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. The Lancet 359:9301, 118-123
CrossRef1231
Michael T. Nurmohamed, Vokko P. van Halm, Ben A.C. Dijkmans. (2002) Cardiovascular Risk Profile of Antirheumatic Agents in Patients with Osteoarthritis and Rheumatoid Arthritis. Drugs 62:11, 1599-1609
CrossRef1232
Francis KL Chan, KF To, Justin CY Wu, MY Yung, WK Leung, Timothy Kwok, Y Hui, Henry LY Chan, Cynthia SY Chan, Elsie Hui, Jean Woo, Joseph JY Sung. (2002) Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. The Lancet 359:9300, 9-13
CrossRef1233
Jane Chandramouli. (2002) What Is the Most Effective Therapy for Preventing NSAID-Induced Gastropathy?. Journal of Pain and Palliative Care Pharmacotherapy 16:2, 23-36
CrossRef1234
Laurence G. Howes, Henry Krum. (2002) Selective Cyclo-Oxygenase-2 Inhibitors and Myocardial Infarction. Drug Safety 25:12, 829-835
CrossRef1235
John D. Bradley, Douglas K. Heilman, Barry P. Katz, Patricia G'Sell, Janine E. Wallick, Kenneth D. Brandt. (2002) Tidal irrigation as treatment for knee osteoarthritis: A sham-controlled, randomized, double-blinded evaluation. Arthritis & Rheumatism 46:1, 100-108
CrossRef1236
Albert T. Leung, Kerstin Malmstrom, Alberto E. Gallacher, Brian Sarembock, Gyula Poor, Andre Beaulieu, Ricardo Castro, Matilde Sanchez, Jennifer Ng. (2002) Efficacy and Tolerability Profile of Etoricoxib in Patients with Osteoarthritis: A Randomized, Double-blind, Placebo and Active-comparator Controlled 12-Week Efficacy Trial. Current Medical Research and Opinion 18:2, 49-58
CrossRef1237
Mario S??nchez-Borges, Arnaldo Capriles-Hulett, Fernan Caballero-Fonseca. (2002) NSAID-Induced Urticaria and Angioedema. American Journal of Clinical Dermatology 3:9, 599-607
CrossRef1238
Roy E Pounder. (2002) Helicobacter pylori and NSAIDs—the end of the debate?. The Lancet 359:9300, 3-4
CrossRef1239
Warren A. Katz. (2002) Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases. Current Opinion in Rheumatology 14:1, 63-71
CrossRef1240
Crofford, Leslie J., . (2001) Rational Use of Analgesic and Antiinflammatory Drugs. New England Journal of Medicine 345:25, 1844-1846
Full Text1241
Catella-Lawson, Francesca, Reilly, Muredach P., Kapoor, Shiv C., Cucchiara, Andrew J., DeMarco, Susan, Tournier, Barbara, Vyas, Sachin N., FitzGerald, Garret A., . (2001) Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. New England Journal of Medicine 345:25, 1809-1817
Full Text1242
(2001) The Coxibs, Selective Inhibitors of Cyclooxygenase-2. New England Journal of Medicine 345:23, 1708-1709
Full Text1243
Elizabeth Stack, Raymond N. DuBois. (2001) ROLE OF CYCLOOXYGENASE INHIBITORS FOR THE PREVENTION OF COLORECTAL CANCER. Gastroenterology Clinics of North America 30:4, 1001-1010
CrossRef1244
Alex Macario, Arthur G. Lipman. (2001) Ketorolac in the Era of Cyclo-Oxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Efficacy, Side Effects, and Regulatory Issues. Pain Medicine 2:4, 336-351
CrossRef1245
Marc C. Hochberg. (2001) What a difference a year makes: Reflections on the ACR recommendations for the medical management of osteoarthritis. Current Rheumatology Reports 3:6, 473-478
CrossRef1246
M Dougados. (2001) Treatment of spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine 68:6, 557-563
CrossRef1247
G BOUVENOT. (2001) Comment prévenir le risque thérapeutique médicamenteuxHow to minimize therapeutic risk.. La Revue de Médecine Interne 22:12, 1237-1243
CrossRef1248
J.L. Wallace, M.N. Muscará. (2001) Selective cyclo-oxygenase-2 inhibitors: cardiovascular and gastrointestinal toxicity. Digestive and Liver Disease 33, S21-S28
CrossRef1249
Jørgen Naesdal, Ingalill Wilson. (2001) Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs. European Journal of Gastroenterology & Hepatology 13:12, 1401-1406
CrossRef1250
Francis K.L. Chan. (2001) HELICOBACTER PYLORIAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. Gastroenterology Clinics of North America 30:4, 937-952
CrossRef1251
Christopher J. Hawkey. (2001) GASTROINTESTINAL SAFETY OF COX-2 SPECIFIC INHIBITORS. Gastroenterology Clinics of North America 30:4, 921-936
CrossRef1252
J.I.W. Jones, C.J. Hawkey. (2001) Physiology and organ-related pathology of the elderly: stomach ulcers. Best Practice & Research Clinical Gastroenterology 15:6, 943-961
CrossRef1253
Philip Schoenfeld. (2001) AN EVIDENCE-BASED APPROACH TO THE GASTROINTESTINAL SAFETY PROFILE OF COX-2-SELECTIVE ANTI-INFLAMMATORIES. Gastroenterology Clinics of North America 30:4, 1027-1044
CrossRef1254
A. Lanas. (2001) Cyclo-oxygenase-1/cyclo-oxygenase-2 non-selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events. Digestive and Liver Disease 33, S29-S34
CrossRef1255
Courtney W. Houchen. (2001) CLINICAL IMPLICATIONS OF PROSTAGLANDIN INHIBITION IN THE SMALL BOWEL. Gastroenterology Clinics of North America 30:4, 953-970
CrossRef1256
Thomas J. Schnitzer, Sheldon X. Kong, Panagiotis Mavros, Walter L. Straus, Douglas J. Watson. (2001) Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2—selective inhibitors: analysis of a large United States claims database. Clinical Therapeutics 23:12, 1984-1998
CrossRef1257
Joyce Weaver, Renan A. Bonnel, Claudia B. Karwoski, Allen D. Brinker, Julie Beitz. (2001) GI events leading to death in association with celecoxib and rofecoxib*. The American Journal of Gastroenterology 96:12, 3449-3450
CrossRef1258
Lee S. Simon. (2001) COX-2 INHIBITORS. Gastroenterology Clinics of North America 30:4, 1011-1026
CrossRef1259
K Rainsford. (2001) The ever-emerging anti-inflammatories. Have there been any real advances?. Journal of Physiology-Paris 95:1-6, 11-19
CrossRef1260
Bryron Cryer. (2001) Nonsteroidal anti-inflammatory drug gastrointestinal toxicity. Current Opinion in Gastroenterology 17:6, 503-512
CrossRef1261
J A Louw, I N Marks. (2001) The medical treatment of peptic ulcer disease. Current Opinion in Gastroenterology 17:6, 497-502
CrossRef1262
Ignatius A Tavares, Alan Bennett. (2001) COX-2 inhibitors compared and contrasted. Expert Opinion on Pharmacotherapy 2:11, 1859-1876
CrossRef1263
Y S Bakhle. (2001) COX-2 and cancer: a new approach to an old problem. British Journal of Pharmacology 134:6, 1137-1150
CrossRef1264
Kenneth D. Brandt. (2001) A critique of the 2000 update of the American College of Rheumatology recommendations for management of hip and knee osteoarthritis. Arthritis & Rheumatism 44:10, 2451-2455
CrossRef1265
Claus Aalykke, Karsten Lauritsen. (2001) Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Practice & Research Clinical Gastroenterology 15:5, 705-722
CrossRef1266
Michelle Bidaut-Russell, Sherine E Gabriel. (2001) Adverse gastrointestinal effects of NSAIDs: consequences and costs. Best Practice & Research Clinical Gastroenterology 15:5, 739-753
CrossRef1267
C.J. Hawkey. (2001) COX-1 and COX-2 inhibitors. Best Practice & Research Clinical Gastroenterology 15:5, 801-820
CrossRef1268
Marc C. Hochberg, Maxime Dougados. (2001) Pharmacological therapy of osteoarthritis. Best Practice & Research Clinical Rheumatology 15:4, 583-593
CrossRef1269
John L. Wallace. (2001) Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Practice & Research Clinical Gastroenterology 15:5, 691-703
CrossRef1270
Karl-Erik Giercksky. (2001) COX-2 inhibition and prevention of cancer. Best Practice & Research Clinical Gastroenterology 15:5, 821-833
CrossRef1271
Franco Bazzoli, Luca De Luca, David Y. Graham. (2001) Helicobacter pylori infection and the use of NSAIDs. Best Practice & Research Clinical Gastroenterology 15:5, 775-785
CrossRef1272
Denis M. McCarthy. (2001) Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Practice & Research Clinical Gastroenterology 15:5, 755-773
CrossRef1273
Elliott A. Schulman. (2001) Overview of tension-type headache. Current Pain and Headache Reports 5:5, 454-462
CrossRef1274
Joshua M Cox, Marco Pappagallo. (2001) Contemporary and emergent pharmacological therapies for chronic pain: nonopioid analgesia. Expert Review of Neurotherapeutics 1:1, 81-91
CrossRef1275
P. Y. Martin, J. Desmeules. (2001) Risques rénaux des anti-inflammatoires non stéroïdiens COX 2 sélectifs. Douleur et Analgésie 14:3, 163-167
CrossRef1276
Cynthia J. Harris, D. Craig Brater. (2001) Renal effects of cyclooxygenase-2 selective inhibitors. Current Opinion in Nephrology and Hypertension 10:5, 603-610
CrossRef1277
Wood, Alastair J.J., , FitzGerald, Garret A., Patrono, Carlo, . (2001) The Coxibs, Selective Inhibitors of Cyclooxygenase-2. New England Journal of Medicine 345:6, 433-442
Full Text1278
Carlo Patrono, Paola Patrignani, Luis A. García Rodríguez. (2001) Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. Journal of Clinical Investigation 108:1, 7-13
CrossRef1279
Christopher G Jackson. (2001) Therapeutic potential of COX-2 inhibitors in arthritis. Expert Opinion on Investigational Drugs 10:7, 1317-1325
CrossRef1280
Charles N. Serhan, Ernst Oliw. (2001) Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. Journal of Clinical Investigation 107:12, 1481-1489
CrossRef1281
Garret A. FitzGerald, Patrick Loll. (2001) Series Introduction: COX in a crystal ball: current status and future promise of prostaglandin research. Journal of Clinical Investigation 107:11, 1335-1338
CrossRef1282
Lee S. Simon. (2001) COX-2 inhibition: an advance or only pharmaceutical ?hype??. Arthritis & Rheumatism 45:3, 209-215
CrossRef1283
David Francois. (2001) Spin Doctors. JCR: Journal of Clinical Rheumatology 7:3, 139-141
CrossRef1284
John D. Bradley. (2001) Celecoxib and Rofecoxib: A Distinction with a Difference?. JCR: Journal of Clinical Rheumatology 7:3, 137-138
CrossRef1285
Angel Lanas. (2001) Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of reducing the risk of complications. European Journal of Gastroenterology & Hepatology 13:6, 623-626
CrossRef1286
J Chelly. (2001) Continuous femoral blocks improve recovery and outcome of patients undergoing total knee arthroplasty. The Journal of Arthroplasty 16:4, 436-445
CrossRef1287
(2001) Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen. New England Journal of Medicine 344:18, 1398-1399
Full Text1288
Frank A. Wollheim. (2001) Approaches to rheumatoid arthritis in 2000. Current Opinion in Rheumatology 13:3, 193-201
CrossRef1289
Robert McMurray. (2001) Cyclooxygenase 2 inhibition and thrombosis: Comment on the article by Crofford et al. Arthritis & Rheumatism 44:4, 984-984
CrossRef1290
Maarten Boers. (2001) NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. The Lancet 357:9264, 1222-1223
CrossRef1291
Murray Epstein. (2001) Cardiovascular and Renal Effects of COX-2???Specific Inhibitors: Recent Insights and Evolving Clinical Implications. American Journal of Therapeutics 8:2, 81-83
CrossRef1292
Thomas J. Schnitzer. (2001) Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors. Clinical Therapeutics 23:3, 313-326
CrossRef1293
Andrew Whelton, John G. Fort, Joseph A. Puma, Diane Normandin, Alfonso E. Bello, Kenneth M. Verburg. (2001) Cyclooxygenase-2???Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients. American Journal of Therapeutics 8:2, 85-95
CrossRef1294
(2001) Current Awareness. Pharmacoepidemiology and Drug Safety 10:2, 173-188
CrossRef1295
P Emery, CJ Hawkey, Andrew Moore. (2001) Prescribing in the UK. The Lancet 357:9258, 809
CrossRef1296
A. Mark Fendrick, James M. Scheiman. (2001) Helicobacter pylori and NSAID gastropathy: An ambiguous association. Current Rheumatology Reports 3:2, 107-111
CrossRef1297
P. S. Penglis, M. J. James, L. G. Cleland. (2001) Cyclooxygenase inhibitors: any reservations?. Internal Medicine Journal 31:1, 37-41
CrossRef1298
Serge Steinfeld, Stefaan Poriau. (2001) Patient and Physician Satisfaction with Rofecoxib in Osteoarthritis: Results of the EVA (Experience with VIOXX in Arthritis) Survey *. Current Medical Research and Opinion 17:2, 81-87
CrossRef1299
Anna J. Matheson, David P. Figgitt. (2001) Rofecoxib. Drugs 61:6, 833-865
CrossRef1300
Hideo NAKAMURA. (2001) Cyclooxygenase(COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors.. Folia Pharmacologica Japonica 118:3, 219-230
CrossRef1301
Jaime A. Oviedo, M. Michael Wolfe. (2001) Clinical Potential of Cyclo-Oxygenase-2 Inhibitors. BioDrugs 15:9, 563-572
CrossRef1302
&NA;. (2000) News in brief .... Reactions Weekly &NA;:830, 4
CrossRef
- Letters
